

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 March 2003 (06.03.2003)

PCT

(10) International Publication Number
WO 03/018810 A2

- (51) International Patent Classification⁷: **C12N 15/31**, 15/82, C07K 14/325, A01H 5/00
- (74) Agent: **BASTIAN, Werner**; Syngenta Participations AG, Intellectual Property, P.O. Box, CH-4002 Basel (CH).
- (21) International Application Number: PCT/EP02/09789
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date:
2 September 2002 (02.09.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/316,421 31 August 2001 (31.08.2001) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **SYNGENTA PARTICIPATIONS AG** [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **CHEN, Eric** [US/US]; Syngenta Biotechnology, Inc., 3054 Cornwallis Road, Research Triangle Park, NC 27709 (US). **STACY, Cheryl** [US/US]; Syngenta Biotechnology, Inc., 3054 Cornwallis Road, Research Triangle Park, NC 27709 (US).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MODIFIED CRY3A TOXINS AND NUCLEIC ACID SEQUENCES CODING THEREFOR

(57) Abstract: Compositions and methods for controlling plant pests are disclosed. In particular, novel nucleic acid sequences encoding modified Cry3A toxins having increased toxicity to corn rootworm are provided. By inserting a protease recognition site, such as cathepsin G, that is recognized by a gut protease of a target insect in at least one position of a Cry3A toxin a modified Cry3A toxin having significantly greater toxicity, particularly to western and northern corn rootworm is designed. Further, a method of making the modified Cry3A toxins and methods of using the modified Cry3A nucleic acid sequences, for example in microorganisms to control insects or in transgenic plants to confer protection from insect damage, and a method of using the modified Cry3A toxins, and compositions and formulations comprising the modified Cry3A toxins, for example applying the modified Cry3A toxins or compositions or formulations to insect-infested areas, or to prophylactically treat insect-susceptible areas or plants to confer protection against the insect pests are disclosed.



WO 03/018810 A2

Modified Cry3A Toxins and Nucleic Acid Sequences Coding Therefor

The present invention relates to the fields of protein engineering, plant molecular biology and pest control. More particularly, the present invention relates to novel modified Cry3A toxins and nucleic acid sequences whose expression results in the modified Cry3A toxins, and
5 methods of making and methods of using the modified Cry3A toxins and corresponding nucleic acid sequences to control insects.

Species of corn rootworm are considered to be the most destructive corn pests. In the United States the three important species are *Diabrotica virgifera virgifera*, the western corn
10 rootworm; *D. longicornis barberi*, the northern corn rootworm and *D. undecimpunctata howardi*, the southern corn rootworm. Only western and northern corn rootworms are considered primary pests of corn in the US Corn Belt. Corn rootworm larvae cause the most substantial plant damage by feeding almost exclusively on corn roots. This injury has been
15 shown to increase plant lodging, to reduce grain yield and vegetative yield as well as alter the nutrient content of the grain. Larval feeding also causes indirect effects on maize by opening avenues through the roots for bacterial and fungal infections which lead to root and stalk rot diseases. Adult corn rootworms are active in cornfields in late summer where they feed on ears, silks and pollen, interfering with normal pollination.

Corn rootworms are mainly controlled by intensive applications of chemical pesticides, which
20 are active through inhibition of insect growth, prevention of insect feeding or reproduction, or cause death. Good corn rootworm control can thus be reached, but these chemicals can sometimes also affect other, beneficial organisms. Another problem resulting from the wide use of chemical pesticides is the appearance of resistant insect varieties. Yet another problem is due to the fact that corn rootworm larvae feed underground thus making it difficult to apply
25 rescue treatments of insecticides. Therefore, most insecticide applications are made prophylactically at the time of planting. This practice results in a large environmental burden. This has been partially alleviated by various farm management practices, but there is an increasing need for alternative pest control mechanisms.

Biological pest control agents, such as *Bacillus thuringiensis* (Bt) strains expressing pesticidal
30 toxins like δ -endotoxins, have also been applied to crop plants with satisfactory results against

primarily lepidopteran insect pests. The δ -endotoxins are proteins held within a crystalline matrix that are known to possess insecticidal activity when ingested by certain insects. The various δ -endotoxins have been classified based upon their spectrum of activity and sequence homology. Prior to 1990, the major classes were defined by their spectrum of activity with the Cry1 proteins active against Lepidoptera (moths and butterflies), Cry2 proteins active against both Lepidoptera and Diptera (flies and mosquitoes), Cry3 proteins active against Coleoptera (beetles) and Cry4 proteins active against Diptera (Hofte and Whitely, 1989, Microbiol. Rev. 53:242-255). Recently a new nomenclature was developed which systematically classifies the Cry proteins based on amino acid sequence homology rather than insect target specificities (Crickmore *et al.* 1998, Microbiol. Molec. Biol. Rev. 62:807-813).

The spectrum of insecticidal activity of an individual δ -endotoxin from Bt is quite narrow, with a given δ -endotoxin being active against only a few species within an Order. For instance, the Cry3A protein is known to be very toxic to the Colorado potato beetle, *Leptinotarsa decemlineata*, but has very little or no toxicity to related beetles in the genus *Diabrotica* (Johnson *et al.*, 1993, J. Econ. Entomol. 86:330-333). According to Slaney *et al.* (1992, Insect Biochem. Molec. Biol. 22:9-18) the Cry3A protein is at least 2000 times less toxic to southern corn rootworm larvae than to the Colorado potato beetle. It is also known that Cry3A has little or no toxicity to the western corn rootworm.

Specificity of the δ -endotoxins is the result of the efficiency of the various steps involved in producing an active toxin protein and its subsequent interaction with the epithelial cells in the insect mid-gut. To be insecticidal, most known δ -endotoxins must first be ingested by the insect and proteolytically activated to form an active toxin. Activation of the insecticidal crystal proteins is a multi-step process. After ingestion, the crystals must first be solubilized in the insect gut. Once solubilized, the δ -endotoxins are activated by specific proteolytic cleavages. The proteases in the insect gut can play a role in specificity by determining where the δ -endotoxin is processed. Once the δ -endotoxin has been solubilized and processed it binds to specific receptors on the surface of the insects' mid-gut epithelium and subsequently integrates into the lipid bilayer of the brush border membrane. Ion channels then form disrupting the normal function of the midgut eventually leading to the death of the insect.

In Lepidoptera, gut proteases process δ -endotoxins from 130-140 kDa protoxins to toxic proteins of approximately 60-70 kDa. Processing of the protoxin to toxin has been reported to proceed by removal of both N- and C-terminal amino acids with the exact location of processing being dependent on the specific insect gut fluids involved (Ogiwara *et al.*, 1992, J. Invert. Pathol. 60:121-126). The proteolytic activation of a δ -endotoxin can play a significant role in determining its specificity. For example, a δ -endotoxin from Bt var. *aizawa*, called IC1, has been classified as a Cry1Ab protein based on its sequence homology with other known Cry1Ab proteins. Cry1Ab proteins are typically active against lepidopteran insects. However, the IC1 protein has activity against both lepidopteran and dipteran insects depending upon how the protein is processed (Haider *et al.* 1986, Euro. J. Biochem. 156: 531-540). In a dipteran gut, a 53 kDa active IC1 toxin is obtained, whereas in a lepidopteran gut, a 55 kDa active IC1 toxin is obtained. IC1 differs from the holotype HD-1 Cry1Ab protein by only four amino acids, so gross changes in the receptor binding region do not seem to account for the differences in activity. The different proteolytic cleavages in the two different insect guts possibly allow the activated molecules to fold differently thus exposing different regions capable of binding different receptors. The specificity therefore, appears to reside with the gut proteases of the different insects.

Coleopteran insects have guts that are more neutral to acidic and coleopteran-specific δ -endotoxins are similar to the size of the activated lepidopteran-specific toxins. Therefore, the processing of coleopteran-specific δ -endotoxins was formerly considered unnecessary for toxicity. However, recent data suggests that coleopteran-active δ -endotoxins are solubilized and proteolyzed to smaller toxic polypeptides. The 73 kDa Cry3A δ -endotoxin protein produced by *B. thuringiensis* var. *tenebrionis* is readily processed in the bacterium at the N-terminus, losing 49-57 residues during or after crystal formation to produce the commonly isolated 67 kDa form (Carroll *et al.*, 1989, Biochem. J. 261:99-105). McPherson *et al.*, 1988 (Biotechnology 6:61-66) also demonstrated that the native *cry3A* gene contains two functional translational initiation codons in the same reading frame, one coding for the 73 kDa protein and the other coding for the 67 kDa protein starting at Met-1 and Met-48 respectively, of the deduced amino acid sequence (See SEQ ID NO: 2). Both proteins then can be considered naturally occurring full-length Cry3A proteins. Treatment of soluble 67 kDa Cry3A protein

with either trypsin or insect gut extract results in a cleavage product of 55 kDa with Asn-159 of the deduced amino acid sequence at the N-terminus. This polypeptide was found to be as toxic to a susceptible coleopteran insect as the native 67 kDa Cry3A toxin. (Carroll *et al. Ibid*). Thus, a natural trypsin recognition site exists between Arg-158 and Asn-159 of the deduced amino acid sequence of the native Cry3A toxin (SEQ ID NO: 2). Cry3A can also be cleaved by chymotrypsin, resulting in three polypeptides of 49, 11, and 6 kDa. N-terminal analysis of the 49 and 6 kDa components showed the first amino acid residue to be Ser-162 and Tyr-588, respectively (Carroll *et al.*, 1997 J. Invert. Biol. 70:41-49). Thus, natural chymotrypsin recognition sites exist in Cry3A between His-161 and Ser-162 and between Tyr-587 and Tyr-588 of the deduced amino acid sequence (SEQ ID NO: 2). The 49 kDa chymotrypsin product appears to be more soluble at neutral pH than the native 67 kDa protein or the 55 kDa trypsin product and retains full insecticidal activity against the Cry3A-susceptible insects, Colorado potato beetle and mustard beetle, (*Phaedon cochleariae*). Insect gut proteases typically function in aiding the insect in obtaining needed amino acids from dietary protein. The best understood insect digestive proteases are serine proteases that appear to be the most common (Englemann and Geraerts, 1980, J. Insect Physiol. 26:703-710), particularly in lepidopteran species. The majority of coleopteran larvae and adults, for example Colorado potato beetle, have slightly acidic midguts, and cysteine proteases provide the major proteolytic activity (Wolfson and Mudock, 1990, J. Chem. Ecol. 16:1089-1102). More precisely, Thie and Houseman (1990, Insect Biochem. 20:313-318) identified and characterized the cysteine proteases, cathepsin B and H, and the aspartyl protease, cathepsin D in Colorado potato beetle. Gillikin *et al.* (1992, Arch. Insect Biochem. Physiol. 19:285-298) characterized the proteolytic activity in the guts of western corn rootworm larvae and found 15, primarily cysteine, proteases. Until disclosed in this invention, no reports have indicated that the serine protease, cathepsin G, exists in western corn rootworm. The diversity and different activity levels of the insect gut proteases may influence an insect's sensitivity to a particular Bt toxin.

Many new and novel Bt strains and δ -endotoxins with improved or novel biological activities have been described over the past five years including strains active against nematodes (EP 0517367A1). However, relatively few of these strains and toxins have activity against coleopteran insects. Further, none of the now known coleopteran-active δ -endotoxins, for

example Cry3A, Cry3B, Cry3C, Cry7A, Cry8A, Cry8B, and Cry8C, have sufficient oral toxicity against corn rootworm to provide adequate field control if delivered, for example, through microbes or transgenic plants. Therefore, other approaches for producing novel toxins active against corn rootworm need to be explored.

5 As more knowledge has been gained as to how the δ -endotoxins function, attempts to engineer δ -endotoxins to have new activities have increased. Engineering δ -endotoxins was made more possible by the solving of the three dimensional structure of Cry3A in 1991 (Li *et al.*, 1991, Nature 353:815-821). The protein has three structural domains: the N-terminal domain I, from residues 1-290, consists of 7 alpha helices, domain II, from residues 291-500,
10 contains three beta-sheets and the C-terminal domain III, from residues 501-644, is a beta-sandwich. Based on this structure, a hypothesis has been formulated regarding the structure/function relationship of the δ -endotoxins. It is generally thought that domain I is primarily responsible for pore formation in the insect gut membrane (Gazit and Shai, 1993, Appl. Environ. Microbiol. 57:2816-2820), domain II is primarily responsible for interaction
15 with the gut receptor (Ge *et al.*, 1991, J. Biol. Chem. 32:3429-3436) and that domain III is most likely involved with protein stability (Li *et al.* 1991, *supra*) as well as having a regulatory impact on ion channel activity (Chen *et al.*, 1993, PNAS 90:9041-9045).

Lepidopteran-active δ -endotoxins have been engineered in attempts to improve specific activity or to broaden the spectrum of insecticidal activity. For example, the silk moth
20 (*Bombyx mori*) specificity domain from Cry1Aa was moved to Cry1Ac, thus imparting a new insecticidal activity to the resulting chimeric protein (Ge *et al.* 1989, PNAS 86: 4037-4041). Also, Bosch *et al.* 1998 (US Patent 5,736,131), created a new lepidopteran-active toxin by substituting domain III of Cry1E with domain III of Cry1C thus producing a Cry1E-Cry1C hybrid toxin with a broader spectrum of lepidopteran activity.

25 Several attempts at engineering the coleopteran-active δ -endotoxins have been reported. Van Rie *et al.*, 1997, (US Patent No. 5,659,123) engineered Cry3A by randomly replacing amino acids, thought to be important in solvent accessibility, in domain II with the amino acid alanine. Several of these random replacements confined to receptor binding domain II were reportedly involved in increased western corn rootworm toxicity. However, others have shown
30 that some alanine replacements in domain II of Cry3A result in disruption of receptor binding or structural instability (Wu and Dean, 1996, J. Mol. Biol. 255: 628-640). English *et al.*, 1999,

(Intl. Pat. Appl. Publ. No. WO 99/31248) reported amino acid substitutions in Cry3Bb that caused increases in toxicity to southern and western corn rootworm. However, of the 35 reported Cry3Bb mutants, only three, with mutations primarily in domain II and the domain II-domain I interface, were active against western corn rootworm. Further, the differences in toxicity of wild-type Cry3Bb against western corn rootworm in the same assays were greater than any of the differences between the mutated Cry3Bb toxins and the wild-type Cry3Bb. Therefore, improvements in toxicity of the Cry3Bb mutants appear to be confined primarily to southern corn rootworm.

There remains a need to design new and effective pest control agents that provide an economic benefit to farmers and that are environmentally acceptable. Particularly needed are modified Cry3A toxins that control western corn rootworm, the major pest of corn in the United States, that are or could become resistant to existing insect control agents. Furthermore, agents whose application minimizes the burden on the environment, as through transgenic plants, are desirable.

In view of these needs, it is an object of the present invention to provide novel nucleic acid sequences encoding modified Cry3A toxins having increased toxicity to corn rootworm. By inserting a protease recognition site that is recognized by a target-insect gut protease in at least one position of a Cry3A toxin, in accordance with the present invention, a modified Cry3A toxin having significantly greater toxicity, particularly to western and northern corn rootworm is designed. The invention is further drawn to the novel modified Cry3A toxins resulting from the expression of the nucleic acid sequences, and to compositions and formulations containing the modified Cry3A toxins, which are capable of inhibiting the ability of insect pests to survive, grow and reproduce, or of limiting insect-related damage or loss to crop plants. The invention is further drawn to a method of making the modified Cry3A toxins and to methods of using the modified *cry3A* nucleic acid sequences, for example in microorganisms to control insects or in transgenic plants to confer protection from insect damage, and to a method of using the modified Cry3A toxins, and compositions and formulations comprising the modified Cry3A toxins, for example applying the modified Cry3A toxins or compositions or formulations to insect-infested areas, or to prophylactically treat insect-susceptible areas or plants to confer protection against the insect pests.

The novel modified Cry3A toxins described herein are highly active against insects. For example, the modified Cry3A toxins of the present invention can be used to control economically important insect pests such as western corn rootworm (*Diabrotica virgifera virgifera*) and northern corn rootworm (*D. longicornis barberi*). The modified Cry3A toxins
5 can be used singly or in combination with other insect control strategies to confer maximal pest control efficiency with minimal environmental impact.

According to one aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a modified Cry3A toxin, wherein the modified Cry3A toxin comprises at least one additional protease recognition site that does not naturally
10 occur in a Cry3A toxin. The additional protease recognition site, which is recognized by a gut protease of a target insect, is inserted at approximately the same position as a naturally occurring protease recognition site in the Cry3A toxin. The modified Cry3A toxin causes higher mortality to a target insect than the mortality caused by a Cry3A toxin to the same target insect. Preferably, the modified Cry3A toxin causes at least about 50 % mortality to a
15 target insect to which a Cry3A toxin causes only up to about 30% mortality.

In one embodiment of this aspect, the gut protease of a target insect is selected from the group consisting of serine proteases, cysteine proteases and aspartic proteases. Preferable serine proteases according to this embodiment include cathepsin G, trypsin, chymotrypsin, carboxypeptidase, endopeptidase and elastase, most preferably cathepsin G.

20 In another embodiment of this aspect, the additional protease recognition site is inserted in either domain I or domain III or in both domain I and domain III of the Cry3A toxin. Preferably, the additional protease recognition site is inserted in either domain I or domain III or in both domain I and domain III at a position that replaces, is adjacent to, or is within a naturally occurring protease recognition site.

25 In a yet another embodiment, the additional protease recognition site is inserted in domain I between amino acids corresponding to amino acid numbers 154 and 162 of SEQ ID NO: 2. Preferably, the additional protease recognition site is inserted between amino acid numbers 154 and 162 of SEQ ID NO: 2 or between amino acid numbers 107 and 115 of SEQ ID NO: 4.

30 In still another embodiment, the additional protease recognition site is inserted between amino acids corresponding to amino acid numbers 154 and 160 of SEQ ID NO: 2. Preferably, the

additional protease recognition site is inserted between amino acid numbers 154 and 160 of SEQ ID NO: 2 or between amino acid numbers 107 and 113 of SEQ ID NO: 4.

In a further embodiment, the additional protease recognition site is inserted in domain I between amino acids corresponding to amino acid numbers 154 and 158 of SEQ ID NO: 2.

- 5 Preferably, the additional protease recognition site is inserted in domain I between amino acid numbers 154 and 158 of SEQ ID NO: 2 or between amino acid numbers 107 and 111 of SEQ ID NO: 4.

In another embodiment, the additional protease recognition site is inserted in domain III between amino acids corresponding to amino acid numbers 583 and 589 of SEQ ID NO: 2.

- 10 Preferably, the additional protease site is inserted in domain III between amino acid numbers 583 and 589 of SEQ ID NO: 2 or between amino acid numbers 536 and 542 of SEQ ID NO: 4.

In still another embodiment, the additional protease recognition site is inserted in domain III between amino acids corresponding to amino acid numbers 583 and 588 of SEQ ID NO: 2.

- 15 Preferably, the additional protease site is inserted in domain III between amino acid numbers 583 and 588 of SEQ ID NO: 2 or between amino acid numbers 536 and 541 of SEQ ID NO: 4.

In yet another embodiment, the additional protease recognition site is inserted in domain III between amino acids corresponding to amino acid numbers 587 and 588 of SEQ ID NO: 2.

- 20 Preferably, the additional protease site is inserted in domain III between amino acid numbers 587 and 588 of SEQ ID NO: 2 or between amino acid numbers 540 and 541 of SEQ ID NO: 4.

In one embodiment, the additional protease recognition site is inserted in domain I and domain III of the unmodified Cry3A toxin. Preferably, the additional protease recognition site is inserted in domain I at a position that replaces or is adjacent to a naturally occurring protease recognition site and in domain III at a position that is within, replaces, or is adjacent to a naturally occurring protease recognition site.

- 25 In another embodiment, the additional protease recognition site is inserted in domain I between amino acids corresponding to amino acid numbers 154 and 160 and in domain III between amino acids corresponding to amino acid numbers 587 and 588 of SEQ ID NO: 2.
- 30 Preferably, the additional protease recognition site is inserted in domain I between amino acid numbers 154 and 160 and in domain III between amino acid numbers 587 and 588 of SEQ ID

NO: 2 or in domain I between amino acid numbers 107 and 113 and in domain III between amino acid numbers 540 and 541 of SEQ ID NO: 4.

In yet another embodiment, the additional protease recognition site is located in domain I between amino acids corresponding to amino acid numbers 154 and 158 and in domain III between amino acids corresponding to amino acid numbers 587 and 588 of SEQ ID NO: 2.

Preferably, the additional protease recognition site is inserted in domain I between amino acid numbers 154 and 158 and in domain III between amino acid numbers 587 and 588 of SEQ ID NO: 2 or in domain I between amino acid numbers 107 and 111 and in domain III between amino acid numbers 540 and 541 of SEQ ID NO: 4.

In another embodiment, the additional protease recognition site is located in domain I between amino acids corresponding to amino acid numbers 154 and 158 and in domain III between amino acids corresponding to amino acid numbers 583 and 588 of SEQ ID NO: 2. Preferably, the additional protease recognition site is inserted in domain I between amino acid numbers 154 and 158 and in domain III between amino acid numbers 583 and 588 of SEQ ID NO: 2 or in domain I between amino acid numbers 107 and 111 and in domain III between amino acid numbers 536 and 541 of SEQ ID NO: 4.

In a preferred embodiment, the isolated nucleic acid molecule of the present invention comprises nucleotides 1-1791 of SEQ ID NO: 6, nucleotides 1-1806 of SEQ ID NO: 8, nucleotides 1-1818 of SEQ ID NO: 10, nucleotides 1-1794 of SEQ ID NO: 12, nucleotides 1-1812 of SEQ ID NO: 14, nucleotides 1-1812 of SEQ ID NO: 16, nucleotides 1-1818 of SEQ ID NO: 18, or nucleotides 1-1791 of SEQ ID NO: 20.

In another preferred embodiment, the isolated nucleic acid molecule of the invention encodes a modified Cry3A toxin comprising the amino acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21.

According to one embodiment of the invention, the isolated nucleic acid molecule encodes a modified Cry3A toxin that is active against a coleopteran insect. Preferably, the modified Cry3A toxin has activity against western corn rootworm.

The present invention provides a chimeric gene comprising a heterologous promoter sequence operatively linked to the nucleic acid molecule of the invention. The present invention also provides a recombinant vector comprising such a chimeric gene. Further, the present invention

provides a transgenic non-human host cell comprising such a chimeric gene. A transgenic host cell according to this aspect of the invention may be a bacterial cell or a plant cell, preferably, a plant cell. The present invention further provides a transgenic plant comprising such a plant cell. A transgenic plant according to this aspect of the invention may be sorghum, wheat,
5 sunflower, tomato, potato, cole crops, cotton, rice, soybean, sugar beet, sugarcane, tobacco, barley, oilseed rape, or maize, preferably, maize. The present invention also provides seed from the group of transgenic plants consisting of sorghum, wheat, sunflower, tomato, potato, cole crops, cotton, rice, soybean, sugar beet, sugarcane, tobacco, barley, oilseed rape, and maize. In a particularly preferred embodiment, the seed is from a transgenic maize plant.

10 In another aspect, the present invention provides toxins produced by the expression of the nucleic acid molecules of the present invention. In a preferred embodiment, the toxin is produced by the expression of the nucleic acid molecule comprising nucleotides 1-1791 of SEQ ID NO: 6, nucleotides 1-1806 of SEQ ID NO: 8, nucleotides 1-1818 of SEQ ID NO: 10, nucleotides 1-1794 of SEQ ID NO: 12, nucleotides 1-1812 of SEQ ID NO: 14, nucleotides 1-
15 1812 of SEQ ID NO: 16, nucleotides 1-1818 of SEQ ID NO: 18, or nucleotides 1-1791 of SEQ ID NO: 20.

In another embodiment, the toxins of the invention are active against coleopteran insects, preferably against western corn rootworm.

In one embodiment, a toxin of the present invention comprises the amino acid sequence set
20 forth in SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21.

The present invention also provides a composition comprising an effective insect-controlling amount of a toxin according to the invention.

In another aspect, the present invention provides a method of producing a toxin that is active
25 against insects, comprising: (a) obtaining a host cell comprising a chimeric gene, which itself comprises a heterologous promoter sequence operatively linked to the nucleic acid molecule of the invention; and (b) expressing the nucleic acid molecule in the transgenic host cell, which results in at least one toxin that is active against insects.

In a further aspect, the present invention provides a method of producing an insect-resistant
30 transgenic plant, comprising introducing a nucleic acid molecule of the invention into the transgenic plant, wherein the nucleic acid molecule is expressible in the transgenic plant in an

effective amount to control insects. In a preferred embodiment, the insects are coleopteran insects, preferably western corn rootworm.

In yet a further aspect, the present invention provides a method of controlling insects, comprising delivering to the insects an effective amount of a toxin of the invention. According to one embodiment, the insects are coleopteran insects, preferably, western corn rootworm. Preferably, the toxin is delivered to the insects orally. In one preferred embodiment, the toxin is delivered orally through a transgenic plant comprising a nucleic acid sequence that expresses a toxin of the present invention.

Also provided by the present invention is a method of making a modified Cry3A toxin,

comprising: (a) obtaining a *cry3A* toxin gene which encodes a Cry3A toxin; (b) identifying a gut protease of a target insect; (c) obtaining a nucleotide sequence which encodes a recognition sequence for the gut protease; (d) inserting the nucleotide sequence of (c) into either domain I or domain III or both domain I and domain III at a position that replaces, is within, or adjacent to a nucleotide sequence that codes for a naturally occurring protease recognition site in a *cry3A* toxin gene, thus creating a modified *cry3A* toxin gene; (e) inserting the modified *cry3A* toxin gene in an expression cassette; (f) expressing the modified *cry3A* toxin gene in a non-human host cell, resulting in the host cell producing a modified Cry3A toxin; and, (g) bioassaying the modified Cry3A toxin against a target insect, whereby the modified Cry3A toxin causes higher mortality to the target insect than the mortality caused by a Cry3A toxin. In a preferred embodiment, the modified Cry3A toxin causes at least about 50% mortality to the target insect when the Cry3A toxin causes up to about 30% mortality.

The present invention further provides a method of controlling insects wherein the transgenic plant further comprises a second nucleic acid sequence or groups of nucleic acid sequences that encode a second pesticidal principle. Particularly preferred second nucleic acid sequences are those that encode a δ -endotoxin, those that encode a Vegetative Insecticidal Protein toxin, disclosed in U.S. Patents 5,849,870 and 5,877,012, incorporated herein by reference, or those that encode a pathway for the production of a non-proteinaceous pesticidal principle.

Yet another aspect of the present invention is the provision of a method for mutagenizing a nucleic acid molecule according to the present invention, wherein the nucleic acid molecule has been cleaved into populations of double-stranded random fragments of a desired size, comprising: (a) adding to the population of double-stranded random fragments one or more

single- or double-stranded oligonucleotides, wherein the oligonucleotides each comprise an area of identity and an area of heterology to a double-stranded template polynucleotide; (b) denaturing the resultant mixture of double-stranded random fragments and oligonucleotides into single-stranded fragments; (c) incubating the resultant population of single-stranded
5 fragments with polymerase under conditions which result in the annealing of the single-stranded fragments at the areas of identity to form pairs of annealed fragments, the areas of identity being sufficient for one member of the pair to prime replication of the other, thereby forming a mutagenized double-stranded polynucleotide; and (d) repeating the second and third steps for at least two further cycles, wherein the resultant mixture in the second step of a
10 further cycle includes the mutagenized double-stranded polynucleotide from the third step of the previous cycle, and wherein the further cycle forms a further mutagenized double-stranded polynucleotide.

Other aspects and advantages of the present invention will become apparent to those skilled in the art from a study of the following description of the invention and non-limiting examples.

15

SEQ ID NO: 1 is the native *cry3A* coding region.

SEQ ID NO: 2 is the amino acid sequence of the Cry3A toxin encoded by the native *cry3A* gene.

20 SEQ ID NO: 3 is the maize optimized *cry3A* coding region beginning at nucleotide 144 of the native *cry3A* coding region.

SEQ ID NO: 4 is the amino acid sequence of the Cry3A toxin encoded by the maize optimized *cry3A* gene.

SEQ ID NO: 5 is the nucleotide sequence of pCIB6850.

25 SEQ ID NO: 6 is the maize optimized modified *cry3A054* coding sequence.

SEQ ID NO: 7 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 6.

SEQ ID NO: 8 is the maize optimized modified *cry3A055* coding sequence.

30 SEQ ID NO: 9 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 8.

SEQ ID NO: 10 is the maize optimized modified *cry3A085* coding sequence.

SEQ ID NO: 11 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 10.

SEQ ID NO: 12 is the maize optimized modified *cry3A082* coding sequence.

SEQ ID NO: 13 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 12.

SEQ ID NO: 14 is the maize optimized modified *cry3A058* coding sequence.

SEQ ID NO: 15 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 14.

SEQ ID NO: 16 is the maize optimized modified *cry3A057* coding sequence.

SEQ ID NO: 17 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 16.

SEQ ID NO: 18 is the maize optimized modified *cry3A056* coding sequence.

SEQ ID NO: 19 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 18.

SEQ ID NO: 20 is the maize optimized modified *cry3A083* coding sequence.

SEQ ID NO: 21 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 20.

SEQ ID NOS: 22-34 are PCR primers useful in the present invention.

SEQ ID NO: 35 is an amino acid sequence comprising a cathepsin G recognition site.

SEQ ID NO: 36 is an amino acid sequence comprising a cathepsin G recognition site.

SEQ ID NO: 37 is an amino acid sequence comprising a cathepsin G recognition site.

SEQ ID NO: 38 is an amino acid sequence comprising a cathepsin G recognition site.

For clarity, certain terms used in the specification are defined and presented as follows:

"Activity" of the modified Cry3A toxins of the invention is meant that the modified Cry3A toxins function as orally active insect control agents, have a toxic effect, or are able to disrupt or deter insect feeding, which may or may not cause death of the insect. When a modified Cry3A toxin of the invention is delivered to the insect, the result is typically death of the insect, or the insect does not feed upon the source that makes the modified Cry3A toxin available to the insect.

“Adjacent to”- According to the present invention, an additional protease recognition site is “adjacent to” a naturally occurring protease recognition site when the additional protease recognition site is within four residues, preferably within three residues, more preferably within two residues, and most preferably within one residue of a naturally occurring protease recognition site. For example, an additional protease recognition site inserted between Pro-154 and Arg-158 of the deduced amino acid sequence of a Cry3A toxin (SEQ ID NO: 2) is “adjacent to” the naturally occurring trypsin recognition site located between Arg-158 and Asn-159 of the deduced amino acid sequence of the Cry3A toxin (SEQ ID NO: 2).

The phrase “approximately the same position” as used herein to describe the location where an additional protease recognition site is inserted into a Cry3A toxin in relation to a naturally occurring protease recognition site, means that the location is at most four residues away from a naturally occurring protease recognition site. The location can also be three or two residues away from a naturally occurring protease recognition site. The location can also be one residue away from a naturally occurring protease recognition site. “Approximately the same position” can also mean that the additional protease recognition site is inserted within a naturally occurring protease recognition site.

"Associated with / operatively linked" refer to two nucleic acid sequences that are related physically or functionally. For example, a promoter or regulatory DNA sequence is said to be "associated with" a DNA sequence that codes for an RNA or a protein if the two sequences are operatively linked, or situated such that the regulatory DNA sequence will affect the expression level of the coding or structural DNA sequence.

A "chimeric gene" or “chimeric construct” is a recombinant nucleic acid sequence in which a promoter or regulatory nucleic acid sequence is operatively linked to, or associated with, a nucleic acid sequence that codes for an mRNA or which is expressed as a protein, such that the regulatory nucleic acid sequence is able to regulate transcription or expression of the associated nucleic acid coding sequence. The regulatory nucleic acid sequence of the chimeric gene is not normally operatively linked to the associated nucleic acid sequence as found in nature.

A "coding sequence" is a nucleic acid sequence that is transcribed into RNA such as mRNA, rRNA, tRNA, snRNA, sense RNA or antisense RNA. Preferably the RNA is then translated in an organism to produce a protein.

To "control" insects means to inhibit, through a toxic effect, the ability of insect pests to survive, grow, feed, and/or reproduce, or to limit insect-related damage or loss in crop plants. To "control" insects may or may not mean killing the insects, although it preferably means killing the insects.

5 Corresponding to: in the context of the present invention, "corresponding to" means that when the amino acid sequences of variant Cry3A δ -endotoxins are aligned with each other, the amino acids that "correspond to" certain enumerated positions in the present invention are those that align with these positions in the Cry3A toxin (SEQ ID NO: 2), but that are not necessarily in these exact numerical positions relative to the particular Cry3A amino acid
10 sequence of the invention. For example, the maize optimized *cry3A* gene (SEQ ID NO: 3) of the invention encodes a Cry3A toxin (SEQ ID NO: 4) that begins at Met-48 of the Cry3A toxin (SEQ ID NO: 2) encoded by the native *cry3A* gene (SEQ ID NO: 1). Therefore, according to the present invention, amino acid numbers 107-115, including all numbers in between, and 536-541, including all numbers in between, of SEQ ID NO: 4 correspond to
15 amino acid numbers 154-163, and all numbers in between, and 583-588, and all numbers in between, respectively, of SEQ ID NO: 2.

A "Cry3A toxin", as used herein, refers to an approximately 73 kDa *Bacillus thuringiensis* var. *tenebrionis* (Kreig *et al.*, 1983, Z. Angew. Entomol. 96:500-508) (Bt) coleopteran-active protein (Sekar *et al.*, 1987, Proc. Nalt. Acad. Sci. 84:7036-7040), for example SEQ ID NO: 2,
20 as well as any truncated lower molecular weight variants, derivable from a Cry3A toxin, for example SEQ ID NO: 4, and retaining substantially the same toxicity as the Cry3A toxin. The lower molecular weight variants can be obtained by protease cleavage of naturally occurring protease recognition sites of the Cry3A toxin or by a second translational initiation codon in the same frame as the translational initiation codon coding for the 73 kDa Cry3A toxin. The
25 amino acid sequence of a Cry3A toxin and the lower molecular weight variants thereof can be found in a toxin naturally occurring in Bt. A Cry3A toxin can be encoded by a native Bt gene as in SEQ ID NO: 1 or by a synthetic coding sequence as in SEQ ID NO: 3. A "Cry3A toxin" does not have any additional protease recognition sites over the protease recognition sites that naturally occur in the Cry3A toxin. A Cry3A toxin can be isolated, purified or expressed in a
30 heterologous system.

A "*cry3A* gene", as used herein, refers to the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3. A *cry3A* gene (Sekar *et al.*, 1987, Proc. Natl. Acad. Sci. 84:7036-7040) can be naturally occurring, as found in *Bacillus thuringiensis* var. *tenebrionis* (Kreig *et al.*, 1983, Z. Angew. Entomol. 96:500-508), or synthetic and encodes a Cry3A toxin. The *cry3A* gene of
5 this invention can be referred to as the native *cry3A* gene as in SEQ ID NO: 1 or the maize-optimized *cry3A* gene as in SEQ ID NO: 3.

To "deliver" a toxin means that the toxin comes in contact with an insect, resulting in toxic effect and control of the insect. The toxin can be delivered in many recognized ways, e.g., orally by ingestion by the insect or by contact with the insect via transgenic plant expression,
10 formulated protein composition(s), sprayable protein composition(s), a bait matrix, or any other art-recognized toxin delivery system.

"Effective insect-controlling amount" means that concentration of toxin that inhibits, through a toxic effect, the ability of insects to survive, grow, feed and/or reproduce, or to limit insect-related damage or loss in crop plants. "Effective insect-controlling amount" may or may not
15 mean killing the insects, although it preferably means killing the insects.

"Expression cassette" as used herein means a nucleic acid sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operably linked to the nucleotide sequence of interest which is operably linked to termination signals. It also typically comprises sequences required for proper translation of the
20 nucleotide sequence. The expression cassette comprising the nucleotide sequence of interest may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The expression cassette may also be one that is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Typically, however, the expression cassette is heterologous with respect to the host, i.e., the
25 particular nucleic acid sequence of the expression cassette does not occur naturally in the host cell and must have been introduced into the host cell or an ancestor of the host cell by a transformation event. The expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter that initiates transcription only when the host cell is exposed to some particular external stimulus. In the
30 case of a multicellular organism, such as a plant, the promoter can also be specific to a particular tissue, or organ, or stage of development.

A "gene" is a defined region that is located within a genome and that, besides the aforementioned coding nucleic acid sequence, comprises other, primarily regulatory, nucleic acid sequences responsible for the control of the expression, that is to say the transcription and translation, of the coding portion. A gene may also comprise other 5' and 3' untranslated sequences and termination sequences. Further elements that may be present are, for example, introns.

"Gene of interest" refers to any gene which, when transferred to a plant, confers upon the plant a desired characteristic such as antibiotic resistance, virus resistance, insect resistance, disease resistance, or resistance to other pests, herbicide tolerance, improved nutritional value, improved performance in an industrial process or altered reproductive capability. The "gene of interest" may also be one that is transferred to plants for the production of commercially valuable enzymes or metabolites in the plant.

A "gut protease" is a protease naturally found in the digestive tract of an insect. This protease is usually involved in the digestion of ingested proteins.

A "heterologous" nucleic acid sequence is a nucleic acid sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring nucleic acid sequence.

A "homologous" nucleic acid sequence is a nucleic acid sequence naturally associated with a host cell into which it is introduced.

"Homologous recombination" is the reciprocal exchange of nucleic acid fragments between homologous nucleic acid molecules.

"Insecticidal" is defined as a toxic biological activity capable of controlling insects, preferably by killing them.

A nucleic acid sequence is "isocoding with" a reference nucleic acid sequence when the nucleic acid sequence encodes a polypeptide having the same amino acid sequence as the polypeptide encoded by the reference nucleic acid sequence.

An "isolated" nucleic acid molecule or an isolated toxin is a nucleic acid molecule or toxin that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule or toxin may exist in a purified form or may exist in a non-native environment such as, for example, a recombinant host cell.

A "modified Cry3A toxin" of this invention, refers to a Cry3A-derived toxin having at least one additional protease recognition site that is recognized by a gut protease of a target insect, which does not naturally occur in a Cry3A toxin. A modified Cry3A toxin is not naturally occurring and, by the hand of man, comprises an amino acid sequence that is not identical to a naturally occurring toxin found in *Bacillus thuringiensis*. The modified Cry3A toxin causes higher mortality to a target insect than the mortality caused by a Cry3A toxin to the same target insect.

A "modified *cry3A* gene" according to this invention, refers to a *cry3A*-derived gene comprising the coding sequence of at least one additional protease recognition site that does not naturally occur in an unmodified *cry3A* gene. The modified *cry3A* gene can be derived from a native *cry3A* gene or from a synthetic *cry3A* gene.

A "naturally occurring protease recognition site" is a location within a Cry3A toxin that is cleaved by a non-insect derived protease or by a protease or gut extract from an insect species susceptible to the Cry3A toxin. For example, a naturally occurring protease recognition site, recognized by trypsin and proteases found in a susceptible insect gut extract, exists between Arg-158 and Asn-159 of the deduced Cry3A toxin amino acid sequence (SEQ ID NO: 2). Naturally occurring protease recognition sites, recognized by chymotrypsin, exist between His-161 and Ser-162 as well as between Tyr-587 and Tyr-588 of the deduced Cry3A toxin amino acid sequence (SEQ ID NO: 2).

A "nucleic acid molecule" or "nucleic acid sequence" is a linear segment of single- or double-stranded DNA or RNA that can be isolated from any source. In the context of the present invention, the nucleic acid molecule is preferably a segment of DNA.

A "plant" is any plant at any stage of development, particularly a seed plant.

A "plant cell" is a structural and physiological unit of a plant, comprising a protoplast and a cell wall. The plant cell may be in the form of an isolated single cell or a cultured cell, or as a part of a higher organized unit such as, for example, plant tissue, a plant organ, or a whole plant.

"Plant cell culture" means cultures of plant units such as, for example, protoplasts, cell culture cells, cells in plant tissues, pollen, pollen tubes, ovules, embryo sacs, zygotes and embryos at various stages of development.

"Plant material" refers to leaves, stems, roots, flowers or flower parts, fruits, pollen, egg cells, zygotes, seeds, cuttings, cell or tissue cultures, or any other part or product of a plant.

A "plant organ" is a distinct and visibly structured and differentiated part of a plant such as a root, stem, leaf, flower bud, or embryo.

5 "Plant tissue" as used herein means a group of plant cells organized into a structural and functional unit. Any tissue of a plant *in planta* or in culture is included. This term includes, but is not limited to, whole plants, plant organs, plant seeds, tissue culture and any groups of plant cells organized into structural and/or functional units. The use of this term in conjunction with, or in the absence of, any specific type of plant tissue as listed above or
10 otherwise embraced by this definition is not intended to be exclusive of any other type of plant tissue.

A "promoter" is an untranslated DNA sequence upstream of the coding region that contains the binding site for RNA polymerase and initiates transcription of the DNA. The promoter region may also include other elements that act as regulators of gene expression.

15 A "protoplast" is an isolated plant cell without a cell wall or with only parts of the cell wall. "Regulatory elements" refer to sequences involved in controlling the expression of a nucleotide sequence. Regulatory elements comprise a promoter operably linked to the nucleotide sequence of interest and termination signals. They also typically encompass sequences required for proper translation of the nucleotide sequence.

20 "Replaces" a naturally occurring protease recognition site - According to the present invention, an additional protease recognition site "replaces" a naturally occurring protease recognition site when insertion of the additional protease recognition site eliminates the naturally occurring protease recognition site. For example, an additional protease recognition site inserted between Pro-154 and Pro-160 of the deduced amino acid sequence of a Cry3A
25 toxin (SEQ ID NO: 2) which eliminates the Arg-158 and Asn-159 residues "replaces" the naturally occurring trypsin recognition site located between Arg-158 and Asn-159 of the deduced amino acid sequence of the Cry3A toxin (SEQ ID NO: 2).

"Serine proteases", describe the same group of enzymes that catalyze the hydrolysis of covalent peptidic bonds using a mechanism based on nucleophilic attack of the targeted
30 peptidic bond by a serine. Serine proteases are sequence specific. That is, each serine protease recognizes a specific sub-sequence within a protein where enzymatic recognition occurs.

A "target insect" is an insect pest species that has little or no susceptibility to a Cry3A toxin and is identified as being a candidate for using the technology of the present invention to control. This control can be achieved through several means but most preferably through the expression of the nucleic acid molecules of the invention in transgenic plants.

5 A "target insect gut protease" is a protease found in the gut of a target insect whose recognition site can be inserted into a Cry3A toxin to create a modified Cry3A toxin of the invention.

"Transformation" is a process for introducing heterologous nucleic acid into a host cell or organism. In particular, "transformation" means the stable integration of a DNA molecule into
10 the genome of an organism of interest.

"Transformed / transgenic / recombinant" refer to a host organism such as a bacterium or a plant into which a heterologous nucleic acid molecule has been introduced. The nucleic acid molecule can be stably integrated into the genome of the host or the nucleic acid molecule can also be present as an extrachromosomal molecule. Such an extrachromosomal molecule can
15 be auto-replicating. Transformed cells, tissues, or plants are understood to encompass not only the end product of a transformation process, but also transgenic progeny thereof. A "non-transformed", "non-transgenic", or "non-recombinant" host refers to a wild-type organism, e.g., a bacterium or plant, which does not contain the heterologous nucleic acid molecule.

"Within" a naturally occurring protease recognition site – According to the present invention,
20 an additional protease recognition site is "within" a naturally occurring protease recognition site when the additional protease recognition site lies between the amino acid residue that comes before and the amino acid residue that comes after the naturally occurring protease recognition site. For example, an additional protease recognition site inserted between Tyr-587 and Tyr-588 of the deduced amino acid sequence of a Cry3A toxin (SEQ ID NO: 2) is
25 "within" a naturally occurring chymotrypsin recognition site located between Tyr-587 and Tyr-588 of the deduced amino acid sequence of the Cry3A toxin (SEQ ID NO: 2). The insertion of an additional protease recognition site within a naturally occurring protease recognition site may or may not change the recognition of the naturally occurring protease recognition site by a protease.

30 Nucleotides are indicated by their bases by the following standard abbreviations: adenine (A), cytosine (C), thymine (T), and guanine (G). Amino acids are likewise indicated by the

following standard abbreviations: alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C), glutamine (Gln; Q), glutamic acid (Glu; E), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T),
5 tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).

This invention relates to modified *cry3A* nucleic acid sequences whose expression results in modified Cry3A toxins, and to the making and using of the modified Cry3A toxins to control insect pests. The expression of the modified *cry3A* nucleic acid sequences results in modified
10 Cry3A toxins that can be used to control coleopteran insects such as western corn rootworm and northern corn rootworm. A modified Cry3A toxin of the present invention comprises at least one additional protease recognition site that does not naturally occur in a Cry3A toxin. The additional protease recognition site, which is recognized by a gut protease of a target insect, is inserted at approximately the same position as a naturally occurring protease
15 recognition site in a Cry3A toxin. The modified Cry3A toxin causes higher mortality to a target insect than the mortality caused by a Cry3A toxin to the same target insect. Preferably, the modified Cry3A toxin causes at least about 50 % mortality to the target insect to which a Cry3A toxin causes up to about 30% mortality.

In one preferred embodiment, the invention encompasses an isolated nucleic acid molecule
20 that encodes a modified Cry3A toxin, wherein the additional protease recognition site is recognized by the target insect gut protease, cathepsin G. Cathepsin G activity is determined to be present in the gut of the target insect, western corn rootworm, as described in Example 2. Preferably, the substrate amino acid sequence, AAPF (SEQ ID NO: 35), used to determine the presence of the cathepsin G activity is inserted into the Cry3A toxin according to the
25 present invention. Other cathepsin G recognition sites can also be used according to the present invention, for example, AAPM (SEQ ID NO: 36), AVPF (SEQ ID NO: 37), PFLF (SEQ ID NO: 38) or other cathepsin G recognition sites as determined by the method of Tanaka *et al.*, 1985 (Biochemistry 24:2040-2047), incorporated herein by reference. Protease recognition sites of other proteases identified in a target insect gut can be used, for example,
30 protease recognition sites recognized by other serine proteases, cysteine proteases and aspartic

proteases. Preferable serine proteases encompassed by this embodiment include trypsin, chymotrypsin, carboxypeptidase, endopeptidase and elastase.

In another preferred embodiment, the invention encompasses an isolated nucleic acid molecule that encodes a modified Cry3A toxin wherein the additional protease recognition site is inserted in either domain I or domain III or in both domain I and domain III of the Cry3A toxin. Preferably, the additional protease recognition site is inserted in domain I, domain III, or domain I and domain III at a position that replaces, is adjacent to, or is within a naturally occurring protease recognition site in the Cry3A toxin. Specifically exemplified herein are nucleic acid molecules that encode modified Cry3A toxins that comprise a cathepsin G recognition site inserted in domain I, domain III, or domain I and domain III at a position that replaces, is adjacent to, or is within a naturally occurring protease recognition site in the unmodified Cry3A toxin.

Specifically exemplified teachings of methods to make modified *cry3A* nucleic acid molecules that encode modified Cry3A toxins can be found in Example 3. Those skilled in the art will recognize that other methods known in the art can also be used to insert additional protease recognition sites into Cry3A toxins according to the present invention.

In another preferred embodiment, the invention encompasses an isolated nucleic acid molecule that encodes a modified Cry3A toxin wherein the additional protease recognition site is inserted in domain I between amino acids corresponding to amino acid numbers 154 and 162 of SEQ ID NO: 2. Preferably, the additional protease recognition site is inserted between amino acid numbers 154 and 162 of SEQ ID NO: 2 or between amino acid numbers 107 and 115 of SEQ ID NO: 4. In a preferred embodiment, the additional protease recognition site is inserted between amino acids corresponding to amino acid numbers 154 and 160 of SEQ ID NO: 2. Preferably, the additional protease recognition site is inserted between amino acid number 154 and 160 of SEQ ID NO: 2 or between amino acid numbers 107 and 113 of SEQ ID NO: 4. Specifically exemplified herein is a nucleic acid molecule, designated *cry3A054* (SEQ ID NO: 6), that encodes the modified Cry3A054 toxin (SEQ ID NO: 7) comprising a cathepsin G recognition site inserted in domain I between amino acid numbers 107 and 113 of SEQ ID NO: 4. The cathepsin G recognition site replaces a naturally occurring trypsin recognition site and is adjacent to a naturally occurring chymotrypsin recognition site. When expressed in a heterologous host, the nucleic acid molecule of SEQ ID

NO: 6 results in insect control activity against western corn rootworm and northern corn rootworm, showing that the nucleic acid sequence set forth in SEQ ID NO: 6 is sufficient for such insect control activity.

In another preferred embodiment, the additional protease recognition site is inserted in domain

I between amino acids corresponding to amino acid numbers 154 and 158 of SEQ ID NO: 2.

Preferably, the additional protease recognition site is inserted in domain I between amino acid numbers 154 and 158 of SEQ ID NO: 2 or between amino acid numbers 107 and 111 of SEQ ID NO: 4. Specifically exemplified herein are nucleic acid molecules, designated *cry3A055*

(SEQ ID NO: 8), that encodes the modified Cry3A055 toxin (SEQ ID NO: 9), and *cry3A085*

(SEQ ID NO: 10), that encodes the modified Cry3A085 toxin (SEQ ID NO: 11), comprising a cathepsin G recognition site inserted in domain I between amino acid numbers 107 and 111 of

SEQ ID NO: 4. The cathepsin G recognition site is adjacent to naturally occurring trypsin and chymotrypsin recognition sites. When expressed in a heterologous host, the nucleic acid molecule of SEQ ID NO: 8 or SEQ ID NO: 10 results in insect control activity against western

corn rootworm and northern corn rootworm, showing that the nucleic acid sequence set forth in SEQ ID NO: 8 or SEQ ID NO: 10 is sufficient for such insect control activity.

In a preferred embodiment, the invention encompasses an isolated nucleic acid molecule that encodes a modified Cry3A toxin wherein the additional protease recognition site is inserted in domain III between amino acids corresponding to amino acid numbers 583 and 589 of SEQ

ID NO: 2. Preferably, the additional protease site is inserted in domain III between amino acid numbers 583 and 589 of SEQ ID NO: 2 or between amino acid numbers 536 and 542 of SEQ ID NO: 4.

In another preferred embodiment, the invention encompasses an isolated nucleic acid

molecule that encodes a modified Cry3A toxin wherein the additional protease recognition

site is inserted in domain III between amino acids corresponding to amino acid numbers 583 and 588 of SEQ ID NO: 2. Preferably, the additional protease site is inserted in domain III

between amino acid numbers 583 and 588 of SEQ ID NO: 2 or between amino acid numbers 536 and 541 of SEQ ID NO: 4. Specifically exemplified herein is a nucleic acid molecule,

designated *cry3A082* (SEQ ID NO: 12), that encodes the modified Cry3A082 toxin (SEQ ID

NO: 13) comprising a cathepsin G recognition site inserted in domain III between amino acid numbers 536 and 541 of SEQ ID NO: 4. The cathepsin G recognition site replaces a naturally

occurring chymotrypsin recognition site. When expressed in a heterologous host, the nucleic acid molecule of SEQ ID NO: 12 results in insect control activity against western corn rootworm and northern corn rootworm, showing that the nucleic acid sequence set forth in SEQ ID NO: 12 is sufficient for such insect control activity.

5 In another preferred embodiment, the additional protease recognition site is inserted in domain III between amino acids corresponding to amino acid numbers 587 and 588 of SEQ ID NO: 2. Preferably, the additional protease site is inserted in domain III between amino acid numbers 587 and 588 of SEQ ID NO: 2 or between amino acid numbers 540 and 541 of SEQ ID NO: 4. Specifically exemplified herein is a nucleic acid molecule, designated *cry3A058* (SEQ ID NO: 14), that encodes the modified Cry3A058 toxin (SEQ ID NO: 15) comprising a cathepsin G recognition site inserted in domain III between amino acid numbers 540 and 541 of SEQ ID NO: 4. The cathepsin G recognition site is within a naturally occurring chymotrypsin recognition site. When expressed in a heterologous host, the nucleic acid molecule of SEQ ID NO: 14 results in insect control activity against western corn rootworm and northern corn rootworm, showing that the nucleic acid sequence set forth in SEQ ID NO: 14 is sufficient for such insect control activity.

In yet another preferred embodiment, the invention encompasses an isolated nucleic acid molecule that encodes a modified Cry3A toxin wherein the additional protease recognition site is inserted in domain I between amino acids corresponding to amino acid numbers 154 and 160 and in domain III between amino acids corresponding to amino acid numbers 587 and 588 of SEQ ID NO: 2. Preferably, the additional protease recognition site is inserted in domain I between amino acid numbers 154 and 160 and in domain III between amino acid numbers 587 and 588 of SEQ ID NO: 2 or in domain I between amino acid numbers 107 and 113 and in domain III between amino acid numbers 540 and 541 of SEQ ID NO: 4.

25 Specifically exemplified herein is a nucleic acid molecule, designated *cry3A057* (SEQ ID NO: 16), that encodes the modified Cry3A057 toxin (SEQ ID NO: 17) comprising a cathepsin G recognition site inserted in domain I between amino acid numbers 107 and 113 and in domain III between amino acid numbers 540 and 541 of SEQ ID NO: 4. The cathepsin G recognition site replaces a naturally occurring trypsin recognition site and is adjacent to a naturally occurring chymotrypsin recognition site in domain I and is within a naturally occurring chymotrypsin recognition site in domain III. When expressed in a heterologous host, the

nucleic acid molecule of SEQ ID NO: 16 results in insect control activity against western corn rootworm and northern corn rootworm, showing that the nucleic acid sequence set forth in SEQ ID NO: 16 is sufficient for such insect control activity.

In yet another preferred embodiment, the additional protease recognition site is located in domain I between amino acids corresponding to amino acid numbers 154 and 158 and in domain III between amino acids corresponding to amino acid numbers 587 and 588 of SEQ ID NO: 2. Preferably, the additional protease recognition site is inserted in domain I between amino acid numbers 154 and 158 and in domain III between amino acid numbers 587 and 588 of SEQ ID NO: 2 or in domain I between amino acid numbers 107 and 111 and in domain III between amino acid numbers 540 and 541 of SEQ ID NO: 4. Specifically exemplified herein is the nucleic acid molecule designated *cry3A056* (SEQ ID NO: 18), which encodes the modified Cry3A056 toxin (SEQ ID NO: 19) comprising a cathepsin G recognition site inserted in domain I between amino acid numbers 107 and 111 and in domain III between amino acid numbers 540 and 541 of SEQ ID NO: 4. The cathepsin G recognition site is adjacent to naturally occurring trypsin and chymotrypsin recognition sites in domain I and is within a naturally occurring chymotrypsin recognition site in domain III. When expressed in a heterologous host, the nucleic acid molecule of SEQ ID NO: 18 results in insect control activity against western corn rootworm and northern corn rootworm, showing that the nucleic acid sequence set forth in SEQ ID NO: 18 is sufficient for such insect control activity.

In still another preferred embodiment, the additional protease recognition site is located in domain I between amino acids corresponding to amino acid numbers 154 and 158 and in domain III between amino acids corresponding to amino acid numbers 583 and 588 of SEQ ID NO: 2. Preferably, the additional protease recognition site is inserted in domain I between amino acid numbers 154 and 158 and in domain III between amino acid numbers 583 and 588 of SEQ ID NO: 2 or in domain I between amino acid numbers 107 and 111 and in domain III between amino acid numbers 536 and 541 of SEQ ID NO: 4. Specifically exemplified herein is a nucleic acid molecule, designated *cry3A083* (SEQ ID NO: 20), which encodes the modified Cry3A083 toxin (SEQ ID NO: 21) comprising a cathepsin G recognition site inserted in domain I between amino acid numbers 107 and 111 and in domain III between amino acid numbers 536 and 541 of SEQ ID NO: 4. The cathepsin G recognition site is adjacent to naturally occurring trypsin and chymotrypsin recognition sites in domain I and

replaces a naturally occurring chymotrypsin recognition site in domain III. When expressed in a heterologous host, the nucleic acid molecule of SEQ ID NO: 20 results in insect control activity against western corn rootworm and northern corn rootworm, showing that the nucleic acid sequence set forth in SEQ ID NO: 20 is sufficient for such insect control activity.

5 In a preferred embodiment, the isolated nucleic acid molecule of the present invention comprises nucleotides 1-1791 of SEQ ID NO: 6, nucleotides 1-1806 of SEQ ID NO: 8, nucleotides 1-1812 of SEQ ID NO: 10, nucleotides 1-1794 of SEQ ID NO: 12, nucleotides 1-1818 of SEQ ID NO: 14, nucleotides 1-1812 of SEQ ID NO: 16, nucleotides 1-1791 of SEQ ID NO: 18, and nucleotides 1-1818 of SEQ ID NO: 20.

10 In another preferred embodiment, the invention encompasses the isolated nucleic acid molecule that encodes a modified Cry3A toxin comprising the amino acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21.

The present invention also encompasses recombinant vectors comprising the nucleic acid sequences of this invention. In such vectors, the nucleic acid sequences are preferably comprised in expression cassettes comprising regulatory elements for expression of the nucleotide sequences in a host cell capable of expressing the nucleotide sequences. Such regulatory elements usually comprise promoter and termination signals and preferably also comprise elements allowing efficient translation of polypeptides encoded by the nucleic acid sequences of the present invention. Vectors comprising the nucleic acid sequences are usually capable of replication in particular host cells, preferably as extrachromosomal molecules, and are therefore used to amplify the nucleic acid sequences of this invention in the host cells. In one embodiment, host cells for such vectors are microorganisms, such as bacteria, in particular *Bacillus thuringiensis* or *E. coli*. In another embodiment, host cells for such recombinant vectors are endophytes or epiphytes. A preferred host cell for such vectors is a eukaryotic cell, such as a plant cell. Plant cells such as maize cells are most preferred host cells. In another preferred embodiment, such vectors are viral vectors and are used for replication of the nucleotide sequences in particular host cells, e.g. insect cells or plant cells. Recombinant vectors are also used for transformation of the nucleotide sequences of this invention into host cells, whereby the nucleotide sequences are stably integrated into the DNA of such host cells. In one, such host cells are prokaryotic cells. In a preferred embodiment,

15
20
25
30

such host cells are eukaryotic cells, such as plant cells. In a most preferred embodiment, the host cells are plant cells, such as maize cells.

In another aspect, the present invention encompasses modified Cry3A toxins produced by the expression of the nucleic acid molecules of the present invention.

- 5 In preferred embodiments, the modified Cry3A toxins of the invention comprise a polypeptide encoded by a nucleotide sequence of the invention. In a further preferred embodiment, the modified Cry3A toxin is produced by the expression of the nucleic acid molecule comprising nucleotides 1-1791 of SEQ ID NO: 6, nucleotides 1-1806 of SEQ ID NO: 8, nucleotides 1-1812 of SEQ ID NO: 10, nucleotides 1-1794 of SEQ ID NO: 12, nucleotides 1-1818 of SEQ ID NO: 14, nucleotides 1-1812 of SEQ ID NO: 16, nucleotides 1-1791 of SEQ ID NO: 18, and nucleotides 1-1818 of SEQ ID NO: 20.

In a preferred embodiment, a modified Cry3A toxin of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21.

- 15 The modified Cry3A toxins of the present invention have insect control activity when tested against insect pests in bioassays. In another preferred embodiment, the modified Cry3A toxins of the invention are active against coleopteran insects, preferably against western corn rootworm and northern corn rootworm. The insect controlling properties of the modified Cry3A toxins of the invention are further illustrated in Examples 4 and 6.

- 20 The present invention also encompasses a composition comprising an effective insect-controlling amount of a modified Cry3A toxin according to the invention.

- In another preferred embodiment, the invention encompasses a method of producing a modified Cry3A toxin that is active against insects, comprising: (a) obtaining a host cell comprising a chimeric gene, which itself comprises a heterologous promoter sequence
25 operatively linked to the nucleic acid molecule of the invention; and (b) expressing the nucleic acid molecule in the transgenic host cell, which results in at least one modified Cry3A toxin that is active against insects.

- In a further preferred embodiment, the invention encompasses a method of producing an insect-resistant transgenic plant, comprising introducing a nucleic acid molecule of the invention into the transgenic plant, wherein the nucleic acid molecule is expressible in the
30 transgenic plant in an effective amount to control insects. In a preferred embodiment, the

insects are coleopteran insects, preferably western corn rootworm and northern corn rootworm.

In yet a further preferred embodiment, the invention encompasses a method of controlling insects, comprising delivering to the insects an effective amount of a modified Cry3A toxin of the invention. According to this embodiment, the insects are coleopteran insects, preferably, western corn rootworm and northern corn rootworm. Preferably, the modified Cry3A toxin is delivered to the insects orally. In one preferred aspect, the toxin is delivered orally through a transgenic plant comprising a nucleic acid sequence that expresses a modified Cry3A toxin of the present invention.

The present invention also encompasses a method of making a modified Cry3A toxin, comprising: (a) obtaining a *cry3A* toxin gene which encodes a Cry3A toxin; (b) identifying a gut protease of a target insect; (c) obtaining a nucleotide sequence which encodes a recognition site for the gut protease; (d) inserting the nucleotide sequence of (c) into either domain I or domain III or both domain I and domain III at a position that replaces, is within, or adjacent to a nucleotide sequence that codes for a naturally occurring protease recognition site in the *cry3A* toxin gene, thus creating a modified *cry3A* toxin gene; (e) inserting the modified *cry3A* toxin gene in an expression cassette; (f) expressing the modified *cry3A* toxin gene in a non-human host cell, resulting in the host cell producing a modified Cry3A toxin; and, (g) bioassaying the modified Cry3A toxin against a target insect, which causes higher mortality to the target insect than the mortality caused by a Cry3A toxin. In a preferred embodiment, the modified Cry3A toxin causes at least about 50% mortality to the target insect when the Cry3A toxin causes up to about 30% mortality.

The present invention further encompasses a method of controlling insects wherein the transgenic plant further comprises a second nucleic acid sequence or groups of nucleic acid sequences that encode a second pesticidal principle. Particularly preferred second nucleic acid sequences are those that encode a δ -endotoxin, those that encode a Vegetative Insecticidal Protein toxin, disclosed in U.S. Patents 5,849,870 and 5,877,012, incorporated herein by reference, or those that encode a pathway for the production of a non-proteinaceous principle. In further embodiments, the nucleotide sequences of the invention can be further modified by incorporation of random mutations in a technique known as *in vitro* recombination or DNA shuffling. This technique is described in Stemmer *et al.*, Nature 370:389-391 (1994) and U.S.

Patent 5,605,793, which are incorporated herein by reference. Millions of mutant copies of a nucleotide sequence are produced based on an original nucleotide sequence of this invention and variants with improved properties, such as increased insecticidal activity, enhanced stability, or different specificity or ranges of target-insect pests are recovered. The method encompasses forming a mutagenized double-stranded polynucleotide from a template double-stranded polynucleotide comprising a nucleotide sequence of this invention, wherein the template double-stranded polynucleotide has been cleaved into double-stranded-random fragments of a desired size, and comprises the steps of adding to the resultant population of double-stranded random fragments one or more single or double-stranded oligonucleotides, wherein said oligonucleotides comprise an area of identity and an area of heterology to the double-stranded template polynucleotide; denaturing the resultant mixture of double-stranded random fragments and oligonucleotides into single-stranded fragments; incubating the resultant population of single-stranded fragments with a polymerase under conditions which result in the annealing of said single-stranded fragments at said areas of identity to form pairs of annealed fragments, said areas of identity being sufficient for one member of a pair to prime replication of the other, thereby forming a mutagenized double-stranded polynucleotide; and repeating the second and third steps for at least two further cycles, wherein the resultant mixture in the second step of a further cycle includes the mutagenized double-stranded polynucleotide from the third step of the previous cycle, and the further cycle forms a further mutagenized double-stranded polynucleotide. In a preferred embodiment, the concentration of a single species of double-stranded random fragment in the population of double-stranded random fragments is less than 1% by weight of the total DNA. In a further preferred embodiment, the template double-stranded polynucleotide comprises at least about 100 species of polynucleotides. In another preferred embodiment, the size of the double-stranded random fragments is from about 5 bp to 5 kb. In a further preferred embodiment, the fourth step of the method comprises repeating the second and the third steps for at least 10 cycles.

Expression of the Nucleotide Sequences in Heterologous Microbial Hosts

As biological insect control agents, the insecticidal modified Cry3A toxins are produced by expression of the nucleotide sequences in heterologous host cells capable of expressing the

nucleotide sequences. In a first embodiment, *B. thuringiensis* cells comprising modifications of a nucleotide sequence of this invention are made. Such modifications encompass mutations or deletions of existing regulatory elements, thus leading to altered expression of the nucleotide sequence, or the incorporation of new regulatory elements controlling the expression of the nucleotide sequence. In another embodiment, additional copies of one or more of the nucleotide sequences are added to *Bacillus thuringiensis* cells either by insertion into the chromosome or by introduction of extrachromosomally replicating molecules containing the nucleotide sequences.

In another embodiment, at least one of the nucleotide sequences of the invention is inserted into an appropriate expression cassette, comprising a promoter and termination signal.

Expression of the nucleotide sequence is constitutive, or an inducible promoter responding to various types of stimuli to initiate transcription is used. In a preferred embodiment, the cell in which the toxin is expressed is a microorganism, such as a virus, bacteria, or a fungus. In a preferred embodiment, a virus, such as a baculovirus, contains a nucleotide sequence of the invention in its genome and expresses large amounts of the corresponding insecticidal toxin after infection of appropriate eukaryotic cells that are suitable for virus replication and expression of the nucleotide sequence. The insecticidal toxin thus produced is used as an insecticidal agent. Alternatively, baculoviruses engineered to include the nucleotide sequence are used to infect insects *in vivo* and kill them either by expression of the insecticidal toxin or by a combination of viral infection and expression of the insecticidal toxin.

Bacterial cells are also hosts for the expression of the nucleotide sequences of the invention.

In a preferred embodiment, non-pathogenic symbiotic bacteria, which are able to live and replicate within plant tissues, so-called endophytes, or non-pathogenic symbiotic bacteria, which are capable of colonizing the phyllosphere or the rhizosphere, so-called epiphytes, are used. Such bacteria include bacteria of the genera *Agrobacterium*, *Alcaligenes*, *Azospirillum*, *Azotobacter*, *Bacillus*, *Clavibacter*, *Enterobacter*, *Erwinia*, *Flavobacter*, *Klebsiella*, *Pseudomonas*, *Rhizobium*, *Serratia*, *Streptomyces* and *Xanthomonas*. Symbiotic fungi, such as *Trichoderma* and *Gliocladium* are also possible hosts for expression of the inventive nucleotide sequences for the same purpose.

Techniques for these genetic manipulations are specific for the different available hosts and are known in the art. For example, the expression vectors pKK223-3 and pKK223-2 can be

used to express heterologous genes in *E. coli*, either in transcriptional or translational fusion, behind the *tac* or *trc* promoter. For the expression of operons encoding multiple ORFs, the simplest procedure is to insert the operon into a vector such as pKK223-3 in transcriptional fusion, allowing the cognate ribosome binding site of the heterologous genes to be used.

5 Techniques for overexpression in gram-positive species such as *Bacillus* are also known in the art and can be used in the context of this invention (Quax et al. In: Industrial Microorganisms: Basic and Applied Molecular Genetics, Eds. Baltz *et al.*, American Society for Microbiology, Washington (1993)). Alternate systems for overexpression rely for example, on yeast vectors and include the use of *Pichia*, *Saccharomyces* and *Kluyveromyces* (Sreekrishna, In: Industrial microorganisms: basic and applied molecular genetics, Baltz, 10 Hegeman, and Skatrud eds., American Society for Microbiology, Washington (1993); Dequin & Barre, Biotechnology L2:173-177 (1994); van den Berg *et al.*, Biotechnology 8:135-139 (1990)).

15 Plant transformation

In a particularly preferred embodiment, at least one of the insecticidal modified Cry3A toxins of the invention is expressed in a higher organism, e.g., a plant. In this case, transgenic plants expressing effective amounts of the modified Cry3A toxins protect themselves from insect pests. When the insect starts feeding on such a transgenic plant, it also ingests the expressed 20 modified Cry3A toxins. This will deter the insect from further biting into the plant tissue or may even harm or kill the insect. A nucleotide sequence of the present invention is inserted into an expression cassette, which is then preferably stably integrated in the genome of said plant. In another preferred embodiment, the nucleotide sequence is included in a non-pathogenic self-replicating virus. Plants transformed in accordance with the present invention 25 may be monocots or dicots and include, but are not limited to, maize, wheat, barley, rye, sweet potato, bean, pea, chicory, lettuce, cabbage, cauliflower, broccoli, turnip, radish, spinach, asparagus, onion, garlic, pepper, celery, squash, pumpkin, hemp, zucchini, apple, pear, quince, melon, plum, cherry, peach, nectarine, apricot, strawberry, grape, raspberry, blackberry, pineapple, avocado, papaya, mango, banana, soybean, tomato, sorghum, sugarcane, sugar

beet, sunflower, rapeseed, clover, tobacco, carrot, cotton, alfalfa, rice, potato, eggplant, cucumber, Arabidopsis, and woody plants such as coniferous and deciduous trees.

Once a desired nucleotide sequence has been transformed into a particular plant species, it may be propagated in that species or moved into other varieties of the same species,

5 particularly including commercial varieties, using traditional breeding techniques.

A nucleotide sequence of this invention is preferably expressed in transgenic plants, thus causing the biosynthesis of the corresponding modified Cry3A toxin in the transgenic plants.

In this way, transgenic plants with enhanced resistance to insects are generated. For their expression in transgenic plants, the nucleotide sequences of the invention may require other

10 modifications and optimization. Although in many cases genes from microbial organisms can be expressed in plants at high levels without modification, low expression in transgenic plants may result from microbial nucleotide sequences having codons that are not preferred in plants.

It is known in the art that all organisms have specific preferences for codon usage, and the codons of the nucleotide sequences described in this invention can be changed to conform

15 with plant preferences, while maintaining the amino acids encoded thereby. Furthermore, high expression in plants is best achieved from coding sequences that have at least about 35% GC content, preferably more than about 45%, more preferably more than about 50%, and most preferably more than about 60%. Microbial nucleotide sequences that have low GC contents

20 may express poorly in plants due to the existence of ATTTA motifs that may destabilize messages, and AATAAA motifs that may cause inappropriate polyadenylation. Although preferred gene sequences may be adequately expressed in both monocotyledonous and dicotyledonous plant species, sequences can be modified to account for the specific codon preferences and GC content preferences of monocotyledons or dicotyledons as these preferences have been shown to differ (Murray *et al.* Nucl. Acids Res. 17:477-498 (1989)). In

25 addition, the nucleotide sequences are screened for the existence of illegitimate splice sites that may cause message truncation. All changes required to be made within the nucleotide sequences such as those described above are made using well known techniques of site directed mutagenesis, PCR, and synthetic gene construction using the methods described in the published patent applications EP 0 385 962 (to Monsanto), EP 0 359 472 (to Lubrizol, and
30 WO 93/07278 (to Ciba-Geigy).

In one embodiment of the invention a *cry3A* gene is made according to the procedure disclosed in U.S. Patent 5,625,136, herein incorporated by reference. In this procedure, maize preferred codons, i.e., the single codon that most frequently encodes that amino acid in maize, are used. The maize preferred codon for a particular amino acid might be derived, for example, from known gene sequences from maize. Maize codon usage for 28 genes from maize plants is found in Murray et al., Nucleic Acids Research 17:477-498 (1989), the disclosure of which is incorporated herein by reference. A synthetic sequence made with maize optimized codons is set forth in SEQ ID NO: 3.

In this manner, the nucleotide sequences can be optimized for expression in any plant. It is recognized that all or any part of the gene sequence may be optimized or synthetic. That is, synthetic or partially optimized sequences may also be used.

For efficient initiation of translation, sequences adjacent to the initiating methionine may require modification. For example, they can be modified by the inclusion of sequences known to be effective in plants. Joshi has suggested an appropriate consensus for plants (NAR 15:6643-6653 (1987)) and Clontech suggests a further consensus translation initiator (1993/1994 catalog, page 210). These consensus are suitable for use with the nucleotide sequences of this invention. The sequences are incorporated into constructions comprising the nucleotide sequences, up to and including the ATG (whilst leaving the second amino acid unmodified), or alternatively up to and including the GTC subsequent to the ATG (with the possibility of modifying the second amino acid of the transgene).

Expression of the nucleotide sequences in transgenic plants is driven by promoters that function in plants. The choice of promoter will vary depending on the temporal and spatial requirements for expression, and also depending on the target species. Thus, expression of the nucleotide sequences of this invention in leaves, in stalks or stems, in ears, in inflorescences (e.g. spikes, panicles, cobs, etc.), in roots, and/or seedlings is preferred. In many cases, however, protection against more than one type of insect pest is sought, and thus expression in multiple tissues is desirable. Although many promoters from dicotyledons have been shown to be operational in monocotyledons and vice versa, ideally dicotyledonous promoters are selected for expression in dicotyledons, and monocotyledonous promoters for expression in monocotyledons. However, there is no restriction to the provenance of selected promoters; it

is sufficient that they are operational in driving the expression of the nucleotide sequences in the desired cell.

Preferred promoters that are expressed constitutively include promoters from genes encoding actin or ubiquitin and the CaMV 35S and 19S promoters. The nucleotide sequences of this

invention can also be expressed under the regulation of promoters that are chemically regulated. This enables the insecticidal modified Cry3A toxins to be synthesized only when the crop plants are treated with the inducing chemicals. Preferred technology for chemical induction of gene expression is detailed in the published application EP 0 332 104 (to Ciba-Geigy) and U.S. Patent 5,614,395. A preferred promoter for chemical induction is the tobacco PR-1a promoter.

A preferred category of promoters is that which is wound inducible. Numerous promoters have been described which are expressed at wound sites and also at the sites of phytopathogen infection. Ideally, such a promoter should only be active locally at the sites of infection, and in this way the insecticidal modified Cry3A toxins only accumulate in cells that need to

synthesize the insecticidal modified Cry3A toxins to kill the invading insect pest. Preferred promoters of this kind include those described by Stanford *et al.* Mol. Gen. Genet. 215:200-208 (1989), Xu *et al.* Plant Molec. Biol. 22:573-588 (1993), Logemann *et al.* Plant Cell 1:151-158 (1989), Rohrmeier & Lehle, Plant Molec. Biol. 22:783-792 (1993), Firek *et al.* Plant Molec. Biol. 22:129-142 (1993), and Warner *et al.* Plant J. 3:191-201 (1993).

Tissue-specific or tissue-preferential promoters useful for the expression of the modified Cry3A toxin genes in plants, particularly maize, are those which direct expression in root, pith, leaf or pollen, particularly root. Such promoters, e.g. those isolated from PEPC or trpA, are disclosed in U.S. Pat. No. 5,625,136, or MTL, disclosed in U.S. Pat. No. 5,466,785. Both U. S. patents are herein incorporated by reference in their entirety.

Further preferred embodiments are transgenic plants expressing the nucleotide sequences in a wound-inducible or pathogen infection-inducible manner.

In addition to promoters, a variety of transcriptional terminators are also available for use in chimeric gene construction using the modified Cry3A toxin genes of the present invention.

Transcriptional terminators are responsible for the termination of transcription beyond the

transgene and its correct polyadenylation. Appropriate transcriptional terminators and those that are known to function in plants include the CaMV 35S terminator, the tml terminator, the

nopaline synthase terminator, the pea *rbcs* E9 terminator and others known in the art. These can be used in both monocotyledons and dicotyledons. Any available terminator known to function in plants can be used in the context of this invention.

Numerous other sequences can be incorporated into expression cassettes described in this invention. These include sequences that have been shown to enhance expression such as intron sequences (e.g. from *Adhl* and *bronzel*) and viral leader sequences (e.g. from TMV, MCMV and AMV).

It may be preferable to target expression of the nucleotide sequences of the present invention to different cellular localizations in the plant. In some cases, localization in the cytosol may be desirable, whereas in other cases, localization in some subcellular organelle may be preferred. Subcellular localization of transgene-encoded enzymes is undertaken using techniques well known in the art. Typically, the DNA encoding the target peptide from a known organelle-targeted gene product is manipulated and fused upstream of the nucleotide sequence. Many such target sequences are known for the chloroplast and their functioning in heterologous constructions has been shown. The expression of the nucleotide sequences of the present invention is also targeted to the endoplasmic reticulum or to the vacuoles of the host cells. Techniques to achieve this are well known in the art.

Vectors suitable for plant transformation are described elsewhere in this specification. For *Agrobacterium*-mediated transformation, binary vectors or vectors carrying at least one T-DNA border sequence are suitable, whereas for direct gene transfer any vector is suitable and linear DNA containing only the construction of interest may be preferred. In the case of direct gene transfer, transformation with a single DNA species or co-transformation can be used (Schocher *et al.* *Biotechnology* 4:1093- 1096 (1986)). For both direct gene transfer and *Agrobacterium*-mediated transfer, transformation is usually (but not necessarily) undertaken with a selectable marker that may provide resistance to an antibiotic (kanamycin, hygromycin or methotrexate) or a herbicide (basta). Plant transformation vectors comprising the modified *Cry3A* toxin genes of the present invention may also comprise genes (e.g. phosphomannose isomerase; *PMI*) which provide for positive selection of the transgenic plants as disclosed in U.S. Patents 5,767,378 and 5,994,629, herein incorporated by reference. The choice of selectable marker is not, however, critical to the invention.

In another embodiment, a nucleotide sequence of the present invention is directly transformed into the plastid genome. A major advantage of plastid transformation is that plastids are generally capable of expressing bacterial genes without substantial codon optimization, and plastids are capable of expressing multiple open reading frames under control of a single promoter. Plastid transformation technology is extensively described in U.S. Patent Nos. 5,451,513, 5,545,817, and 5,545,818, in PCT application no. WO 95/16783, and in McBride *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91, 7301-7305. The basic technique for chloroplast transformation involves introducing regions of cloned plastid DNA flanking a selectable marker together with the gene of interest into a suitable target tissue, e.g., using biolistics or protoplast transformation (e.g., calcium chloride or PEG mediated transformation). The 1 to 1.5 kb flanking regions, termed targeting sequences, facilitate homologous recombination with the plastid genome and thus allow the replacement or modification of specific regions of the plastome. Initially, point mutations in the chloroplast 16S rRNA and *rps12* genes conferring resistance to spectinomycin and/or streptomycin are utilized as selectable markers for transformation (Svab, Z., Hajdukiewicz, P., and Maliga, P. (1990) *Proc. Natl. Acad. Sci. USA* 87, 8526-8530; Staub, J. M., and Maliga, P. (1992) *Plant Cell* 4, 39-45). This resulted in stable homoplasmic transformants at a frequency of approximately one per 100 bombardments of target leaves. The presence of cloning sites between these markers allowed creation of a plastid targeting vector for introduction of foreign genes (Staub, J.M., and Maliga, P. (1993) *EMBO J.* 12, 601-606). Substantial increases in transformation frequency are obtained by replacement of the recessive rRNA or r-protein antibiotic resistance genes with a dominant selectable marker, the bacterial *aadA* gene encoding the spectinomycin-cleaving enzyme aminoglycoside- 3'- adenylyltransferase (Svab, Z., and Maliga, P. (1993) *Proc. Natl. Acad. Sci. USA* 90, 913-917). Previously, this marker had been used successfully for high-frequency transformation of the plastid genome of the green alga *Chlamydomonas reinhardtii* (Goldschmidt- Clermont, M. (1991) *Nucl. Acids Res.* 19:4083-4089). Other selectable markers useful for plastid transformation are known in the art and encompassed within the scope of the invention. Typically, approximately 15-20 cell division cycles following transformation are required to reach a homoplastidic state. Plastid expression, in which genes are inserted by homologous recombination into all of the several thousand copies of the circular plastid genome present in each plant cell, takes advantage of the enormous copy

number advantage over nuclear- expressed genes to permit expression levels that can readily exceed 10% of the total soluble plant protein. In a preferred embodiment, a nucleotide sequence of the present invention is inserted into a plastid-targeting vector and transformed into the plastid genome of a desired plant host. Plants homoplastic for plastid genomes
5 containing a nucleotide sequence of the present invention are obtained, and are preferentially capable of high expression of the nucleotide sequence.

Combinations of Insect Control Principles

The modified Cry3A toxins of the invention can be used in combination with Bt δ -endotoxins
10 or other pesticidal principles to increase pest target range. Furthermore, the use of the modified Cry3A toxins of the invention in combination with Bt δ -endotoxins or other pesticidal principles of a distinct nature has particular utility for the prevention and/or management of insect resistance.

Other insecticidal principles include, for example, lectins, α -amylase, peroxidase and
15 cholesterol oxidase. Vegetative Insecticidal Protein genes, such as *vip1A(a)* and *vip2A(a)* as disclosed in U.S. Pat. No. 5,889,174 and herein incorporated by reference, are also useful in the present invention.

This co-expression of more than one insecticidal principle in the same transgenic plant can be achieved by genetically engineering a plant to contain and express all the genes necessary.

20 Alternatively, a plant, Parent 1, can be genetically engineered for the expression of genes of the present invention. A second plant, Parent 2, can be genetically engineered for the expression of a supplemental insect control principle. By crossing Parent 1 with Parent 2, progeny plants are obtained which express all the genes introduced into Parents 1 and 2.

Transgenic seed of the present invention can also be treated with an insecticidal seed coating
25 as described in U. S. Patent Nos. 5,849,320 and 5,876,739, herein incorporated by reference.

Where both the insecticidal seed coating and the transgenic seed of the invention are active against the same target insect, the combination is useful (i) in a method for enhancing activity of a modified Cry3A toxin of the invention against the target insect and (ii) in a method for preventing development of resistance to a modified Cry3A toxin of the invention by providing
30 a second mechanism of action against the target insect. Thus, the invention provides a method

of enhancing activity against or preventing development of resistance in a target insect, for example corn rootworm, comprising applying an insecticidal seed coating to a transgenic seed comprising one or more modified Cry3A toxins of the invention.

Even where the insecticidal seed coating is active against a different insect, the insecticidal seed coating is useful to expand the range of insect control, for example by adding an insecticidal seed coating that has activity against lepidopteran insects to the transgenic seed of the invention, which has activity against coleopteran insects, the coated transgenic seed produced controls both lepidopteran and coleopteran insect pests.

EXAMPLES

The invention will be further described by reference to the following detailed examples. These examples are provided for the purposes of illustration only, and are not intended to be limiting unless otherwise specified. Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by J. Sambrook, *et al.*, Molecular Cloning: *A Laboratory Manual*, 3d Ed., Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press (2001); by T.J. Silhavy, M.L. Berman, and L.W. Enquist, *Experiments with Gene Fusions*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and by Ausubel, F.M. *et al.*, *Current Protocols in Molecular Biology*, New York, John Wiley and Sons Inc., (1988), Reiter, *et al.*, *Methods in Arabidopsis Research*, World Scientific Press (1992), and Schultz *et al.*, *Plant Molecular Biology Manual*, Kluwer Academic Publishers (1998).

Example 1: Maize Optimized cry3A Gene Construction

The maize optimized cry3A gene is made according to the procedure disclosed in U.S. Patent 5,625,136. In this procedure, maize preferred codons, i.e., the single codon that most frequently encodes that amino acid in maize, are used. The maize preferred codon for a particular amino acid is derived from known gene sequences from maize. Maize codon usage for 28 genes from maize plants is found in Murray *et al.*, Nucleic Acids Research 17:477-498 (1989). The synthetic sequence made with maize optimized codons is set forth in SEQ ID NO:

3.

Example 2: Identification of Cathepsin-G Enzymatic Activity in Western Corn Rootworm Guts

Cathepsin G-like (serine protease) and cathepsin B-like (cysteine protease) enzymatic activities in western corn rootworm guts are measured using colorimetric substrates. Each 1 ml reaction contains five homogenized midguts of the 3rd instar of western corn rootworm and 1 mg of substrate dissolved in reaction buffer (10 mM Tris, 5 mM NaCl, 0.01 M DTT, pH 7.5). The cathepsin G substrate tested is Ala-Ala-Pro-Phe (SEQ ID NO: 35)-pNA and cathepsin B substrate, Arg-Arg-pNA. The reactions are incubated at 28°C for 1hr. The intensity of yellow color formation, indicative of the efficiency of a protease to recognize the appropriate substrate, is compared in treatments vs. controls. The reactions are scored as negative (-) if no color or slight background color is detected. Reactions which are 25%, 50%, 75% or 100% above background are scored as +, ++, +++, or +++++, respectively. Results of the enzymatic assays are shown in the following table.

Table 1

Reaction	Product Color intensity
WCR gut only	-
Cathepsin B substrate only	-
Cathepsin G substrate only	-
WCR gut + Cathepsin B substrate	+
WCR gut + Cathepsin G substrate	+++

This is the first time that the serine protease cathepsin G activity has been identified in western corn rootworm guts. Western corn rootworm guts clearly have stronger cathepsin G, the serine protease, activity compared to cathepsin B, the cysteine protease, activity. The AAPF sequence (SEQ ID NO: 35) is selected as the cathepsin G protease recognition site for creating modified Cry3A toxins of the present invention.

Example 3: Construction of Modified *cry3A* Genes

Modified *cry3A* genes comprising a nucleotide sequence that encodes the cathepsin G recognition site in domain I, domain III, or domain I and domain III are made using overlap

PCR. The maize optimized *cry3A* gene (SEQ ID NO: 2), comprised in plasmid pCIB6850 (SEQ ID NO: 5), is used as the starting template. Eight modified *cry3A* gene constructs, which encode modified Cry3A toxins, are made; *cry3A054*, *cry3A055*, and *cry3A085*, which comprise the cathepsin G recognition site coding sequence in domain I; *cry3A058*, *cry3A082*,
 5 *cry3A056*, *cry3A057*, *cry3A083*, which comprise the cathepsin G recognition site coding sequence in domain I and domain III. The eight modified *cry3A* genes and the modified Cry3A toxins they encode are described as follows:

10 *cry3A054* comprised in pCMS054

cry3A054 (SEQ ID NO: 6) comprises a nucleotide sequence encoding a modified Cry3A toxin. Three overlap PCR primer pairs are used to insert the nucleotide sequence encoding the cathepsin G recognition site into the unmodified maize optimized *cry3A*:

- 15 1. BamExt1 – 5'-GGATCCACCATGACGGCCGAC-3' (SEQ ID NO: 22)
 AAPFtail3 – 5'-GAACGGTGCAGCGGGGTTCTTCTGCCAGC-3' (SEQ ID NO: 23)
2. Tail5mod – 5'-GCTGCACCGTTCCCCACAGCCAGGGCCG-3' (SEQ ID NO: 24)
 XbaIExt2 – 5'-TCTAGACCCACGTTGTACCAC-3' (SEQ ID NO: 25)
- 20 3. BamExt1 – 5'-GGATCCACCATGACGGCCGAC-3' (SEQ ID NO: 22)
 XbaIExt2 – 5'-TCTAGACCCACGTTGTACCAC-3' (SEQ ID NO: 25)

Primer pair 1 and primer pair 2 generate two unique PCR products. These products are then
 25 combined in equal parts and primer pair 3 is used to join the products to generate one PCR fragment that is cloned back into the original pCIB6850 template. The modified *cry3A054* gene is then transferred to pBluescript (Stratagene). The resulting plasmid is designated pCMS054 and comprises the *cry3A054* gene (SEQ ID NO: 6).

The modified Cry3A054 toxin (SEQ ID NO: 7), encoded by the modified *cry3A* gene
 30 comprised in pCMS054, has a cathepsin G recognition site, comprising the amino acid sequence AAPF (SEQ ID NO: 35), inserted in domain I between amino acids 107 and 113 of

the unmodified Cry3A toxin (SEQ ID NO: 4). The cathepsin G recognition site replaces the naturally occurring trypsin recognition site and is adjacent to a naturally occurring chymotrypsin recognition site.

5 *cry3A055* comprised in pCMS055

cry3A055 (SEQ ID NO: 8) comprises a nucleotide sequence encoding a modified Cry3A toxin. Three overlap PCR primer pairs are used to insert the nucleotide sequence encoding the cathepsin G recognition site into the unmodified maize optimized *cry3A*:

- 10 1. BamExt1 – 5'-GGATCCACCATGACGGCCGAC-3' (SEQ ID NO: 22)
 AAPFtail3 – 5'-GAACGGTGCAGCGGGGTTCTTCTGCCAGC-3' (SEQ ID NO: 23)
2. AAPFtail4 – 5'-GCTGCACCGTTCCGCAACCCCCACAGCCA-3' (SEQ ID NO: 26)
 XbaIExt2 – 5'-TCTAGACCCACGTTGTACCAC-3' (SEQ ID NO: 25)
- 15 3. BamExt1 – 5'-GGATCCACCATGACGGCCGAC-3' (SEQ ID NO: 22)
 XbaIExt2 – 5'-TCTAGACCCACGTTGTACCAC-3' (SEQ ID NO: 25)

Primer pair 1 and primer pair 2 generate two unique PCR products. These products are then
 20 combined in equal parts and primer pair 3 is used to join the products to generate one PCR fragment that is cloned back into the original pCIB6850 template. The modified *cry3A055* gene is then transferred to pBluescript (Stratagene). The resulting plasmid is designated pCMS055 and comprises the *cry3A055* gene (SEQ ID NO: 8).

The modified Cry3A055 toxin (SEQ ID NO: 9), encoded by the modified *cry3A* gene
 25 comprised in pCMS055, has a cathepsin G recognition site, comprising the amino acid sequence AAPF (SEQ ID NO: 35), inserted in domain I between amino acids 107 and 111 of the unmodified Cry3A toxin (SEQ ID NO: 4). The cathepsin G recognition site is adjacent to a natural trypsin and chymotrypsin recognition site.

cry3A058 comprised in pCMS058

cry3A058 (SEQ ID NO: 14) comprises a nucleotide sequence encoding a modified Cry3A toxin. Three overlap PCR primer pairs are used to insert the nucleotide sequence encoding the cathepsin G recognition site into the unmodified maize optimized *cry3A*:

5

1. SalExt – 5'-GAGCGTCGACTTCTTCAAC-3' (SEQ ID NO: 27)

AAPF-Y2 – 5'-GAACGGTGCAGCGTATTGGTTGAAGGGGGC-3' (SEQ ID NO: 28)

2. AAPF-Y1 – 5'-GCTGCACCGTTCTACTTCGACAAGACCATC-3' (SEQ ID NO: 29)

10 SacExt – 5'-GAGCTCAGATCTAGTTCACGG-3' (SEQ ID NO: 30)

3. SalExt – 5'-GAGCGTCGACTTCTTCAAC-3' (SEQ ID NO: 27)

SacExt – 5'-GAGCTCAGATCTAGTTCACGG-3' (SEQ ID NO: 30)

15 Primer pair 1 and primer pair 2 generate two unique PCR products. These products are then combined in equal parts and primer pair 3 is used to join the products to generate one PCR fragment that is cloned back into the original pCIB6850 template. The modified *cry3A058* gene is then transferred to pBluescript (Stratagene). The resulting plasmid is designated pCMS058 and comprises the *cry3A058* gene (SEQ ID NO: 14).

20 The modified Cry3A058 toxin (SEQ ID NO: 15), encoded by the modified *cry3A* gene, has a cathepsin G recognition site, comprising the amino acid sequence AAPF (SEQ ID NO: 35), inserted in domain III between amino acids 540 and 541 of the unmodified Cry3A toxin (SEQ ID NO: 4). The cathepsin G recognition site is within a naturally occurring chymotrypsin recognition site.

25

pCMS082 comprising *cry3A082*

cry3A082 (SEQ ID NO: 12) comprises a nucleotide sequence encoding a modified Cry3A toxin. A QuikChange Site Directed Mutagenesis PCR primer pair is used to insert the nucleotide sequence encoding the cathepsin G recognition site into the unmodified maize optimized *cry3A*:

30

BBmod1 – 5'-CGGGGCCCCCGCTGCACCGTTCTACTTCGACA-3' (SEQ ID NO: 31)

BBmod2 – 5'-TGTCGAAGTAGAACGGTGCAGCGGGGGCCCCG-3' (SEQ ID NO: 32)

5 The primer pair generates a unique PCR product. This product is cloned back into the original pCIB6850 template. The modified *cry3A082* gene is then transferred to pBluescript (Stratagene). The resulting plasmid is designated pCMS082 and comprises the *cry3A082* gene (SEQ ID NO: 12).

The modified Cry3A082 toxin (SEQ ID NO: 13), encoded by the modified *cry3A* gene, has a
 10 cathepsin G recognition site, comprising the amino acid sequence AAPF (SEQ ID NO: 35), inserted in domain III between amino acids 539 and 542 of the unmodified Cry3A toxin (SEQ ID NO: 4). The cathepsin G recognition site replaces a naturally occurring chymotrypsin recognition site.

15 *cry3A056* comprised in pCMS056

cry3A056 (SEQ ID NO: 18) comprises a nucleotide sequence encoding a modified Cry3A toxin. Six overlap PCR primer pairs are used to insert two cathepsin G recognition sites into the unmodified *cry3A*:

20 1. BamExt1 – 5'-GGATCCACCATGACGGCCGAC-3' (SEQ ID NO: 22)

AAPFtail3 – 5'-GAACGGTGCAGCGGGGTTCTTCTGCCAGC-3' (SEQ ID NO: 23)

2. AAPFtail4 – 5'-GCTGCACCGTTCCGCAACCCCCACAGCCA-3' (SEQ ID NO: 26)

XbaIExt2 – 5'-TCTAGACCCACGTTGTACCAC-3' (SEQ ID NO: 25)

25

3. BamExt1 – 5'-GGATCCACCATGACGGCCGAC-3' (SEQ ID NO: 22)

XbaIExt2 – 5'-TCTAGACCCACGTTGTACCAC-3' (SEQ ID NO: 25)

4. SalExt – 5'-GAGCGTCGACTTCTTCAAC-3' (SEQ ID NO: 27)

30 AAPF-Y2 – 5'-GAACGGTGCAGCGTATTGGTTGAAGGGGGC-3' (SEQ ID NO: 28)

5. AAPF-Y1 – 5'-GCTGCACCGTTCTACTTCGACAAGACCATC-3' (SEQ ID NO: 29)

SacExt – 5'-GAGCTCAGATCTAGTTCACGG-3' (SEQ ID NO: 30)

6. SalExt – 5'-GAGCGTCGACTTCTTCAAC-3' (SEQ ID NO: 27)

5 SacExt – 5'-GAGCTCAGATCTAGTTCACGG-3' (SEQ ID NO: 30)

Primer pair 1 and primer pair 2 generate two unique PCR products. These products are combined in equal parts and primer pair 3 is used to join the products to generate one PCR fragment that is cloned back into the original pCIB6850 plasmid. The modified *cry3A055* gene is then transferred to pBluescript (Stratagene). The resulting plasmid is designated pCMS055. Primer pair 4 and primer pair 5 generate another unique set of fragments that are joined by another PCR with primer pair 6. This fragment is cloned into domain III of the modified *cry3A055* gene comprised in pCMS055. The resulting plasmid is designated pCMS056 and comprises the *cry3A056* gene (SEQ ID NO: 18).

15 The modified Cry3A056 toxin (SEQ ID NO: 19), encoded by the modified *cry3A* gene, has a cathepsin G recognition site, comprising the amino acid sequence AAPF (SEQ ID NO: 35), inserted in domain I between amino acids 107 and 111 and in domain III between amino acids 540 and 541 of the unmodified Cry3A toxin (SEQ ID NO: 4). The cathepsin G recognition site is adjacent to a naturally occurring trypsin and chymotrypsin recognition site in domain I
20 and is within a naturally occurring chymotrypsin recognition site in domain III.

cry3A057 comprised in pCMS057

cry3A057 (SEQ ID NO: 16) comprises a nucleotide sequence encoding a modified Cry3A toxin. Six overlap PCR primer pairs are used to insert two cathepsin G recognition sites into
25 the unmodified *cry3A*:

1. BamExt1 – 5'-GGATCCACCATGACGGCCGAC-3' (SEQ ID NO: 22)

AAPFtail3 – 5'-GAACGGTGCAGCGGGGTTCTTCTGCCAGC-3' (SEQ ID NO: 23)

30 2. Tail5mod – 5'-GCTGCACCGTTCCCCACAGCCAGGGCCG-3' (SEQ ID NO: 24)

XbaExt2 – 5'-TCTAGACCCACGTTGTACCAC-3' (SEQ ID NO: 25)

3. BamExt1 – 5'-GGATCCACCATGACGGCCGAC-3' (SEQ ID NO: 22)

XbaIExt2 – 5'-TCTAGACCCACGTTGTACCAC-3' (SEQ ID NO: 25)

5 4. SalExt – 5'-GAGCGTCGACTTCTTCAAC-3' (SEQ ID NO: 27)

AAPF-Y2 – 5'-GAACGGTGCAGCGTATTGGTTGAAGGGGGC-3' (SEQ ID NO: 28)

5. AAPF-Y1 – 5'-GCTGCACCGTTCTACTTCGACAAGACCATC-3' (SEQ ID NO: 29)

SacExt – 5'-GAGCTCAGATCTAGTTCACGG-3' (SEQ ID NO: 30)

10

6. SalExt – 5'-GAGCGTCGACTTCTTCAAC-3' (SEQ ID NO: 27)

SacExt – 5'-GAGCTCAGATCTAGTTCACGG-3' (SEQ ID NO: 30)

Primer pair 1 and primer pair 2 generate two unique PCR products. These products are
 15 combined in equal parts and primer pair 3 is used to join the products to generate one PCR
 fragment that is cloned back into the original pCIB6850 plasmid. The modified *cry3A054*
 gene is then transferred to pBluescript (Stratagene). The resulting plasmid is designated
 pCMS054. Primer pair 4 and primer pair 5 generate another unique set of fragments that are
 joined by another PCR with primer pair 6. This fragment is cloned into domain III of the
 20 modified *cry3A054* gene comprised in pCMS054. The resulting plasmid is designated
 pCMS057 and comprises the *cry3A057* gene (SEQ ID NO: 16).

The modified Cry3A057 toxin (SEQ ID NO: 17), encoded by the modified *cry3A* gene, has a
 cathepsin G recognition site, comprising the amino acid sequence AAPF (SEQ ID NO: 35),
 inserted in domain I between amino acids 107 and 113 and in domain III between amino acids
 25 540 and 541 of the unmodified Cry3A toxin (SEQ ID NO: 4). The cathepsin G recognition
 site replaces a naturally occurring trypsin recognition site and is adjacent to a naturally
 occurring chymotrypsin recognition site in domain I and is within a naturally occurring
 chymotrypsin recognition site in domain III.

cry3A083 comprised in pCMS083

cry3A083 (SEQ ID NO: 20) comprises a nucleotide sequence encoding a modified Cry3A toxin. Three overlap PCR primer pairs and one QuikChange Site Directed Mutagenesis PCR primer pair are used to insert two cathepsin G recognition sites into the unmodified *cry3A*:

5

1. BamExt1 – 5'-GGATCCACCATGACGGCCGAC-3' (SEQ ID NO: 22)

AAPFtail3 – 5'-GAACGGTGCAGCGGGGTTCTTCTGCCAGC-3' (SEQ ID NO: 23)

2. AAPFtail4 – 5'-GCTGCACCGTTCCGCAACCCCCACAGCCA-3' (SEQ ID NO: 26)

10 XbaIExt2 – 5'-TCTAGACCCACGTTGTACCAC-3' (SEQ ID NO: 25)

3. BamExt1 – 5'-GGATCCACCATGACGGCCGAC-3' (SEQ ID NO: 22)

XbaIExt2 – 5'-TCTAGACCCACGTTGTACCAC-3' (SEQ ID NO: 25)

15 BBmod1 – 5'-CGGGGCCCCCGCTGCACCGTTCTACTTCGACA-3 (SEQ ID NO: 31)

BBmod2 – 5'-TGTCGAAGTAGAACGGTGCAGCGGGGGCCCCG-3' (SEQ ID NO: 32)

Primer pair 1 and primer pair 2 generate two unique PCR products. These products are combined in equal parts and primer pair 3 is used to join the products to generate one PCR
20 fragment that is cloned back into the original pCIB6850 plasmid. The modified *cry3A055* gene is then transferred to pBluescript (Stratagene). The resulting plasmid is designated pCMS055. Primer pair 4 generates another unique fragment that is cloned into domain III of the modified *cry3A* comprised in pCMS055. The resulting plasmid is designated pCMS083 and comprises the *cry3A083* gene (SEQ ID NO: 20).

25 The modified Cry3A083 toxin (SEQ ID NO: 21), encoded by the modified *cry3A* gene, has a cathepsin G recognition site, comprising the amino acid sequence AAPF (SEQ ID NO: 35), inserted in domain I between amino acids 107 and 111 and between amino acids 539 and 542 of the unmodified Cry3A toxin (SEQ ID NO: 4). The cathepsin G recognition site is adjacent to a naturally occurring trypsin and chymotrypsin recognition site in domain I and replaces a
30 naturally occurring chymotrypsin recognition site in domain III.

cry3A085 comprised in pCMS085

The *cry3A085* gene (SEQ ID NO: 10) comprises a cathepsin G coding sequence at the same position as in the *cry3A055* gene described above. The *cry3A085* gene has an additional 24 nucleotides inserted at the 5' end which encode amino acids 41-47 of the deduced amino acid sequence set forth in SEQ ID NO: 2 as well as an additional methionine. The additional nucleotides are inserted at the 5' end of the *cry3A055* gene using the following PCR primer pair:

mo3Aext- 5'-GGATCCACCATGAACTACAAGGAGTTCCTCCGC-
ATGACCGCCGACAAC-3'

(SEQ ID NO: 33)

CMS16 – 5'-CCTCCACCTGCTCCATGAAG-3'

(SEQ ID NO: 34)

The modified Cry3A085 toxin (SEQ ID NO: 11), encoded by the modified *cry3A* gene, has a cathepsin G recognition site, comprising the amino acid sequence AAPF (SEQ ID NO: 35), inserted in domain I between amino acids corresponding to 107 and 111 of the unmodified Cry3A toxin (SEQ ID NO: 4) and has an additional eight amino acid residues at the N-terminus of which the second residue corresponds to amino acid number 41 of the amino acid sequence set forth in SEQ ID NO: 2.

Example 4: Insecticidal Activity of Modified Cry3A Toxins

Modified Cry3A toxins are tested for insecticidal activity against western corn rootworm, northern corn rootworm and southern corn rootworm in insect bioassays. Bioassays are performed using a diet incorporation method. *E. coli* clones that express one of the modified Cry3A toxins of the invention are grown overnight. 500 µl of an overnight culture is sonicated and then mixed with 500 µl of molten artificial diet (Marrone et al. (1985) J. of Economic Entomology 78:290-293). Once the diet solidifies, it is dispensed in a petri-dish and 20 neonate corn rootworm are placed on the diet. The petri-dishes are held at 30°C. Mortality is recorded after 6 days. All of the modified Cry3A toxins cause 50%-100% mortality to western and northern corn rootworm whereas the unmodified Cry3A toxin causes 0%-30% mortality. None of the modified Cry3A toxins have activity against southern corn rootworm.

Example 5: Creation of Transgenic Maize Plants Comprising Modified *cry3A* Coding Sequences

Three modified *cry3A* genes, *cry3A055*, representative of a domain I modification,
5 *cry3A058*, representative of a domain III modification, and *cry3A056*, representative of a domain I and domain III modification, are chosen for transformation into maize plants. An expression cassette comprising a modified *cry3A* coding sequence is transferred to a suitable vector for *Agrobacterium*-mediated maize transformation. For this example, an expression cassette comprises, in addition to the modified *cry3A* gene, the MTL promoter (U.S. Pat. No.
10 5,466,785) and the *nos* terminator which is known in the art.

Transformation of immature maize embryos is performed essentially as described in Negrotto *et al.*, 2000, Plant Cell Reports 19: 798-803. For this example, all media constituents are as described in Negrotto *et al.*, *supra*. However, various media constituents known in the art may be substituted.

15 The genes used for transformation are cloned into a vector suitable for maize transformation. Vectors used in this example contain the phosphomannose isomerase (PMI) gene for selection of transgenic lines (Negrotto *et al.* (2000) Plant Cell Reports 19: 798-803).

Agrobacterium strain LBA4404 (pSB1) containing the plant transformation plasmid is grown on YEP (yeast extract (5 g/L), peptone (10g/L), NaCl (5g/L), 15g/l agar, pH 6.8) solid
20 medium for 2 – 4 days at 28°C. Approximately 0.8×10^9 *Agrobacterium* are suspended in LS-inf media supplemented with 100 µM As (Negrotto *et al.*, (2000) Plant Cell Rep 19: 798-803). Bacteria are pre-induced in this medium for 30-60 minutes.

Immature embryos from A188 or other suitable genotype are excised from 8 – 12 day old ears into liquid LS-inf + 100 µM As. Embryos are rinsed once with fresh infection medium.

25 *Agrobacterium* solution is then added and embryos are vortexed for 30 seconds and allowed to settle with the bacteria for 5 minutes. The embryos are then transferred scutellum side up to LSAs medium and cultured in the dark for two to three days. Subsequently, between 20 and 25 embryos per petri plate are transferred to LSDc medium supplemented with cefotaxime (250 mg/l) and silver nitrate (1.6 mg/l) and cultured in the dark for 28°C for 10 days.

30 Immature embryos, producing embryogenic callus are transferred to LSD1M0.5S medium. The cultures are selected on this medium for 6 weeks with a subculture step at 3 weeks.

Surviving calli are transferred to Reg1 medium supplemented with mannose. Following culturing in the light (16 hour light/ 8 hour dark regiment), green tissues are then transferred to Reg2 medium without growth regulators and incubated for 1-2 weeks. Plantlets are transferred to Magenta GA-7 boxes (Magenta Corp, Chicago Ill.) containing Reg3 medium and grown in the light. After 2-3 weeks, plants are tested for the presence of the PMI genes and the modified *cry3A* genes by PCR. Positive plants from the PCR assay are transferred to the greenhouse and tested for resistance to corn rootworm.

Example 6: Analysis of Transgenic Maize Plants

Corn Rootworm Efficacy

Root Excision Bioassay

Plants are sampled as they are being transplanted from Magenta GA-7 boxes into soil. This allows the roots to be sampled from a reasonably sterile environment relative to soil conditions. Sampling consists of cutting a small piece of root (ca. 2-4 cm long) and placing it onto enriched phytagar (phytagar, 12 g., sucrose, 9 g., MS salts, 3 ml., MS vitamins, 3 ml., Nystatin(25mg/ml), 3 ml., Cefotaxime (50mg/ml), 7 ml., Aureomycin (50 mg/ml), 7 ml., Streptomycin (50mg/ml), 7 ml., dH₂O, 600 ml) in a small petri-dish. Negative controls are either transgenic plants that are PCR negative for the modified *cry3A* gene from the same experiment, or from non-transgenic plants (of a similar size to test plants) that are being grown in the phytotron. If sampling control roots from soil, the root samples are washed with water to remove soil residue, dipped in Nystatin solution (5mg/ml), removed from the dip, blotted dry with paper toweling, and placed into a phytagar dish.

Root samples are inoculated with western corn rootworms by placing 10 first instar larvae onto the inside surface of the lid of each phytagar dish and the lids then tightly resealed.

Larvae are handled using a fine tip paintbrush. After all dishes are inoculated, the tray of dishes is placed in the dark at room temperature until data collection.

At 3-4 days post inoculation, data is collected. The percent mortality of the larvae is calculated along with a visual damage rating of the root. Feeding damage is rated as high, moderate, low, or absent and given a numerical value of 3, 2, 1 or 0, respectively. Root

samples causing at least 40% mortality and having a damage rating of 2 or less are considered positive.

Results in the following table show that plants expressing a modified Cry3A toxin cause from 40-100% mortality to western corn rootworm whereas control plants cause 0-30% mortality.

- 5 Also, plants expressing a modified Cry3A toxin sustain significantly less feeding damage than control plants.

Table 2

T0 Event	Modified Cry3A Toxin Expressed	Percent Mortality Per Plant					Mean Damage Rating Per Event
		A	B	C	D	E	
240A7	Cry3A055	80	40	80	60		0.8
240B2	Cry3A055	60	60	60	80		1.25
240B9	Cry3A055	40	60	60	100		1
240B10	Cry3A055	80	40	60	60		1
240A15	Cry3A055	80	60	50	70	70	0.6
240A5	Cry3A055	60	80	60			0.33
240A9	Cry3A055	50	60	60	70	70	1.6
244A4	Cry3A058	50					1
244A7	Cry3A058	40	40	60			1.3
244A5	Cry3A058	50					1
244B7	Cry3A058	90					1
244B6	Cry3A058	50	40	60			1
243A3	Cry3A056	50	90	80	60		1.25
243A4	Cry3A056	50	80	60			1.7
243B1	Cry3A056	80	90				0.5
243B4	Cry3A056	70	60	50	80		1.5
245B2	Cry3A056	90	50	70	60		1
WT1	-	0	10	20	10	0	2.6
WT2	-	0	30	0	0	20	2.8

Whole Plant Bioassay

Some positive plants identified using the root excision bioassay described above are evaluated for western corn rootworm resistance using a whole plant bioassay. Plants are infested generally within 3 days after the root excision assay is completed.

- 5 Western corn rootworm eggs are preincubated so that hatch occurs 2-3 days after plant inoculation. Eggs are suspended in 0.2% agar and applied to the soil around test plants at approximately 200 eggs/plant.

- Two weeks after the eggs hatch, plants are evaluated for damage caused by western corn rootworm larvae. Plant height attained, lodging, and root mass are criteria used to determine
10 if plants are resistant to western corn rootworm feeding damage. At the time of evaluation, control plants typically are smaller than modified Cry3A plants. Also, non-transgenic control plants and plants expressing the unmodified Cry3A toxin encoded by the maize optimized *cry3A* gene have lodged during this time due to severe pruning of most of the roots resulting in no root mass accumulation. At the time of evaluation, plants expressing a modified Cry3A
15 toxin of the invention are taller than control plants, have not lodged, and have a large intact root mass due to the insecticidal activity of the modified Cry3A toxin.

ELISA Assay

- 20 ELISA analysis according to the method disclosed in U.S. Patent No. 5,625,136 is used for the quantitative determination of the level of modified and unmodified Cry3A protein in transgenic plants.

Table 3: Whole Plant Bioassay Results and Protein Levels

Transgenic Maize Plant	Type of Cry3A Toxin Expressed	Cry3A Protein Level in Roots (ng/mg)	Plant Lodged	Intact Root Mass
240A2E	modified Cry3A055	224	-	+
240A9C	modified Cry3A055	71	-	+
240B9D	modified Cry3A055	204	-	+
240B9E	modified Cry3A055	186	-	+
240B10D	modified Cry3A055	104	-	+
240B10E	modified Cry3A055	70	-	+
240A15E	modified Cry3A055	122	-	+
240B4D	modified Cry3A055	97	-	+
243B5A	modified Cry3A056	41	-	+
244A7A	modified Cry3A058	191	-	+
710-2-51	maize optimized	39	+	-
710-2-54	maize optimized	857	+	-
710-2-61	maize optimized	241	+	-
710-2-67	maize optimized	1169	+	-
710-2-68	maize optimized	531	+	-
710-2-79	maize optimized	497	+	-
710-2-79	maize optimized	268	+	-
WT1 Control	-	0	+	-
WT2 Control	-	0	+	-

What is claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a modified Cry3A toxin comprising a non-naturally occurring protease recognition site, wherein said protease recognition site modifies a Cry3A toxin and is located at a position selected from the group consisting of:
 - a) a position between amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4;
 - b) a position between amino acids corresponding to amino acid numbers 536 and 542 of SEQ ID NO:4; and
 - c) a position between amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4, and between amino acids corresponding to amino acid numbers 536 and 542 of SEQ ID NO:4,wherein said protease recognition site is recognizable by a gut protease of western corn rootworm, and wherein said modified Cry3A toxin causes higher mortality to western corn rootworm than the mortality caused by said Cry3A toxin to western corn rootworm in an artificial diet bioassay.
2. The isolated nucleic acid molecule according to claim 1, wherein said gut protease is cathepsin G.
3. The isolated nucleic acid molecule according to claim 1, wherein said protease recognition site is located between amino acid numbers 107 and 115 of SEQ ID NO:4.
4. The isolated nucleic acid molecule according to claim 1, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 107 and 113 of SEQ ID NO:4.
5. The isolated nucleic acid molecule according to claim 4, wherein said protease recognition site is located between amino acid numbers 107 and 113 of SEQ ID NO:4.
6. The isolated nucleic acid molecule according to claim 1, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 107 and 111 of SEQ ID NO:4.
7. The isolated nucleic acid molecule according to claim 6, wherein said protease recognition site is located between amino acid numbers 107 and 111 of SEQ ID NO:4.

8. The isolated nucleic acid molecule according to claim 1, wherein said protease site is located between amino acid numbers 536 and 542 of SEQ ID NO:4.
9. The isolated nucleic acid molecule according to claim 1, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 536 and 541 of SEQ ID NO:4.
10. The isolated nucleic acid molecule according to claim 9, wherein said additional protease site is located between amino acid numbers 536 and 541 of SEQ ID NO:4.
11. The isolated nucleic acid molecule according to claim 1, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 540 and 541 of SEQ ID NO:4.
12. The isolated nucleic acid molecule according to claim 11, wherein said protease site is located between amino acid numbers 540 and 541 of SEQ ID NO:4.
13. The isolated nucleic acid molecule according to claim 1, wherein said protease recognition site is located between amino acid numbers 107 and 115 of SEQ ID NO:4 and between amino acid numbers 536 and 542 of SEQ ID NO:4.
14. The isolated nucleic acid molecule according to claim 1, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 107 and 113 of SEQ ID NO:4 and between amino acids corresponding to amino acid numbers 540 and 541 of SEQ ID NO:4.
15. The isolated nucleic acid molecule according to claim 14, wherein said protease recognition site is located between amino acid numbers 107 and 113 of SEQ ID NO:4 and between amino acid numbers 540 and 541 of SEQ ID NO:4.
16. The isolated nucleic acid molecule according to claim 1, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 107 and 111 of SEQ ID NO:4 and between amino acids corresponding to amino acid numbers 536 and 541 of SEQ ID NO:4.
17. The isolated nucleic acid molecule according to claim 16, wherein said protease recognition site is located between amino acid numbers 107 and 111 of SEQ ID NO:4 and between amino acid numbers 536 and 541 of SEQ ID NO:4.

18. The isolated nucleic acid molecule according to claim 1, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 107 and 111 of SEQ ID NO:4 and between amino acids corresponding to amino acid numbers 540 and 541 of SEQ ID NO:4.
- 5 19. The isolated nucleic acid molecule according to claim 18, wherein said protease recognition site is located between amino acid numbers 107 and 111 of SEQ ID NO:4 and between amino acid numbers 540 and 541 of SEQ ID NO:4.
20. The isolated nucleic acid molecule according to claim 1, wherein said modified Cry3A toxin causes at least 50% mortality to western corn rootworm to which said Cry3A toxin
10 causes up to 30% mortality.
21. The isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence comprises nucleotides 1-1791 of SEQ ID NO: 6, nucleotides 1-1806 of SEQ ID NO: 8, nucleotides 1-1812 of SEQ ID NO: 10, nucleotides 1-1794 of SEQ ID NO: 12, nucleotides 1-1818 of SEQ ID NO: 14, nucleotides 1-1812 of SEQ ID NO: 16,
15 nucleotides 1-1791 of SEQ ID NO: 18, or nucleotides 1-1818 of SEQ ID NO: 20.
22. The isolated nucleic acid molecule according to claim 1, wherein said modified Cry3A toxin comprises the amino acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21.
- 20 23. The isolated nucleic acid molecule according to claim 1, wherein said modified Cry3A toxin is active against northern corn rootworm.
24. A chimeric construct comprising a heterologous promoter sequence operatively linked to the nucleic acid molecule of claim 1.
25. A recombinant vector comprising the chimeric construct of claim 24.
- 25 26. A transgenic non-human host cell comprising the chimeric construct of claim 24.
27. The transgenic host cell according to claim 26, which is a bacterial cell.
28. The transgenic host cell according to claim 26, which is a plant cell.
29. A transgenic plant comprising the transgenic plant cell of claim 28.
30. The transgenic plant according to claim 29, wherein said plant is a maize plant.
- 30 31. Transgenic seed from the transgenic plant of claim 29.
32. Transgenic seed from the maize plant of claim 30.

33. An isolated toxin produced by the expression of the nucleic acid molecule according to claim 1.
34. The isolated toxin according to claim 33, wherein said toxin is produced by the expression of a nucleic acid molecule comprising nucleotides 1-1791 of SEQ ID NO: 6, nucleotides 1-1806 of SEQ ID NO: 8, nucleotides 1-1812 of SEQ ID NO: 10, nucleotides 1-1794 of SEQ ID NO: 12, nucleotides 1-1818 of SEQ ID NO: 14, nucleotides 1-1812 of SEQ ID NO: 16, nucleotides 1-1791 of SEQ ID NO: 18, or nucleotides 1-1818 of SEQ ID NO: 20.
35. The isolated toxin according to claim 33, wherein said toxin has activity against northern corn rootworm.
36. The isolated toxin according to claim 33, wherein said toxin comprises the amino acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21.
37. A composition comprising an effective amount of the toxin of claim 33 to cause mortality to western corn rootworm.
38. A transgenic maize plant comprising a nucleotide sequence that encodes a modified Cry3A toxin comprising a non-naturally occurring protease recognition site, wherein said protease recognition site modifies a Cry3A toxin and is located at a position selected from the group consisting of:
- a) a position between amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4;
 - b) a position between amino acids corresponding to amino acid numbers 536 and 542 of SEQ ID NO:4; and
 - c) a position between amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4, and between amino acids corresponding to amino acid numbers 536 and 542 of SEQ ID NO:4,
- wherein said protease recognition site is recognizable by a gut protease of western corn rootworm, and wherein said transgenic plant expresses said modified Cry3A toxin in root tissue at a level that causes mortality to western corn rootworm.
39. The transgenic maize plant according to claim 38, wherein said protease recognition site is located between amino acid numbers 107 and 111 of SEQ ID NO:4.

40. The transgenic maize plant according to claim 38, wherein said protease recognition site is located between amino acid numbers 540 and 541 of SEQ ID NO:4.
41. The transgenic maize plant according to claim 38, wherein said protease recognition site is located between amino acid numbers 107 and 111 of SEQ ID NO:4 and between
5 amino acid numbers 540 and 541 of SEQ ID NO:4.
42. The transgenic maize plant according to claim 38, wherein said nucleotide sequence comprises nucleotides 1-1806 of SEQ ID NO: 8, nucleotides 1-1818 of SEQ ID NO: 14, or nucleotides 1-1791 of SEQ ID NO: 18.
43. The transgenic maize plant according to claim 38, wherein said modified Cry3A toxin
10 comprises the amino acid sequence set forth in SEQ ID NO: 9, SEQ ID NO: 15, or SEQ ID NO: 19.
44. The transgenic maize plant according to claim 38, wherein said root tissue causes 100% mortality to western corn rootworm.
45. The transgenic maize plant according to claim 38, wherein said root tissue causes 90%
15 mortality to western corn rootworm.
46. The transgenic maize plant according to claim 38, wherein said root tissue causes 80% mortality to western corn rootworm.
47. The transgenic maize plant according to claim 38, wherein said root tissue causes 70% mortality to western corn rootworm.
- 20 48. The transgenic maize plant according to claim 38, wherein said root tissue causes 60% mortality to western corn rootworm.
49. The transgenic maize plant according to claim 38, wherein said root tissue causes 50% mortality to western corn rootworm.
- 25 50. The transgenic maize plant according to claim 38, wherein said root tissue causes 40% mortality to western corn rootworm.
51. The transgenic maize plant according to claim 38, wherein said transgenic plant expresses said modified Cry3A toxin at a level sufficient to prevent western corn rootworm from severely pruning the roots of the transgenic plant.
- 30 52. The transgenic maize plant according to claim 38, wherein said transgenic plant expresses said modified Cry3A toxin at a level sufficient to prevent western corn rootworm feeding damage from causing the plant to lodge.

53. The transgenic maize plant according to any one of claims 38-52, which is an inbred plant.
54. The transgenic maize plant according to any one of claims 38-52, which is a hybrid plant.
- 5 55. Transgenic seed from the plant of claim 53.
56. Transgenic seed from the plant of claim 54.
57. A modified Cry3A toxin comprising a non-naturally occurring protease recognition site, wherein said protease recognition site modifies a Cry3A toxin and is located at a position selected from the group consisting of:
- 10 a) a position between amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4;
- b) a position between amino acids corresponding to amino acid numbers 536 and 542 of SEQ ID NO:4; and
- c) a position between amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4, and between amino acids corresponding to amino acid numbers
- 15 536 and 542 of SEQ ID NO:4,
- wherein said protease recognition site is recognizable by a gut protease of western corn rootworm, and wherein said modified Cry3A toxin causes higher mortality to western corn rootworm than the mortality caused by said Cry3A toxin to western corn rootworm in an artificial diet bioassay.
- 20 58. The modified Cry3A toxin according to claim 57, wherein said gut protease is cathepsin G.
59. The modified Cry3A toxin according to claim 57, wherein said protease recognition site is located between amino acid numbers 107 and 115 of SEQ ID NO:4.
- 25 60. The modified Cry3A toxin according to claim 57, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 107 and 113 of SEQ ID NO:4.
61. The modified Cry3A toxin according to claim 60, wherein said protease recognition site is located between amino acid numbers 107 and 113 of SEQ ID NO:4.

62. The modified Cry3A toxin according to claim 57, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 107 and 111 of SEQ ID NO:4.
63. The modified Cry3A toxin according to claim 62, wherein said protease recognition site is located between amino acid numbers 107 and 111 of SEQ ID NO:4.
64. The modified Cry3A toxin according to claim 57, wherein said protease site is located between amino acid numbers 536 and 542 of SEQ ID NO:4.
65. The modified Cry3A toxin according to claim 57, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 536 and 541 of SEQ ID NO:4.
66. The modified Cry3A toxin according to claim 65, wherein said additional protease site is located between amino acid numbers 536 and 541 of SEQ ID NO:4.
67. The modified Cry3A toxin according to claim 57, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 540 and 541 of SEQ ID NO:4.
68. The modified Cry3A toxin according to claim 67, wherein said protease site is located between amino acid numbers 540 and 541 of SEQ ID NO:4.
69. The modified Cry3A toxin according to claim 57, wherein said protease recognition site is located between amino acid numbers 107 and 115 and between amino acid numbers 536 and 542 of SEQ ID NO:4.
70. The modified Cry3A toxin according to claim 57, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 107 and 113 of SEQ ID NO:4 and between amino acids corresponding to amino acid numbers 540 and 541 of SEQ ID NO:4.
71. The modified Cry3A toxin according to claim 70, wherein said protease recognition site is located between amino acid numbers 107 and 113 of SEQ ID NO:4 and between amino acid numbers 541 and 541 of SEQ ID NO:4.
72. The modified Cry3A toxin according to claim 57, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 107 and 111 of SEQ ID NO:4 and between amino acids corresponding to amino acid numbers 536 and 541 of SEQ ID NO:4.

73. The modified Cry3A toxin according to claim 72, wherein said protease recognition site is located between amino acid numbers 107 and 111 of SEQ ID NO:4 and between amino acid numbers 536 and 541 of SEQ ID NO:4.
74. The modified Cry3A toxin according to claim 57, wherein said protease recognition site is located between amino acids corresponding to amino acid numbers 107 and 111 of SEQ ID NO:4 and between amino acids corresponding to amino acid numbers 540 and 541 of SEQ ID NO:4.
75. The modified Cry3A toxin according to claim 74, wherein said protease recognition site is located between amino acid numbers 107 and 111 of SEQ ID NO:4 and between amino acid numbers 540 and 541 of SEQ ID NO:4.
76. The modified Cry3A toxin according to claim 57, wherein said modified Cry3A toxin causes at least 50% mortality to western corn rootworm to which said Cry3A toxin causes up to 30% mortality.
77. The modified Cry3A toxin according to claim 57 which is encoded by nucleotides 1-1791 of SEQ ID NO: 6, nucleotides 1-1806 of SEQ ID NO: 8, nucleotides 1-1812 of SEQ ID NO: 10, nucleotides 1-1794 of SEQ ID NO: 12, nucleotides 1-1818 of SEQ ID NO: 14, nucleotides 1-1812 of SEQ ID NO: 16, nucleotides 1-1791 of SEQ ID NO: 18, or nucleotides 1-1818 of SEQ ID NO: 20.
78. The modified Cry3A toxin according to claim 57 comprising the amino acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21.
79. The modified Cry3A toxin according to claim 57 which is active against northern corn rootworm.
80. A method of controlling infestation of maize plants by western corn rootworm, the method comprising:
- (a) providing the transgenic maize plant according to claim 38; and
 - (b) contacting said western corn rootworm with the plant.

81. A method of producing a modified Cry3A toxin, comprising:
- (a) obtaining the transgenic host cell according to claim 27;
 - (b) culturing the transgenic host cell under conditions that allow the expression of the modified Cry3A toxin; and
 - 5 (c) recovering the expressed modified Cry3A toxin.
82. A method of producing insect-resistant plants, comprising:
- (a) stably integrating the nucleic acid molecule according to claim 1 into the genome of plant cells; and
 - (b) regenerating stably transformed plants from said transformed plant cells, wherein
 - 10 said stably transformed plants express an effective amount of a modified Cry3A toxin to render said transformed plant resistant to at least western corn rootworm.
83. A method of controlling at least western corn rootworm, comprising delivering orally to western corn rootworm an effective amount of a toxin according to claim 33.
84. A method of making a modified Cry3A toxin, comprising:
- 15 (a) obtaining a *cry3A* gene which encodes a Cry3A toxin;
 - (b) identifying a gut protease of western corn rootworm;
 - (c) obtaining a nucleotide sequence which encodes a recognition site for said gut protease;
 - (d) inserting said nucleotide sequence into said *cry3A* gene, such that said recognition
 - 20 site is located in said Cry3A toxin at a position between amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4, or at a position between amino acids corresponding to amino acid numbers 536 and 542 of SEQ ID NO:4, or at a position between amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4 and between amino acids corresponding to amino acid
 - 25 numbers 536 and 542 of SEQ ID NO:4, thus creating a modified *cry3A* gene;
 - (e) inserting said modified *cry3A* gene into an expression cassette; and
 - (f) transforming said expression cassette into a non-human host cell, wherein said host cell produces a modified Cry3A toxin.
85. A modified *cry3A* gene comprising a nucleotide sequence that encodes a modified
- 30 Cry3A toxin comprising a non-naturally occurring protease recognition site, wherein said modified *cry3A* gene comprises a coding sequence encoding said protease

recognition site, wherein said coding sequence modifies a *cry3A* gene and is inserted at a position selected from the group consisting of:

- a) a position between the codons that code for amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4;
- b) a position between the codons that code for amino acids corresponding to amino acid numbers 536 and 542 of SEQ ID NO:4; and
- c) a position between the codons that code for amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4, and between codons that code for amino acids corresponding to amino acid numbers 536 and 542 of SEQ ID NO:4,

wherein said protease recognition site is recognizable by a gut protease of western corn rootworm, and wherein said modified Cry3A toxin causes higher mortality to western corn rootworm than the mortality caused by said Cry3A toxin to western corn rootworm in an artificial diet bioassay.

86. The modified *cry3A* gene according to claim 85, wherein said gut protease is cathepsin G.

87. The modified *cry3A* gene according to claim 85, wherein said nucleotide sequence comprises nucleotides 1-1791 of SEQ ID NO: 6, nucleotides 1-1806 of SEQ ID NO: 8, nucleotides 1-1812 of SEQ ID NO: 10, nucleotides 1-1794 of SEQ ID NO: 12, nucleotides 1-1818 of SEQ ID NO: 14, nucleotides 1-1812 of SEQ ID NO: 16, nucleotides 1-1791 of SEQ ID NO: 18, or nucleotides 1-1818 of SEQ ID NO: 20.

88. The modified *cry3A* gene according to claim 85, wherein said modified Cry3A toxin comprises the amino acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21.

89. The modified *cry3A* gene according to claim 85, wherein said modified Cry3A toxin is active against northern corn rootworm.

90. A chimeric construct comprising a heterologous promoter sequence operatively linked to the modified *cry3A* gene of claim 85.

91. A recombinant vector comprising the chimeric construct of claim 90.

92. A transgenic non-human host cell comprising the chimeric construct of claim 90.

93. The transgenic host cell according to claim 92, which is a bacterial cell.

94. The transgenic host cell according to claim 92, which is a plant cell.
95. A transgenic plant comprising the transgenic plant cell of claim 94.
96. The transgenic plant according to claim 95, wherein said plant is a maize plant.
97. Transgenic seed from the transgenic plant of claim 95.
- 5 98. Transgenic seed from the maize plant of claim 96.
99. A transgenic maize plant comprising a modified *cry3A* gene comprising a nucleotide sequence that encodes a modified Cry3A toxin comprising a non-naturally occurring protease recognition site, wherein said modified *cry3A* gene comprises a coding sequence encoding said protease recognition site, wherein said coding sequence
- 10 modifies a *cry3A* gene and is inserted at a position selected from the group consisting of:
- a) a position between the codons that code for amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4;
 - b) a position between the codons that code for amino acids corresponding to amino acid
 - 15 numbers 536 and 542 of SEQ ID NO:4; and
 - c) a position between the codons that code for amino acids corresponding to amino acid numbers 107 and 115 of SEQ ID NO:4, and between codons that code for amino acids corresponding to amino acid numbers 536 and 542 of SEQ ID NO:4,
- wherein said protease recognition site is recognizable by a gut protease of western corn rootworm, and wherein said transgenic plant expresses said modified Cry3A toxin in
- 20 root tissue at a level that causes mortality to western corn rootworm.
100. The transgenic maize plant according to claim 99, wherein said nucleotide sequence comprises nucleotides 1-1806 of SEQ ID NO: 8, nucleotides 1-1818 of SEQ ID NO: 14, or nucleotides 1-1791 of SEQ ID NO: 18.
- 25 101. The transgenic maize plant according to claim 99, wherein said modified Cry3A toxin comprises the amino acid sequence set forth in SEQ ID NO: 9, SEQ ID NO: 15, or SEQ ID NO: 19.
102. The transgenic maize plant according to any one of claims 99-101, which is an inbred plant.
- 30 103. The transgenic maize plant according to any one of claims 99-101, which is a hybrid plant.

104. Transgenic seed from the plant of claim 102.

105. Transgenic seed from the plant of claim 103.

SEQUENCE LISTING

<110> Syngenta Participations AG
 <120> Modified Cry3A Toxins and Nucleic Acid Sequences Coding Therefor
 <130> 60065/PCT
 <140>
 <141>
 <150> US 60/316421
 <151> 2001-08-31
 <160> 34
 <170> PatentIn Ver. 3.0
 <210> 1
 <211> 1932
 <212> DNA
 <213> Bacillus thuringiensis
 <220>
 <221> CDS
 <222> (1)..(1932)
 <223> Native cry3A coding sequence according to Sekar et al. 1987, Proc. Natl. Acad. Sci. 84:7036-7040
 <400> 1
 atg aat ccg aac aat cga agt gaa cat gat aca ata aaa act act gaa 48
 Met Asn Pro Asn Asn Arg Ser Glu His Asp Thr Ile Lys Thr Thr Glu
 1 5 10 15
 aat aat gag gtg cca act aac cat gtt caa tat cct tta gcg gaa act 96
 Asn Asn Glu Val Pro Thr Asn His Val Gln Tyr Pro Leu Ala Glu Thr
 20 25 30
 cca aat cca aca cta gaa gat tta aat tat aaa gag ttt tta aga atg 144
 Pro Asn Pro Thr Leu Glu Asp Leu Asn Tyr Lys Glu Phe Leu Arg Met
 35 40 45
 act gca gat aat aat acg gaa gca cta gat agc tct aca aca aaa gat 192
 Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys Asp
 50 55 60
 gtc att caa aaa ggc att tcc gta gta ggt gat ctc cta ggc gta gta 240
 Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val Val
 65 70 75 80
 ggt ttc ccg ttt ggt gga gcg ctt gtt tcg ttt tat aca aac ttt tta 288
 Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe Leu
 85 90 95

aat act att tgg cca agt gaa gac ccg tgg aag gct ttt atg gaa caa	336
Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu Gln	
100 105 110	
gta gaa gca ttg atg gat cag aaa ata gct gat tat gca aaa aat aaa	384
Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn Lys	
115 120 125	
gct ctt gca gag tta cag ggc ctt caa aat aat gtc gaa gat tat gtg	432
Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr Val	
130 135 140	
agt gca ttg agt tca tgg caa aaa aat cct gtg agt tca cga aat cca	480
Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Val Ser Ser Arg Asn Pro	
145 150 155 160	
cat agc cag ggg cgg ata aga gag ctg ttt tct caa gca gaa agt cat	528
His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser His	
165 170 175	
ttt cgt aat tca atg cct tcg ttt gca att tct gga tac gag gtt cta	576
Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu Val Leu	
180 185 190	
ttt cta aca aca tat gca caa gct gcc aac aca cat tta ttt tta cta	624
Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe Leu Leu	
195 200 205	
aaa gac gct caa att tat gga gaa gaa tgg gga tac gaa aaa gaa gat	672
Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys Glu Asp	
210 215 220	
att gct gaa ttt tat aaa aga caa cta aaa ctt acg caa gaa tat act	720
Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu Tyr Thr	
225 230 235 240	
gac cat tgt gtc aaa tgg tat aat gtt gga tta gat aaa tta aga ggt	768
Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu Arg Gly	
245 250 255	
tca tct tat gaa tct tgg gta aac ttt aac cgt tat cgc aga gag atg	816
Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg Glu Met	
260 265 270	
aca tta aca gta tta gat tta att gca cta ttt cca ttg tat gat gtt	864
Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr Asp Val	
275 280 285	
cgg cta tac cca aaa gaa gtt aaa acc gaa tta aca aga gac gtt tta	912
Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp Val Leu	
290 295 300	
aca gat cca att gtc gga gtc aac aac ctt agg ggc tat gga aca acc	960
Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly Thr Thr	

305	310	315	320	
ttc tct aat ata gaa aat tat att cga aaa cca cat cta ttt gac tat				1008
Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe Asp Tyr	325	330	335	
ctg cat aga att caa ttt cac acg cgg ttc caa cca gga tat tat gga				1056
Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr Tyr Gly	340	345	350	
aat gac tct ttc aat tat tgg tcc ggt aat tat gtt tca act aga cca				1104
Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr Arg Pro	355	360	365	
agc ata gga tca aat gat ata atc aca tct cca ttc tat gga aat aaa				1152
Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly Asn Lys	370	375	380	
tcc agt gaa cct gta caa aat tta gaa ttt aat gga gaa aaa gtc tat				1200
Ser Ser Glu Pro Val Gln Asn Leu Glu Phe Asn Gly Glu Lys Val Tyr	385	390	395	400
aga gcc gta gca aat aca aat ctt gcg gtc tgg ccg tcc gct gta tat				1248
Arg Ala Val Ala Asn Thr Asn Leu Ala Val Trp Pro Ser Ala Val Tyr	405	410	415	
tca ggt gtt aca aaa gtg gaa ttt agc caa tat aat gat caa aca gat				1296
Ser Gly Val Thr Lys Val Glu Phe Ser Gln Tyr Asn Asp Gln Thr Asp	420	425	430	
gaa gca agt aca caa acg tac gac tca aaa aga aat gtt ggc gcg gtc				1344
Glu Ala Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Val Gly Ala Val	435	440	445	
agc tgg gat tct atc gat caa ttg cct cca gaa aca aca gat gaa cct				1392
Ser Trp Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp Glu Pro	450	455	460	
cta gaa aag gga tat agc cat caa ctc aat tat gta atg tgc ttt tta				1440
Leu Glu Lys Gly Tyr Ser His Gln Leu Asn Tyr Val Met Cys Phe Leu	465	470	475	480
atg cag ggt agt aga gga aca atc cca gtg tta act tgg aca cat aaa				1488
Met Gln Gly Ser Arg Gly Thr Ile Pro Val Leu Thr Trp Thr His Lys	485	490	495	
agt gta gac ttt ttt aac atg att gat tcg aaa aaa att aca caa ctt				1536
Ser Val Asp Phe Phe Asn Met Ile Asp Ser Lys Lys Ile Thr Gln Leu	500	505	510	
ccg tta gta aag gca tat aag tta caa tct ggt gct tcc gtt gtc gca				1584
Pro Leu Val Lys Ala Tyr Lys Leu Gln Ser Gly Ala Ser Val Val Ala	515	520	525	

ggt cct agg ttt aca gga gga gat atc att caa tgc aca gaa aat gga 1632
 Gly Pro Arg Phe Thr Gly Gly Asp Ile Ile Gln Cys Thr Glu Asn Gly
 530 535 540
 agt gcg gca act att tac gtt aca ccg gat gtg tcg tac tct caa aaa 1680
 Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser Gln Lys
 545 550 555 560
 tat cga gct aga att cat tat gct tct aca tct cag ata aca ttt aca 1728
 Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr Phe Thr
 565 570 575
 ctc agt tta gac ggg gca cca ttt aat caa tac tat ttc gat aaa acg 1776
 Leu Ser Leu Asp Gly Ala Pro Phe Asn Gln Tyr Tyr Phe Asp Lys Thr
 580 585 590
 ata aat aaa gga gac aca tta acg tat aat tca ttt aat tta gca agt 1824
 Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser Phe Asn Leu Ala Ser
 595 600 605
 ttc agc aca cca ttc gaa tta tca ggg aat aac tta caa ata ggc gtc 1872
 Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu Gln Ile Gly Val
 610 615 620
 aca gga tta agt gct gga gat aaa gtt tat ata gac aaa att gaa ttt 1920
 Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp Lys Ile Glu Phe
 625 630 635 640
 att cca gtg aat 1932
 Ile Pro Val Asn

<210> 2
 <211> 644
 <212> PRT
 <213> Bacillus thuringiensis

<400> 2
 Met Asn Pro Asn Asn Arg Ser Glu His Asp Thr Ile Lys Thr Thr Glu
 1 5 10 15
 Asn Asn Glu Val Pro Thr Asn His Val Gln Tyr Pro Leu Ala Glu Thr
 20 25 30
 Pro Asn Pro Thr Leu Glu Asp Leu Asn Tyr Lys Glu Phe Leu Arg Met
 35 40 45
 Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys Asp
 50 55 60
 Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val Val
 65 70 75 80
 Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe Leu

85								90				95			
Asn	Thr	Ile	Trp	Pro	Ser	Glu	Asp	Pro	Trp	Lys	Ala	Phe	Met	Glu	Gln
			100				105						110		
Val	Glu	Ala	Leu	Met	Asp	Gln	Lys	Ile	Ala	Asp	Tyr	Ala	Lys	Asn	Lys
			115				120						125		
Ala	Leu	Ala	Glu	Leu	Gln	Gly	Leu	Gln	Asn	Asn	Val	Glu	Asp	Tyr	Val
			130				135						140		
Ser	Ala	Leu	Ser	Ser	Trp	Gln	Lys	Asn	Pro	Val	Ser	Ser	Arg	Asn	Pro
145				150						155			160		
His	Ser	Gln	Gly	Arg	Ile	Arg	Glu	Leu	Phe	Ser	Gln	Ala	Glu	Ser	His
			165						170			175			
Phe	Arg	Asn	Ser	Met	Pro	Ser	Phe	Ala	Ile	Ser	Gly	Tyr	Glu	Val	Leu
			180						185			190			
Phe	Leu	Thr	Thr	Tyr	Ala	Gln	Ala	Ala	Asn	Thr	His	Leu	Phe	Leu	Leu
			195						200			205			
Lys	Asp	Ala	Gln	Ile	Tyr	Gly	Glu	Glu	Trp	Gly	Tyr	Glu	Lys	Glu	Asp
			210			215						220			
Ile	Ala	Glu	Phe	Tyr	Lys	Arg	Gln	Leu	Lys	Leu	Thr	Gln	Glu	Tyr	Thr
225				230						235			240		
Asp	His	Cys	Val	Lys	Trp	Tyr	Asn	Val	Gly	Leu	Asp	Lys	Leu	Arg	Gly
			245						250			255			
Ser	Ser	Tyr	Glu	Ser	Trp	Val	Asn	Phe	Asn	Arg	Tyr	Arg	Arg	Glu	Met
			260						265			270			
Thr	Leu	Thr	Val	Leu	Asp	Leu	Ile	Ala	Leu	Phe	Pro	Leu	Tyr	Asp	Val
			275						280			285			
Arg	Leu	Tyr	Pro	Lys	Glu	Val	Lys	Thr	Glu	Leu	Thr	Arg	Asp	Val	Leu
			290			295						300			
Thr	Asp	Pro	Ile	Val	Gly	Val	Asn	Asn	Leu	Arg	Gly	Tyr	Gly	Thr	Thr
305				310						315			320		
Phe	Ser	Asn	Ile	Glu	Asn	Tyr	Ile	Arg	Lys	Pro	His	Leu	Phe	Asp	Tyr
			325						330			335			
Leu	His	Arg	Ile	Gln	Phe	His	Thr	Arg	Phe	Gln	Pro	Gly	Tyr	Tyr	Gly
			340						345			350			
Asn	Asp	Ser	Phe	Asn	Tyr	Trp	Ser	Gly	Asn	Tyr	Val	Ser	Thr	Arg	Pro
			355			360						365			
Ser	Ile	Gly	Ser	Asn	Asp	Ile	Ile	Thr	Ser	Pro	Phe	Tyr	Gly	Asn	Lys

370 375 380
 Ser Ser Glu Pro Val Gln Asn Leu Glu Phe Asn Gly Glu Lys Val Tyr
 385 390 395 400
 Arg Ala Val Ala Asn Thr Asn Leu Ala Val Trp Pro Ser Ala Val Tyr
 405 410 415
 Ser Gly Val Thr Lys Val Glu Phe Ser Gln Tyr Asn Asp Gln Thr Asp
 420 425 430
 Glu Ala Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Val Gly Ala Val
 435 440 445
 Ser Trp Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp Glu Pro
 450 455 460
 Leu Glu Lys Gly Tyr Ser His Gln Leu Asn Tyr Val Met Cys Phe Leu
 465 470 475 480
 Met Gln Gly Ser Arg Gly Thr Ile Pro Val Leu Thr Trp Thr His Lys
 485 490 495
 Ser Val Asp Phe Phe Asn Met Ile Asp Ser Lys Lys Ile Thr Gln Leu
 500 505 510
 Pro Leu Val Lys Ala Tyr Lys Leu Gln Ser Gly Ala Ser Val Val Ala
 515 520 525
 Gly Pro Arg Phe Thr Gly Gly Asp Ile Ile Gln Cys Thr Glu Asn Gly
 530 535 540
 Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser Gln Lys
 545 550 555 560
 Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr Phe Thr
 565 570 575
 Leu Ser Leu Asp Gly Ala Pro Phe Asn Gln Tyr Tyr Phe Asp Lys Thr
 580 585 590
 Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser Phe Asn Leu Ala Ser
 595 600 605
 Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu Gln Ile Gly Val
 610 615 620
 Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp Lys Ile Glu Phe
 625 630 635 640
 Ile Pro Val Asn

<210> 3
 <211> 1803
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> CDS
 <222> (1)..(1794)
 <223> Maize optimized cry3A coding sequence

<400> 3
 atg acg gcc gac aac aac acc gag gcc ctg gac agc agc acc acc aag 48
 Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys
 1 5 10 15
 gac gtg atc cag aag ggc atc agc gtg gtg ggc gac ctg ctg ggc gtg 96
 Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val
 20 25 30
 gtg ggc ttc ccc ttc ggc ggc gcc ctg gtg agc ttc tac acc aac ttc 144
 Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe
 35 40 45
 ctg aac acc atc tgg ccc agc gag gac ccc tgg aag gcc ttc atg gag 192
 Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu
 50 55 60
 cag gtg gag gcc ctg atg gac cag aag atc gcc gac tac gcc aag aac 240
 Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn
 65 70 75 80
 aag gca ctg gcc gag cta cag ggc ctc cag aac aac gtg gag gac tat 288
 Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr
 85 90 95
 gtg agc gcc ctg agc agc tgg cag aag aac ccc gtc tcg agc cgc aac 336
 Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Val Ser Arg Asn
 100 105 110
 ccc cac agc cag ggc cgc atc cgc gag ctg ttc agc cag gcc gag agc 384
 Pro His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser
 115 120 125
 cac ttc cgc aac agc atg ccc agc ttc gcc atc agc ggc tac gag gtg 432
 His Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu Val
 130 135 140
 ctg ttc ctg acc acc tac gcc cag gcc gcc aac acc cac ctg ttc ctg 480
 Leu Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe Leu
 145 150 155 160
 ctg aag gac gcc caa atc tac gga gag gag tgg ggc tac gag aag gag 528
 Leu Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys Glu
 165 170 175

gac atc gcc gag ttc tac aag cgc cag ctg aag ctg acc cag gag tac Asp Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu Tyr 180 185 190	576
acc gac cac tgc gtg aag tgg tac aac gtg ggt cta gac aag ctc cgc Thr Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu Arg 195 200 205	624
ggc agc agc tac gag agc tgg gtg aac ttc aac cgc tac cgc cgc gag Gly Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg Glu 210 215 220	672
atg acc ctg acc gtg ctg gac ctg atc gcc ctg ttc ccc ctg tac gac Met Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr Asp 225 230 235 240	720
gtg cgc ctg tac ccc aag gag gtg aag acc gag ctg acc cgc gac gtg Val Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp Val 245 250 255	768
ctg acc gac ccc atc gtg ggc gtg aac aac ctg cgc ggc tac ggc acc Leu Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly Thr 260 265 270	816
acc ttc agc aac atc gag aac tac atc cgc aag ccc cac ctg ttc gac Thr Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe Asp 275 280 285	864
tac ctg cac cgc atc cag ttc cac acg cgt ttc cag ccc ggc tac tac Tyr Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr Tyr 290 295 300	912
ggc aac gac agc ttc aac tac tgg agc ggc aac tac gtg agc acc cgc Gly Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr Arg 305 310 315 320	960
ccc agc atc ggc agc aac gac atc atc acc agc ccc ttc tac ggc aac Pro Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly Asn 325 330 335	1008
aag agc agc gag ccc gtg cag aac ctt gag ttc aac ggc gag aag gtg Lys Ser Ser Glu Pro Val Gln Asn Leu Glu Phe Asn Gly Glu Lys Val 340 345 350	1056
tac cgc gcc gtg gct aac acc aac ctg gcc gtg tgg ccc tct gca gtg Tyr Arg Ala Val Ala Asn Thr Asn Leu Ala Val Trp Pro Ser Ala Val 355 360 365	1104
tac agc ggc gtg acc aag gtg gag ttc agc cag tac aac gac cag acc Tyr Ser Gly Val Thr Lys Val Glu Phe Ser Gln Tyr Asn Asp Gln Thr 370 375 380	1152
gac gag gcc agc acc cag acc tac gac agc aag cgc aac gtg ggc gcc	1200

Asp Glu Ala Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Val Gly Ala	
385 390 395 400	
gtg agc tgg gac agc atc gac cag ctg ccc ccc gag acc acc gac gag	1248
Val Ser Trp Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp Glu	
405 410 415	
ccc ctg gag aag ggc tac agc cac cag ctg aac tac gtg atg tgc ttc	1296
Pro Leu Glu Lys Gly Tyr Ser His Gln Leu Asn Tyr Val Met Cys Phe	
420 425 430	
ctg atg cag ggc agc cgc ggc acc atc ccc gtg ctg acc tgg acc cac	1344
Leu Met Gln Gly Ser Arg Gly Thr Ile Pro Val Leu Thr Trp Thr His	
435 440 445	
aag agc gtc gac ttc ttc aac atg atc gac agc aag aag atc acc cag	1392
Lys Ser Val Asp Phe Phe Asn Met Ile Asp Ser Lys Lys Ile Thr Gln	
450 455 460	
ctg ccc ctg gtg aag gcc tac aag ctc cag agc ggc gcc agc gtg gtg	1440
Leu Pro Leu Val Lys Ala Tyr Lys Leu Gln Ser Gly Ala Ser Val Val	
465 470 475 480	
gca ggc ccc cgc ttc acc ggc ggc gac atc atc cag tgc acc gag aac	1488
Ala Gly Pro Arg Phe Thr Gly Gly Asp Ile Ile Gln Cys Thr Glu Asn	
485 490 495	
ggc agc gcc gcc acc atc tac gtg acc ccc gac gtg agc tac agc cag	1536
Gly Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser Gln	
500 505 510	
aag tac cgc gcc cgc atc cac tac gcc agc acc agc cag atc acc ttc	1584
Lys Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr Phe	
515 520 525	
acc ctg agc ctg gac ggg gcc ccc ttc aac caa tac tac ttc gac aag	1632
Thr Leu Ser Leu Asp Gly Ala Pro Phe Asn Gln Tyr Tyr Phe Asp Lys	
530 535 540	
acc atc aac aag ggc gac acc ctg acc tac aac agc ttc aac ctg gcc	1680
Thr Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser Phe Asn Leu Ala	
545 550 555 560	
agc ttc agc acc cct ttc gag ctg agc ggc aac aac ctc cag atc ggc	1728
Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu Gln Ile Gly	
565 570 575	
gtg acc ggc ctg agc gcc ggc gac aag gtg tac atc gac aag atc gag	1776
Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp Lys Ile Glu	
580 585 590	
ttc atc ccc gtg aac tag atctgagct	1803
Phe Ile Pro Val Asn	
595	

<210> 4
 <211> 597
 <212> PRT
 <213> Cry3A encoded by SEQ ID NO:3.

<400> 4
 Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys
 1 5 10 15
 Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val
 20 25 30
 Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe
 35 40 45
 Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu
 50 55 60
 Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn
 65 70 75 80
 Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr
 85 90 95
 Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Val Ser Ser Arg Asn
 100 105 110
 Pro His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser
 115 120 125
 His Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu Val
 130 135 140
 Leu Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe Leu
 145 150 155 160
 Leu Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys Glu
 165 170 175
 Asp Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu Tyr
 180 185 190
 Thr Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu Arg
 195 200 205
 Gly Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg Glu
 210 215 220
 Met Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr Asp
 225 230 235 240
 Val Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp Val

					245						250						255
Leu	Thr	Asp	Pro	Ile	Val	Gly	Val	Asn	Asn	Leu	Arg	Gly	Tyr	Gly	Thr		
			260					265					270				
Thr	Phe	Ser	Asn	Ile	Glu	Asn	Tyr	Ile	Arg	Lys	Pro	His	Leu	Phe	Asp		
		275					280					285					
Tyr	Leu	His	Arg	Ile	Gln	Phe	His	Thr	Arg	Phe	Gln	Pro	Gly	Tyr	Tyr		
	290					295					300						
Gly	Asn	Asp	Ser	Phe	Asn	Tyr	Trp	Ser	Gly	Asn	Tyr	Val	Ser	Thr	Arg		
305					310					315					320		
Pro	Ser	Ile	Gly	Ser	Asn	Asp	Ile	Ile	Thr	Ser	Pro	Phe	Tyr	Gly	Asn		
				325					330					335			
Lys	Ser	Ser	Glu	Pro	Val	Gln	Asn	Leu	Glu	Phe	Asn	Gly	Glu	Lys	Val		
			340					345					350				
Tyr	Arg	Ala	Val	Ala	Asn	Thr	Asn	Leu	Ala	Val	Trp	Pro	Ser	Ala	Val		
		355					360					365					
Tyr	Ser	Gly	Val	Thr	Lys	Val	Glu	Phe	Ser	Gln	Tyr	Asn	Asp	Gln	Thr		
	370					375					380						
Asp	Glu	Ala	Ser	Thr	Gln	Thr	Tyr	Asp	Ser	Lys	Arg	Asn	Val	Gly	Ala		
385					390					395				400			
Val	Ser	Trp	Asp	Ser	Ile	Asp	Gln	Leu	Pro	Pro	Glu	Thr	Thr	Asp	Glu		
				405					410					415			
Pro	Leu	Glu	Lys	Gly	Tyr	Ser	His	Gln	Leu	Asn	Tyr	Val	Met	Cys	Phe		
		420						425					430				
Leu	Met	Gln	Gly	Ser	Arg	Gly	Thr	Ile	Pro	Val	Leu	Thr	Trp	Thr	His		
	435						440					445					
Lys	Ser	Val	Asp	Phe	Phe	Asn	Met	Ile	Asp	Ser	Lys	Lys	Ile	Thr	Gln		
	450					455					460						
Leu	Pro	Leu	Val	Lys	Ala	Tyr	Lys	Leu	Gln	Ser	Gly	Ala	Ser	Val	Val		
465					470					475				480			
Ala	Gly	Pro	Arg	Phe	Thr	Gly	Gly	Asp	Ile	Ile	Gln	Cys	Thr	Glu	Asn		
				485					490					495			
Gly	Ser	Ala	Ala	Thr	Ile	Tyr	Val	Thr	Pro	Asp	Val	Ser	Tyr	Ser	Gln		
		500						505					510				
Lys	Tyr	Arg	Ala	Arg	Ile	His	Tyr	Ala	Ser	Thr	Ser	Gln	Ile	Thr	Phe		
	515						520					525					
Thr	Leu	Ser	Leu	Asp	Gly	Ala	Pro	Phe	Asn	Gln	Tyr	Tyr	Phe	Asp	Lys		

530	535	540	
Thr Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser Phe Asn Leu Ala			
545	550	555	560
Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu Gln Ile Gly			
	565	570	575
Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp Lys Ile Glu			
	580	585	590
Phe Ile Pro Val Asn			
595			

<210> 5
 <211> 7208
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <223> pCIB6850

<400> 5

gatccac	cat	gacggcc	gac	aacaacacc	gaggccctgga	cagcagcacc	accaagggacg	60
tgatccagaa	gggcatcagc	gtggtgggcg	acctgctggg	cgtggtgggc	ttcccccttcg			120
gcggcgccct	ggtgagcttc	tacaccaact	tcctgaacac	catctggccc	agcgaggacc			180
cctggaaggc	cttcatggag	caggtggagg	ccctgatgga	ccagaagatc	gccgactacg			240
ccaagaacaa	ggcactggcc	gagctacagg	gcctccagaa	caacgtggag	gactatgtga			300
gcgccttgag	cagctggcag	aagaaccccg	tctcgagccg	caacccccac	agccagggcc			360
gcatccgcga	gctgttcagc	caggccgaga	gccacttcg	caacagcatg	cccagcttcg			420
ccatcagcgg	ctacgaggtg	ctgttctga	ccacctacgc	ccaggccgcc	aacacccacc			480
tgttcctgct	gaaggacgcc	caaactctacg	gagaggagtg	gggctacgag	aaggaggaca			540
tcgccgagtt	ctacaagcgc	cagctgaagc	tgacccagga	gtacaccgac	cactgcgtga			600
agtggtagaa	cgtgggtcta	gacaagctcc	gcggcagcag	ctacgagagc	tgggtgaact			660
tcaaccgcta	ccgcgcgag	atgacctga	ccgtgctgga	cctgatcgcc	ctgttcccc			720
tgtacgacgt	gcgcctgtac	cccaaggagg	tgaagaccga	gctgaccgcg	gacgtgctga			780
ccgaccccat	cgtgggcgtg	aacaacctgc	gcggctacgg	caccaccttc	agcaacatcg			840
agaactacat	ccgcaagccc	cacctgttcg	actacctgca	ccgcatccag	ttccacacgc			900
gtttccagcc	cggctactac	ggcaacgaca	gcttcaacta	ctggagcggc	aactacgtga			960
gcacccgccc	cagcatcggc	agcaacgaca	tcacaccag	ccccttctac	ggcaacaaga			1020
gcagcgagac	cgtgcagaac	cttgagttca	acggcgagaa	ggtgtaccgc	gccgtggcta			1080
acaccaacct	ggccgtgtgg	ccctctgcag	tgtacagcgg	cgtgaccaag	gtggagttca			1140
gccagtacaa	cgaccagacc	gacgaggcca	gcacccagac	ctacgacagc	aagcgcaacg			1200
tgggcgcctg	gagctgggac	agcatcgacc	agctgcccc	cgagaccacc	gacgagcccc			1260
tggagaaggg	ctacagccac	cagctgaact	acgtgatgtg	cttcctgatg	cagggcagcc			1320
gcggcaccat	ccccgtgctg	acctggaccc	acaagagcgt	cgacttcttc	aacatgatcg			1380
acagcaagaa	gatcaccag	ctgcccctgg	tgaaggccta	caagctccag	agcggcgcca			1440
gcgtggtggc	aggccccgcg	ttcacccggc	gcgacatcat	ccagtgcacc	gagaacggca			1500
gcgcgcgccc	catctacgtg	acccccgacg	tgagctacag	ccagaagtac	cgcgcgcgca			1560
tcactacgc	cagcaccagc	cagatcacct	tcacctgag	cctggacggg	gcccccttca			1620
accaatacta	cttcgacaag	accatcaaca	agggcgacac	cctgacctac	aacagcttca			1680
acctggccag	cttcagcacc	cctttcgagc	tgagcggcaa	caacctccag	atcggcgtga			1740

ccggcctgag	cgccggcgac	aaggtgtaca	tcgacaagat	cgagttcatc	cccgtgaact	1800
agatctgagc	tcaagatctg	ttgtacaaaa	accagcaact	cactgcactg	cacttcactt	1860
cacttcactg	tatgaataaa	agtctggtgt	ctgggttcctg	atcgatgact	gactactcca	1920
ctttgtgcag	aacttagtat	gtatttgtat	ttgtaaaata	cttctatcaa	taaaatttct	1980
aattcctaaa	acaaaaatcc	agtgggtacc	gaattcactg	gccgtcgttt	tacaacgtcg	2040
tgactgggaa	aaccttggcg	ttaccaact	taatcgctt	gcagcacatc	ccccttctgc	2100
cagctggcgt	aatagcgaag	aggcccgac	cgatcgccct	tccaacagt	tgcgagcct	2160
gaatggcgaa	tggcgctga	tgcggtat	tctccttacg	catctgtgcg	gtatttcaca	2220
ccgcatatgg	tgcactctca	gtacaatctg	ctctgatgcc	gcatagttaa	gccagccccg	2280
acacccgcca	acacccgctg	acgcgccctg	acgggcttgt	ctgctcccg	catccgctta	2340
cagacaagct	gtgaccgtct	ccgggagctg	catgtgtcag	aggttttcac	cgatcatcacc	2400
gaaacgcgcg	agacgaaagg	gcctcgtgat	acgcctat	ttataggtta	atgtcatgat	2460
aataatggtt	tcttagacgt	cagggtggcac	ttttcgggga	aatgtgcgcg	gaacccctat	2520
ttgtttat	ttctaaatac	attcaaata	gtatccgctc	atgagacaat	aacctgata	2580
aatgcttcaa	taatatggaa	aaaggaagag	tatgagtatt	caacatttcc	gtgtcgccct	2640
tattcccttt	tttgcggcat	tttgccttcc	tgtttttgct	caccagaaa	cgctggtgaa	2700
agtaaaagat	gctgaagatc	agttgggtgc	acgagtgggt	tacatcgaa	tggatctcaa	2760
cagcgtgaag	atccttgaga	gttttcgccc	cgaagaacgt	tttccaatga	tgagcacttt	2820
taaagtctg	ctatgtggcg	cgggtattatc	ccgtattgac	gccgggcaag	agcaactcgg	2880
tcgccgcata	cactattctc	agaatgactt	ggttgagtac	tcaccagtca	cagaaaagca	2940
tcttacggat	ggcatgacag	taagagaatt	atgcagtgt	gccataacca	tgagtataa	3000
cactgcggcc	aacttacttc	tgacaacgat	cggaggaccg	aaggagctaa	ccgctttttt	3060
gcacaacatg	ggggatcatg	taactcgct	tgatcgttgg	gaaccggagc	tgaatgaagc	3120
cataccaaac	gacgagcgtg	acaccacgat	gcctgtagca	atggcaacaa	cgttgcgcaa	3180
actattaact	ggcgaactac	ttactctagc	ttcccggcaa	caattaatag	actggatgga	3240
ggcgataaaa	gttgcaggac	cacttctgcg	ctcggccctt	ccggctggct	ggtttattgc	3300
tgataaatct	ggagccgggtg	agcgtgggtc	tcgcggtatc	attgcagcac	tggggccaga	3360
tggtaagccc	tcccgatatc	tagttatcta	cacgacgggg	agtcaggcaa	ctatggatga	3420
acgaaataga	cagatcgctg	agataggtgc	ctcactgatt	aagcattgg	aactgtcaga	3480
ccaagtttac	tcatatatac	tttagattga	tttaaaactt	cattttta	ttaaaaggat	3540
ctaggtgaag	atcctttttg	ataatctcat	gacaaaatc	ccttaacgtg	agttttcg	3600
ccactgagcg	tcagaccccc	tagaaaagat	caaaggatct	tcttgagatc	ctttttttct	3660
gcgcgtaatc	tgtgtcttgc	aaacaaaaaa	accacgccta	ccagcgggtg	tttgtttgcc	3720
ggatcaagag	ctaccaactc	tttttcgaa	ggtaactggc	ttcagcagag	cgcagatacc	3780
aaatactgtc	cttctagtgt	agccgtagtt	aggccaccac	ttcaagaact	ctgtagcacc	3840
gcctacatac	ctcgtctctg	taatcctgtt	accagtggct	gctgccagt	gcgataagtc	3900
gtgtcttacc	gggttgga	caagacgata	gttaccggat	aaggcgagc	ggtcgggctg	3960
aacggggggt	tcgtgcacac	agcccagctt	ggagcgaacg	acctacaccg	aactgagata	4020
cctacagcgt	gagctatgag	aaagcgccac	gcttcccga	gggagaaagg	cggacaggta	4080
tccggtaa	ggcagggtcg	gaacaggaga	gcgcacgagg	gagcttccag	ggggaaacgc	4140
ctggatctt	tatagtctcg	tcgggtttcg	ccacctctga	cttgagcgtc	gatttttgtg	4200
atgctcgtca	ggggggcgga	gcctatggaa	aaacgccagc	aacgcggcct	ttttacggtt	4260
cctggccttt	tgttggcctt	ttgctcacat	gttcttctct	gcgttatccc	ctgattctgt	4320
ggataaccgt	attaccgctt	ttgagtgc	tgataccgct	cgccgcagcc	gaacgaccga	4380
gcgcagcgag	tcagtgcg	aggaagcgga	agagcgccca	atacgcaa	cgctctccc	4440
cgcgcggttg	ccgattcatt	aatgcagctg	gcacgacagg	ttcccga	ggaaagcg	4500
cagtgcgc	aacgcaatta	atgtgagtta	gctcactcat	taggcacccc	aggctttaca	4560
ctttatgctt	ccggctcgta	tgttgtgtg	aattgtgagc	ggataaca	ttcacacagg	4620
aaacagctat	gaccatgatt	acgccaagct	tgacatgac	aacaattgta	agaggatgga	4680
gaccacaacg	atccaaca	acttctgcga	cgggctgtga	agtatagaga	agttaaacgc	4740
ccaaaagcca	ttgtgtttg	aatttttagt	tattctat	ttcatgatgt	atcttctct	4800
aacatgcctt	aatttgcaaa	tttggtataa	ctactgattg	aaaatatatg	tatgtaaaaa	4860
aatactaagc	atatttgtga	agctaaca	gatgttattt	aagaaaatat	gttgtaaca	4920
gaataagatt	aatatcgaaa	tggaaacatc	tgtaaattag	aatcatctta	caagctaaga	4980

```

gatgttcacg ctttgagaaa cttcttcaga tcatgaccgt agaagtagct ctccaagact 5040
caacgaaggc tgctgcaatt ccacaaatgc atgacatgca tccttgtaac cgtcgtcgcc 5100
gctataaaca cggataactc aattccctgc tccatcaatt tagaaatgag caagcaagca 5160
cccgatcgct caccatcatat gcaccaatct gactcccaag tctctgtttc gcattagtag 5220
cgccagcact ccacatatag ctaccaattg agacctttcc agcctaagca gatcgattga 5280
tcgttagagt caaagagttg gtggtacggg tactttaact accatggaat gatggggcgt 5340
gatgtagagc ggaaagcgcc tccctacgcg gaacaacacc ctcgccatgc cgctcgacta 5400
cagcctcctc ctcgtcggcc gccacaacg agggagcccg tggtcgcagc caccgaccag 5460
catgtctctg tgtcctcgct cgacctcgac atgtcatggc aaacagtcgg acgccagcac 5520
cagactgacg acatgagtct ctgaagagcc cgccacctag aaagatccga gccctgctgc 5580
tggtagtggt aaccattttc gtcgcgctga cgccgagagc gagaggccag aaatttatag 5640
cgactgacgc tgtggcaggc acgctatcgg aggttacgac gtggcgggtc actcgacgcg 5700
gagttcacag gtcctatcct tgcacgcctc gggccggagt ttacgggact tatccttacg 5760
acgtgctcta aggttgcat aacgggcgga ggaaggcgtg tggcgtgcgg agacggttta 5820
tacacgtagt gtgcgggagt gtgtttcgta gacgcgggaa agcacgacga cttacgaagg 5880
ttagtgagg aggaggacac actaaaatca ggacgcaaga aactcttcta ttatagtagt 5940
agagaagaga ttataggagt gtgggttgat tctaaagaaa atcgacgcag gacaaccgtc 6000
aaaacgggtg ctttaatata gtagatatat atatatagag agagagagaa agtacaaagg 6060
atgcatttgt gtctgcatat gatcggagta ttactaacgg ccgtcgtaag aagggtccatc 6120
atgcgtggag cgagcccatt tggttggttg tcaggccgca gttaaggcct ccatatatga 6180
ttgtcgtcgg gcccataaca gcatctcctc caccagttta ttgtaagaat aaattaagta 6240
gagatatttg tcgtcgggca gaagaaactt ggacaagaag aagaagcaag ctaggccaat 6300
ttcttgccgg caagaggaag atagtggcct ctagtttata tatcggcgtg atgatgatgc 6360
tcctagctag aaatgagaga agaaaaacgg acgcgtgttt ggtgtgtgtc aatggcgctc 6420
atccttccat cagatcagaa cgatgaaaaa gtcaagcacg gcatgcatag tatatgtata 6480
gcttggttta gtgtggcttt gctgagacga atgaaagcaa cggcgggcat atttttcagt 6540
ggctgtagct ttcaggctga aagagacgtg gcatgcaata attcaggga ttcgtcagcc 6600
aattgaggta gctagtcaac ttgtacattg gtgcgagcaa ttttccgcac tcaggagggc 6660
tagtttgaga gtccaaaaac tataggagat taaagaggct aaaatcctct ccttatttaa 6720
ttttaaataa gtagtgtatt tgtattttaa ctctccaac ccttccgatt ttatggtct 6780
caaactagca ttcagtctaa tgcacgcatg cttggctaga ggtcgtatgg ggttggtta 6840
agcatagcta gctacaagtt aaccgggtct tttatattta ataaggacag gcaaagtatt 6900
acttacaat aaagaataaa gctaggacga actcgtggat tattactaaa tcgaaatgga 6960
cgtaatatcc caggcaagaa taattgttcg atcaggagac aagtggggca ttggaccggt 7020
tcttgcaagc aagagcctat ggcgtggtga cacggcgcggt tgcccataca tcatgcctcc 7080
atcgatgac catcctcact tgctataaaa agaggtgtcc atggtgctca agctcagcca 7140
agcaaataag acgacttggt tcattgattc ttcaagagat cgagcttctt ttgcaccaca 7200
aggtcgag 7208

```

<210> 6

<211> 1801

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(1791)

<223> Maize optimized modified cry3A054 coding sequence.

<220>

<221> misc_feature

<222> (322)..(333)

<223> cathepsin G recognition site coding sequence

<400> 6
 atg acg gcc gac aac aac acc gag gcc ctg gac agc agc acc acc aag 48
 Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys
 1 5 10 15

gac gtg atc cag aag ggc atc agc gtg gtg ggc gac ctg ctg ggc gtg 96
 Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val
 20 25 30

gtg ggc ttc ccc ttc ggc ggc gcc ctg gtg agc ttc tac acc aac ttc 144
 Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe
 35 40 45

ctg aac acc atc tgg ccc agc gag gac ccc tgg aag gcc ttc atg gag 192
 Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu
 50 55 60

cag gtg gag gcc ctg atg gac cag aag atc gcc gac tac gcc aag aac 240
 Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn
 65 70 75 80

aag gca ctg gcc gag cta cag ggc ctc cag aac aac gtg gag gac tat 288
 Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr
 85 90 95

gtg agc gcc ctg agc agc tgg cag aag aac ccc gct gca ccg ttc ccc 336
 Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Ala Ala Pro Phe Pro
 100 105 110

cac agc cag ggc cgc atc cgc gag ctg ttc agc cag gcc gag agc cac 384
 His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser His
 115 120 125

ttc cgc aac agc atg ccc agc ttc gcc atc agc ggc tac gag gtg ctg 432
 Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu Val Leu
 130 135 140

ttc ctg acc acc tac gcc cag gcc gcc aac acc cac ctg ttc ctg ctg 480
 Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe Leu Leu
 145 150 155 160

aag gac gcc caa atc tac gga gag gag tgg ggc tac gag aag gag gac 528
 Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys Glu Asp
 165 170 175

atc gcc gag ttc tac aag cgc cag ctg aag ctg acc cag gag tac acc 576
 Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu Tyr Thr
 180 185 190

gac cac tgc gtg aag tgg tac aac gtg ggt cta gac aag ctc cgc ggc 624
 Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu Arg Gly
 195 200 205

agc agc tac gag agc tgg gtg aac ttc aac cgc tac cgc cgc gag atg Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg Glu Met 210 215 220	672
acc ctg acc gtg ctg gac ctg atc gcc ctg ttc ccc ctg tac gac gtg Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr Asp Val 225 230 235 240	720
cgc ctg tac ccc aag gag gtg aag acc gag ctg acc cgc gac gtg ctg Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp Val Leu 245 250 255	768
acc gac ccc atc gtg ggc gtg aac aac ctg cgc ggc tac ggc acc acc Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly Thr Thr 260 265 270	816
ttc agc aac atc gag aac tac atc cgc aag ccc cac ctg ttc gac tac Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe Asp Tyr 275 280 285	864
ctg cac cgc atc cag ttc cac acg cgt ttc cag ccc ggc tac tac ggc Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr Tyr Gly 290 295 300	912
aac gac agc ttc aac tac tgg agc ggc aac tac gtg agc acc cgc ccc Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr Arg Pro 305 310 315 320	960
agc atc ggc agc aac gac atc atc acc agc ccc ttc tac ggc aac aag Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly Asn Lys 325 330 335	1008
agc agc gag ccc gtg cag aac ctt gag ttc aac ggc gag aag gtg tac Ser Ser Glu Pro Val Gln Asn Leu Glu Phe Asn Gly Glu Lys Val Tyr 340 345 350	1056
cgc gcc gtg gct aac acc aac ctg gcc gtg tgg ccc tct gca gtg tac Arg Ala Val Ala Asn Thr Asn Leu Ala Val Trp Pro Ser Ala Val Tyr 355 360 365	1104
agc ggc gtg acc aag gtg gag ttc agc cag tac aac gac cag acc gac Ser Gly Val Thr Lys Val Glu Phe Ser Gln Tyr Asn Asp Gln Thr Asp 370 375 380	1152
gag gcc agc acc cag acc tac gac agc aag cgc aac gtg ggc gcc gtg Glu Ala Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Val Gly Ala Val 385 390 395 400	1200
agc tgg gac agc atc gac cag ctg ccc ccc gag acc acc gac gag ccc Ser Trp Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp Glu Pro 405 410 415	1248
ctg gag aag ggc tac agc cac cag ctg aac tac gtg atg tgc ttc ctg Leu Glu Lys Gly Tyr Ser His Gln Leu Asn Tyr Val Met Cys Phe Leu	1296

420	425	430	
atg cag ggc agc cgc ggc acc atc ccc gtg ctg acc tgg acc cac aag			1344
Met Gln Gly Ser Arg Gly Thr Ile Pro Val Leu Thr Trp Thr His Lys			
435	440	445	
agc gtc gac ttc ttc aac atg atc gac agc aag aag atc acc cag ctg			1392
Ser Val Asp Phe Phe Asn Met Ile Asp Ser Lys Lys Ile Thr Gln Leu			
450	455	460	
ccc ctg gtg aag gcc tac aag ctc cag agc ggc gcc agc gtg gtg gca			1440
Pro Leu Val Lys Ala Tyr Lys Leu Gln Ser Gly Ala Ser Val Val Ala			
465	470	475	480
ggc ccc cgc ttc acc ggc ggc gac atc atc cag tgc acc gag aac ggc			1488
Gly Pro Arg Phe Thr Gly Gly Asp Ile Ile Gln Cys Thr Glu Asn Gly			
485	490	495	
agc gcc gcc acc atc tac gtg acc ccc gac gtg agc tac agc cag aag			1536
Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser Gln Lys			
500	505	510	
tac cgc gcc cgc atc cac tac gcc agc acc agc cag atc acc ttc acc			1584
Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr Phe Thr			
515	520	525	
ctg agc ctg gac ggg gcc ccc ttc aac caa tac tac ttc gac aag acc			1632
Leu Ser Leu Asp Gly Ala Pro Phe Asn Gln Tyr Tyr Phe Asp Lys Thr			
530	535	540	
atc aac aag ggc gac acc ctg acc tac aac agc ttc aac ctg gcc agc			1680
Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser Phe Asn Leu Ala Ser			
545	550	555	560
ttc agc acc cct ttc gag ctg agc ggc aac aac ctc cag atc ggc gtg			1728
Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu Gln Ile Gly Val			
565	570	575	
acc ggc ctg agc gcc ggc gac aag gtg tac atc gac aag atc gag ttc			1776
Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp Lys Ile Glu Phe			
580	585	590	
atc ccc gtg aac tag atctgagctc			1801
Ile Pro Val Asn			
595			

<210> 7

<211> 596

<212> PRT

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (322) .. (333)

<223> cathepsin G recognition site coding sequence

<400> 7

```

Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys
1           5           10           15

Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val
           20           25           30

Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe
           35           40           45

Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu
           50           55           60

Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn
65           70           75           80

Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr
           85           90           95

Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Ala Ala Pro Phe Pro
           100          105          110

His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser His
           115          120          125

Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu Val Leu
           130          135          140

Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe Leu Leu
145          150          155          160

Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys Glu Asp
           165          170          175

Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu Tyr Thr
           180          185          190

Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu Arg Gly
           195          200          205

Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg Glu Met
           210          215          220

Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr Asp Val
225          230          235          240

Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp Val Leu
           245          250          255

Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly Thr Thr
           260          265          270

```

Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe Asp Tyr
 275 280 285
 Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr Tyr Gly
 290 295 300
 Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr Arg Pro
 305 310 315 320
 Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly Asn Lys
 325 330 335
 Ser Ser Glu Pro Val Gln Asn Leu Glu Phe Asn Gly Glu Lys Val Tyr
 340 345 350
 Arg Ala Val Ala Asn Thr Asn Leu Ala Val Trp Pro Ser Ala Val Tyr
 355 360 365
 Ser Gly Val Thr Lys Val Glu Phe Ser Gln Tyr Asn Asp Gln Thr Asp
 370 375 380
 Glu Ala Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Val Gly Ala Val
 385 390 395 400
 Ser Trp Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp Glu Pro
 405 410 415
 Leu Glu Lys Gly Tyr Ser His Gln Leu Asn Tyr Val Met Cys Phe Leu
 420 425 430
 Met Gln Gly Ser Arg Gly Thr Ile Pro Val Leu Thr Trp Thr His Lys
 435 440 445
 Ser Val Asp Phe Phe Asn Met Ile Asp Ser Lys Lys Ile Thr Gln Leu
 450 455 460
 Pro Leu Val Lys Ala Tyr Lys Leu Gln Ser Gly Ala Ser Val Val Ala
 465 470 475 480
 Gly Pro Arg Phe Thr Gly Gly Asp Ile Ile Gln Cys Thr Glu Asn Gly
 485 490 495
 Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser Gln Lys
 500 505 510
 Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr Phe Thr
 515 520 525
 Leu Ser Leu Asp Gly Ala Pro Phe Asn Gln Tyr Tyr Phe Asp Lys Thr
 530 535 540
 Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser Phe Asn Leu Ala Ser
 545 550 555 560

Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu Gln Ile Gly Val
 565 570 575

Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp Lys Ile Glu Phe
 580 585 590

Ile Pro Val Asn
 595

<210> 8

<211> 1807

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(1806)

<223> Maize optimized modified cry3A055 coding sequence.

<220>

<221> misc_feature

<222> (322)..(333)

<223> Cthepsin G recognition site coding sequence.

<400> 8

atg	acg	gcc	gac	aac	aac	acc	gag	gcc	ctg	gac	agc	agc	acc	acc	aag	48
Met	Thr	Ala	Asp	Asn	Asn	Thr	Glu	Ala	Leu	Asp	Ser	Ser	Thr	Thr	Lys	
1				5					10					15		

gac	gtg	atc	cag	aag	ggc	atc	agc	gtg	gtg	ggc	gac	ctg	ctg	ggc	gtg	96
Asp	Val	Ile	Gln	Lys	Gly	Ile	Ser	Val	Val	Gly	Asp	Leu	Leu	Gly	Val	
			20					25					30			

gtg	ggc	ttc	ccc	ttc	ggc	ggc	gcc	ctg	gtg	agc	ttc	tac	acc	aac	ttc	144
Val	Gly	Phe	Pro	Phe	Gly	Gly	Ala	Leu	Val	Ser	Phe	Tyr	Thr	Asn	Phe	
		35					40					45				

ctg	aac	acc	atc	tgg	ccc	agc	gag	gac	ccc	tgg	aag	gcc	ttc	atg	gag	192
Leu	Asn	Thr	Ile	Trp	Pro	Ser	Glu	Asp	Pro	Trp	Lys	Ala	Phe	Met	Glu	
	50					55					60					

cag	gtg	gag	gcc	ctg	atg	gac	cag	aag	atc	gcc	gac	tac	gcc	aag	aac	240
Gln	Val	Glu	Ala	Leu	Met	Asp	Gln	Lys	Ile	Ala	Asp	Tyr	Ala	Lys	Asn	
65				70					75						80	

aag	gca	ctg	gcc	gag	cta	cag	ggc	ctc	cag	aac	aac	gtg	gag	gac	tat	288
Lys	Ala	Leu	Ala	Glu	Leu	Gln	Gly	Leu	Gln	Asn	Asn	Val	Glu	Asp	Tyr	
			85					90					95			

gtg	agc	gcc	ctg	agc	agc	tgg	cag	aag	aac	ccc	gct	gca	ccg	ttc	cgc	336
Val	Ser	Ala	Leu	Ser	Ser	Trp	Gln	Lys	Asn	Pro	Ala	Ala	Pro	Phe	Arg	
			100					105					110			

aac ccc cac agc cag ggc cgc atc cgc gag ctg ttc agc cag gcc gag	384
Asn Pro His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu	
115 120 125	
agc cac ttc cgc aac agc atg ccc agc ttc gcc atc agc ggc tac gag	432
Ser His Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu	
130 135 140	
gtg ctg ttc ctg acc acc tac gcc cag gcc gcc aac acc cac ctg ttc	480
Val Leu Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe	
145 150 155 160	
ctg ctg aag gac gcc caa atc tac gga gag gag tgg ggc tac gag aag	528
Leu Leu Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys	
165 170 175	
gag gac atc gcc gag ttc tac aag cgc cag ctg aag ctg acc cag gag	576
Glu Asp Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu	
180 185 190	
tac acc gac cac tgc gtg aag tgg tac aac gtg ggt cta gac aag ctc	624
Tyr Thr Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu	
195 200 205	
cgc ggc agc agc tac gag agc tgg gtg aac ttc aac cgc tac cgc cgc	672
Arg Gly Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg	
210 215 220	
gag atg acc ctg acc gtg ctg gac ctg atc gcc ctg ttc ccc ctg tac	720
Glu Met Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr	
225 230 235 240	
gac gtg cgc ctg tac ccc aag gag gtg aag acc gag ctg acc cgc gac	768
Asp Val Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp	
245 250 255	
gtg ctg acc gac ccc atc gtg ggc gtg aac aac ctg cgc ggc tac ggc	816
Val Leu Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly	
260 265 270	
acc acc ttc agc aac atc gag aac tac atc cgc aag ccc cac ctg ttc	864
Thr Thr Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe	
275 280 285	
gac tac ctg cac cgc atc cag ttc cac acg cgt ttc cag ccc ggc tac	912
Asp Tyr Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr	
290 295 300	
tac ggc aac gac agc ttc aac tac tgg agc ggc aac tac gtg agc acc	960
Tyr Gly Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr	
305 310 315 320	
cgc ccc agc atc ggc agc aac gac atc atc acc agc ccc ttc tac ggc	1008

Arg	Pro	Ser	Ile	Gly	Ser	Asn	Asp	Ile	Ile	Thr	Ser	Pro	Phe	Tyr	Gly	
				325					330					335		
aac	aag	agc	agc	gag	ccc	gtg	cag	aac	ctt	gag	ttc	aac	ggc	gag	aag	1056
Asn	Lys	Ser	Ser	Glu	Pro	Val	Gln	Asn	Leu	Glu	Phe	Asn	Gly	Glu	Lys	
			340					345					350			
gtg	tac	cgc	gcc	gtg	gct	aac	acc	aac	ctg	gcc	gtg	tgg	ccc	tct	gca	1104
Val	Tyr	Arg	Ala	Val	Ala	Asn	Thr	Asn	Leu	Ala	Val	Trp	Pro	Ser	Ala	
			355				360					365				
gtg	tac	agc	ggc	gtg	acc	aag	gtg	gag	ttc	agc	cag	tac	aac	gac	cag	1152
Val	Tyr	Ser	Gly	Val	Thr	Lys	Val	Glu	Phe	Ser	Gln	Tyr	Asn	Asp	Gln	
	370					375					380					
acc	gac	gag	gcc	agc	acc	cag	acc	tac	gac	agc	aag	cgc	aac	gtg	ggc	1200
Thr	Asp	Glu	Ala	Ser	Thr	Gln	Thr	Tyr	Asp	Ser	Lys	Arg	Asn	Val	Gly	
385					390				395					400		
gcc	gtg	agc	tgg	gac	agc	atc	gac	cag	ctg	ccc	ccc	gag	acc	acc	gac	1248
Ala	Val	Ser	Trp	Asp	Ser	Ile	Asp	Gln	Leu	Pro	Pro	Glu	Thr	Thr	Asp	
			405					410					415			
gag	ccc	ctg	gag	aag	ggc	tac	agc	cac	cag	ctg	aac	tac	gtg	atg	tgc	1296
Glu	Pro	Leu	Glu	Lys	Gly	Tyr	Ser	His	Gln	Leu	Asn	Tyr	Val	Met	Cys	
		420						425				430				
ttc	ctg	atg	cag	ggc	agc	cgc	ggc	acc	atc	ccc	gtg	ctg	acc	tgg	acc	1344
Phe	Leu	Met	Gln	Gly	Ser	Arg	Gly	Thr	Ile	Pro	Val	Leu	Thr	Trp	Thr	
	435						440					445				
cac	aag	agc	gtc	gac	ttc	ttc	aac	atg	atc	gac	agc	aag	aag	atc	acc	1392
His	Lys	Ser	Val	Asp	Phe	Phe	Asn	Met	Ile	Asp	Ser	Lys	Lys	Ile	Thr	
	450					455				460						
cag	ctg	ccc	ctg	gtg	aag	gcc	tac	aag	ctc	cag	agc	ggc	gcc	agc	gtg	1440
Gln	Leu	Pro	Leu	Val	Lys	Ala	Tyr	Lys	Leu	Gln	Ser	Gly	Ala	Ser	Val	
465				470					475					480		
gtg	gca	ggc	ccc	cgc	ttc	acc	ggc	ggc	gac	atc	atc	cag	tgc	acc	gag	1488
Val	Ala	Gly	Pro	Arg	Phe	Thr	Gly	Gly	Asp	Ile	Ile	Gln	Cys	Thr	Glu	
			485					490					495			
aac	ggc	agc	gcc	gcc	acc	atc	tac	gtg	acc	ccc	gac	gtg	agc	tac	agc	1536
Asn	Gly	Ser	Ala	Ala	Thr	Ile	Tyr	Val	Thr	Pro	Asp	Val	Ser	Tyr	Ser	
			500					505				510				
cag	aag	tac	cgc	gcc	cgc	atc	cac	tac	gcc	agc	acc	agc	cag	atc	acc	1584
Gln	Lys	Tyr	Arg	Ala	Arg	Ile	His	Tyr	Ala	Ser	Thr	Ser	Gln	Ile	Thr	
	515						520					525				
ttc	acc	ctg	agc	ctg	gac	ggg	gcc	ccc	ttc	aac	caa	tac	tac	ttc	gac	1632
Phe	Thr	Leu	Ser	Leu	Asp	Gly	Ala	Pro	Phe	Asn	Gln	Tyr	Tyr	Phe	Asp	
	530					535					540					

aag acc atc aac aag ggc gac acc ctg acc tac aac agc ttc aac ctg 1680
 Lys Thr Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser Phe Asn Leu
 545 550 555 560

gcc agc ttc agc acc cct ttc gag ctg agc ggc aac aac ctc cag atc 1728
 Ala Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu Gln Ile
 565 570 575

ggc gtg acc ggc ctg agc gcc ggc gac aag gtg tac atc gac aag atc 1776
 Gly Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp Lys Ile
 580 585 590

gag ttc atc ccc gtg aac tag atc tga gct c 1807
 Glu Phe Ile Pro Val Asn Ile Ala
 595 600

<210> 9

<211> 598

<212> PRT

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (322)..(333)

<223> Cthepsin G recognition site coding sequence.

<400> 9

Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys
 1 5 10 15

Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val
 20 25 30

Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe
 35 40 45

Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu
 50 55 60

Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn
 65 70 75 80

Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr
 85 90 95

Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Ala Ala Pro Phe Arg
 100 105 110

Asn Pro His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu
 115 120 125

Ser His Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu

130	135	140
Val Leu Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe 145 150 155 160		
Leu Leu Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys 165 170 175		
Glu Asp Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu 180 185 190		
Tyr Thr Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu 195 200 205		
Arg Gly Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg 210 215 220		
Glu Met Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr 225 230 235 240		
Asp Val Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp 245 250 255		
Val Leu Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly 260 265 270		
Thr Thr Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe 275 280 285		
Asp Tyr Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr 290 295 300		
Tyr Gly Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr 305 310 315 320		
Arg Pro Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly 325 330 335		
Asn Lys Ser Ser Glu Pro Val Gln Asn Leu Glu Phe Asn Gly Glu Lys 340 345 350		
Val Tyr Arg Ala Val Ala Asn Thr Asn Leu Ala Val Trp Pro Ser Ala 355 360 365		
Val Tyr Ser Gly Val Thr Lys Val Glu Phe Ser Gln Tyr Asn Asp Gln 370 375 380		
Thr Asp Glu Ala Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Val Gly 385 390 395 400		
Ala Val Ser Trp Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp 405 410 415		
Glu Pro Leu Glu Lys Gly Tyr Ser His Gln Leu Asn Tyr Val Met Cys		

420	425	430
Phe Leu Met Gln Gly Ser Arg Gly Thr Ile Pro Val Leu Thr Trp Thr		
435	440	445
His Lys Ser Val Asp Phe Phe Asn Met Ile Asp Ser Lys Lys Ile Thr		
450	455	460
Gln Leu Pro Leu Val Lys Ala Tyr Lys Leu Gln Ser Gly Ala Ser Val		
465	470	475
Val Ala Gly Pro Arg Phe Thr Gly Gly Asp Ile Ile Gln Cys Thr Glu		
485	490	495
Asn Gly Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser		
500	505	510
Gln Lys Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr		
515	520	525
Phe Thr Leu Ser Leu Asp Gly Ala Pro Phe Asn Gln Tyr Tyr Phe Asp		
530	535	540
Lys Thr Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser Phe Asn Leu		
545	550	555
Ala Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu Gln Ile		
565	570	575
Gly Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp Lys Ile		
580	585	590
Glu Phe Ile Pro Val Asn		
595		

<210> 10
 <211> 1818
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> CDS
 <222> (1)..(1818)
 <223> Maize optimized modified cry3A085 coding sequence.

<220>
 <221> misc_feature
 <222> (346)..(357)
 <223> Cathepsin G recognition site coding sequence.

<400> 10
 atg aac tac aag gag ttc ctc cgc atg acc gcc gac aac aac acc gag
 Met Asn Tyr Lys Glu Phe Leu Arg Met Thr Ala Asp Asn Asn Thr Glu

48

1	5	10	15	
gcc ctg gac agc agc acc acc aag gac gtg atc cag aag ggc atc agc				96
Ala Leu Asp Ser Ser Thr Thr Lys Asp Val Ile Gln Lys Gly Ile Ser	20	25	30	
gtg gtg ggc gac ctg ctg ggc gtg gtg ggc ttc ccc ttc ggc ggc gcc				144
Val Val Gly Asp Leu Leu Gly Val Val Gly Phe Pro Phe Gly Gly Ala	35	40	45	
ctg gtg agc ttc tac acc aac ttc ctg aac acc atc tgg ccc agc gag				192
Leu Val Ser Phe Tyr Thr Asn Phe Leu Asn Thr Ile Trp Pro Ser Glu	50	55	60	
gac ccc tgg aag gcc ttc atg gag cag gtg gag gcc ctg atg gac cag				240
Asp Pro Trp Lys Ala Phe Met Glu Gln Val Glu Ala Leu Met Asp Gln	65	70	75	80
aag atc gcc gac tac gcc aag aac aag gca ctg gcc gag cta cag ggc				288
Lys Ile Ala Asp Tyr Ala Lys Asn Lys Ala Leu Ala Glu Leu Gln Gly	85	90	95	
ctc cag aac aac gtg gag gac tat gtg agc gcc ctg agc agc tgg cag				336
Leu Gln Asn Asn Val Glu Asp Tyr Val Ser Ala Leu Ser Ser Trp Gln	100	105	110	
aag aac ccc gct gca ccg ttc cgc aac ccc cac agc cag ggc cgc atc				384
Lys Asn Pro Ala Ala Pro Phe Arg Asn Pro His Ser Gln Gly Arg Ile	115	120	125	
cgc gag ctg ttc agc cag gcc gag agc cac ttc cgc aac agc atg ccc				432
Arg Glu Leu Phe Ser Gln Ala Glu Ser His Phe Arg Asn Ser Met Pro	130	135	140	
agc ttc gcc atc agc ggc tac gag gtg ctg ttc ctg acc acc tac gcc				480
Ser Phe Ala Ile Ser Gly Tyr Glu Val Leu Phe Leu Thr Thr Tyr Ala	145	150	155	160
cag gcc gcc aac acc cac ctg ttc ctg ctg aag gac gcc caa atc tac				528
Gln Ala Ala Asn Thr His Leu Phe Leu Leu Lys Asp Ala Gln Ile Tyr	165	170	175	
gga gag gag tgg ggc tac gag aag gag gac atc gcc gag ttc tac aag				576
Gly Glu Glu Trp Gly Tyr Glu Lys Glu Asp Ile Ala Glu Phe Tyr Lys	180	185	190	
cgc cag ctg aag ctg acc cag gag tac acc gac cac tgc gtg aag tgg				624
Arg Gln Leu Lys Leu Thr Gln Glu Tyr Thr Asp His Cys Val Lys Trp	195	200	205	
tac aac gtg ggt cta gac aag ctc cgc ggc agc agc tac gag agc tgg				672
Tyr Asn Val Gly Leu Asp Lys Leu Arg Gly Ser Ser Tyr Glu Ser Trp	210	215	220	

gtg aac ttc aac cgc tac cgc cgc gag atg acc ctg acc gtg ctg gac	720
Val Asn Phe Asn Arg Tyr Arg Arg Glu Met Thr Leu Thr Val Leu Asp	
225 230 235 240	
ctg atc gcc ctg ttc ccc ctg tac gac gtg cgc ctg tac ccc aag gag	768
Leu Ile Ala Leu Phe Pro Leu Tyr Asp Val Arg Leu Tyr Pro Lys Glu	
245 250 255	
gtg aag acc gag ctg acc cgc gac gtg ctg acc gac ccc atc gtg ggc	816
Val Lys Thr Glu Leu Thr Arg Asp Val Leu Thr Asp Pro Ile Val Gly	
260 265 270	
gtg aac aac ctg cgc ggc tac ggc acc acc ttc agc aac atc gag aac	864
Val Asn Asn Leu Arg Gly Tyr Gly Thr Thr Phe Ser Asn Ile Glu Asn	
275 280 285	
tac atc cgc aag ccc cac ctg ttc gac tac ctg cac cgc atc cag ttc	912
Tyr Ile Arg Lys Pro His Leu Phe Asp Tyr Leu His Arg Ile Gln Phe	
290 295 300	
cac acg cgt ttc cag ccc ggc tac tac ggc aac gac agc ttc aac tac	960
His Thr Arg Phe Gln Pro Gly Tyr Tyr Gly Asn Asp Ser Phe Asn Tyr	
305 310 315 320	
tgg agc ggc aac tac gtg agc acc cgc ccc agc atc ggc agc aac gac	1008
Trp Ser Gly Asn Tyr Val Ser Thr Arg Pro Ser Ile Gly Ser Asn Asp	
325 330 335	
atc atc acc agc ccc ttc tac ggc aac aag agc agc gag ccc gtg cag	1056
Ile Ile Thr Ser Pro Phe Tyr Gly Asn Lys Ser Ser Glu Pro Val Gln	
340 345 350	
aac ctt gag ttc aac ggc gag aag gtg tac cgc gcc gtg gct aac acc	1104
Asn Leu Glu Phe Asn Gly Glu Lys Val Tyr Arg Ala Val Ala Asn Thr	
355 360 365	
aac ctg gcc gtg tgg ccc tct gca gtg tac agc ggc gtg acc aag gtg	1152
Asn Leu Ala Val Trp Pro Ser Ala Val Tyr Ser Gly Val Thr Lys Val	
370 375 380	
gag ttc agc cag tac aac gac cag acc gac gag gcc agc acc cag acc	1200
Glu Phe Ser Gln Tyr Asn Asp Gln Thr Asp Glu Ala Ser Thr Gln Thr	
385 390 395 400	
tac gac agc aag cgc aac gtg ggc gcc gtg agc tgg gac agc atc gac	1248
Tyr Asp Ser Lys Arg Asn Val Gly Ala Val Ser Trp Asp Ser Ile Asp	
405 410 415	
cag ctg ccc ccc gag acc acc gac gag ccc ctg gag aag ggc tac agc	1296
Gln Leu Pro Pro Glu Thr Thr Asp Glu Pro Leu Glu Lys Gly Tyr Ser	
420 425 430	
cac cag ctg aac tac gtg atg tgc ttc ctg atg cag ggc agc cgc ggc	1344
His Gln Leu Asn Tyr Val Met Cys Phe Leu Met Gln Gly Ser Arg Gly	

435	440	445	
acc atc ccc gtg ctg acc tgg acc cac aag agc gtc gac ttc ttc aac			1392
Thr Ile Pro Val Leu Thr Trp Thr His Lys Ser Val Asp Phe Phe Asn			
450	455	460	
atg atc gac agc aag aag atc acc cag ctg ccc ctg gtg aag gcc tac			1440
Met Ile Asp Ser Lys Lys Ile Thr Gln Leu Pro Leu Val Lys Ala Tyr			
465	470	475	480
aag ctc cag agc ggc gcc agc gtg gtg gca ggc ccc cgc ttc acc ggc			1488
Lys Leu Gln Ser Gly Ala Ser Val Val Ala Gly Pro Arg Phe Thr Gly			
	485	490	495
ggc gac atc atc cag tgc acc gag aac ggc agc gcc gcc acc atc tac			1536
Gly Asp Ile Ile Gln Cys Thr Glu Asn Gly Ser Ala Ala Thr Ile Tyr			
	500	505	510
gtg acc ccc gac gtg agc tac agc cag aag tac cgc gcc cgc atc cac			1584
Val Thr Pro Asp Val Ser Tyr Ser Gln Lys Tyr Arg Ala Arg Ile His			
	515	520	525
tac gcc agc acc agc cag atc acc ttc acc ctg agc ctg gac ggg gcc			1632
Tyr Ala Ser Thr Ser Gln Ile Thr Phe Thr Leu Ser Leu Asp Gly Ala			
	530	535	540
ccc ttc aac caa tac tac ttc gac aag acc atc aac aag ggc gac acc			1680
Pro Phe Asn Gln Tyr Tyr Phe Asp Lys Thr Ile Asn Lys Gly Asp Thr			
545	550	555	560
ctg acc tac aac agc ttc aac ctg gcc agc ttc agc acc cct ttc gag			1728
Leu Thr Tyr Asn Ser Phe Asn Leu Ala Ser Phe Ser Thr Pro Phe Glu			
	565	570	575
ctg agc ggc aac aac ctc cag atc ggc gtg acc ggc ctg agc gcc ggc			1776
Leu Ser Gly Asn Asn Leu Gln Ile Gly Val Thr Gly Leu Ser Ala Gly			
	580	585	590
gac aag gtg tac atc gac aag atc gag ttc atc ccc gtg aac			1818
Asp Lys Val Tyr Ile Asp Lys Ile Glu Phe Ile Pro Val Asn			
	595	600	605

<210> 11

<211> 606

<212> PRT

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (346)..(357)

<223> Cathepsin G recognition site coding sequence.

<400> 11

Met Asn Tyr Lys Glu Phe Leu Arg Met Thr Ala Asp Asn Asn Thr Glu
 1 5 10 15
 Ala Leu Asp Ser Ser Thr Thr Lys Asp Val Ile Gln Lys Gly Ile Ser
 20 25 30
 Val Val Gly Asp Leu Leu Gly Val Val Gly Phe Pro Phe Gly Gly Ala
 35 40 45
 Leu Val Ser Phe Tyr Thr Asn Phe Leu Asn Thr Ile Trp Pro Ser Glu
 50 55 60
 Asp Pro Trp Lys Ala Phe Met Glu Gln Val Glu Ala Leu Met Asp Gln
 65 70 75 80
 Lys Ile Ala Asp Tyr Ala Lys Asn Lys Ala Leu Ala Glu Leu Gln Gly
 85 90 95
 Leu Gln Asn Asn Val Glu Asp Tyr Val Ser Ala Leu Ser Ser Trp Gln
 100 105 110
 Lys Asn Pro Ala Ala Pro Phe Arg Asn Pro His Ser Gln Gly Arg Ile
 115 120 125
 Arg Glu Leu Phe Ser Gln Ala Glu Ser His Phe Arg Asn Ser Met Pro
 130 135 140
 Ser Phe Ala Ile Ser Gly Tyr Glu Val Leu Phe Leu Thr Thr Tyr Ala
 145 150 155 160
 Gln Ala Ala Asn Thr His Leu Phe Leu Leu Lys Asp Ala Gln Ile Tyr
 165 170 175
 Gly Glu Glu Trp Gly Tyr Glu Lys Glu Asp Ile Ala Glu Phe Tyr Lys
 180 185 190
 Arg Gln Leu Lys Leu Thr Gln Glu Tyr Thr Asp His Cys Val Lys Trp
 195 200 205
 Tyr Asn Val Gly Leu Asp Lys Leu Arg Gly Ser Ser Tyr Glu Ser Trp
 210 215 220
 Val Asn Phe Asn Arg Tyr Arg Arg Glu Met Thr Leu Thr Val Leu Asp
 225 230 235 240
 Leu Ile Ala Leu Phe Pro Leu Tyr Asp Val Arg Leu Tyr Pro Lys Glu
 245 250 255
 Val Lys Thr Glu Leu Thr Arg Asp Val Leu Thr Asp Pro Ile Val Gly
 260 265 270
 Val Asn Asn Leu Arg Gly Tyr Gly Thr Thr Phe Ser Asn Ile Glu Asn
 275 280 285

Tyr Ile Arg Lys Pro His Leu Phe Asp Tyr Leu His Arg Ile Gln Phe
 290 295 300
 His Thr Arg Phe Gln Pro Gly Tyr Tyr Gly Asn Asp Ser Phe Asn Tyr
 305 310 315 320
 Trp Ser Gly Asn Tyr Val Ser Thr Arg Pro Ser Ile Gly Ser Asn Asp
 325 330 335
 Ile Ile Thr Ser Pro Phe Tyr Gly Asn Lys Ser Ser Glu Pro Val Gln
 340 345 350
 Asn Leu Glu Phe Asn Gly Glu Lys Val Tyr Arg Ala Val Ala Asn Thr
 355 360 365
 Asn Leu Ala Val Trp Pro Ser Ala Val Tyr Ser Gly Val Thr Lys Val
 370 375 380
 Glu Phe Ser Gln Tyr Asn Asp Gln Thr Asp Glu Ala Ser Thr Gln Thr
 385 390 395 400
 Tyr Asp Ser Lys Arg Asn Val Gly Ala Val Ser Trp Asp Ser Ile Asp
 405 410 415
 Gln Leu Pro Pro Glu Thr Thr Asp Glu Pro Leu Glu Lys Gly Tyr Ser
 420 425 430
 His Gln Leu Asn Tyr Val Met Cys Phe Leu Met Gln Gly Ser Arg Gly
 435 440 445
 Thr Ile Pro Val Leu Thr Trp Thr His Lys Ser Val Asp Phe Phe Asn
 450 455 460
 Met Ile Asp Ser Lys Lys Ile Thr Gln Leu Pro Leu Val Lys Ala Tyr
 465 470 475 480
 Lys Leu Gln Ser Gly Ala Ser Val Val Ala Gly Pro Arg Phe Thr Gly
 485 490 495
 Gly Asp Ile Ile Gln Cys Thr Glu Asn Gly Ser Ala Ala Thr Ile Tyr
 500 505 510
 Val Thr Pro Asp Val Ser Tyr Ser Gln Lys Tyr Arg Ala Arg Ile His
 515 520 525
 Tyr Ala Ser Thr Ser Gln Ile Thr Phe Thr Leu Ser Leu Asp Gly Ala
 530 535 540
 Pro Phe Asn Gln Tyr Tyr Phe Asp Lys Thr Ile Asn Lys Gly Asp Thr
 545 550 555 560
 Leu Thr Tyr Asn Ser Phe Asn Leu Ala Ser Phe Ser Thr Pro Phe Glu
 565 570 575

Leu Ser Gly Asn Asn Leu Gln Ile Gly Val Thr Gly Leu Ser Ala Gly
 580 585 590

Asp Lys Val Tyr Ile Asp Lys Ile Glu Phe Ile Pro Val Asn
 595 600 605

<210> 12

<211> 1794

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(1794)

<223> Maize optimized modified cry3A082 coding sequence.

<220>

<221> misc_feature

<222> (1609)..(1620)

<223> Cathepsin G recognition site coding sequence

<400> 12

atg acg gcc gac aac aac acc gag gcc ctg gac agc agc acc acc aag 48
 Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys
 1 5 10 15

gac gtg atc cag aag ggc atc agc gtg gtg ggc gac ctg ctg ggc gtg 96
 Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val
 20 25 30

gtg ggc ttc ccc ttc ggc ggc gcc ctg gtg agc ttc tac acc aac ttc 144
 Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe
 35 40 45

ctg aac acc atc tgg ccc agc gag gac ccc tgg aag gcc ttc atg gag 192
 Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu
 50 55 60

cag gtg gag gcc ctg atg gac cag aag atc gcc gac tac gcc aag aac 240
 Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn
 65 70 75 80

aag gca ctg gcc gag cta cag ggc ctc cag aac aac gtg gag gac tat 288
 Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr
 85 90 95

gtg agc gcc ctg agc agc tgg cag aag aac ccc gtc tcg agc cgc aac 336
 Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Val Ser Ser Arg Asn
 100 105 110

ccc cac agc cag ggc cgc atc cgc gag ctg ttc agc cag gcc gag agc 384
 Pro His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser
 115 120 125

cac ttc cgc aac agc atg ccc agc ttc gcc atc agc ggc tac gag gtg His Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu Val 130 135 140	432
ctg ttc ctg acc acc tac gcc cag gcc gcc aac acc cac ctg ttc ctg Leu Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe Leu 145 150 155 160	480
ctg aag gac gcc caa atc tac gga gag gag tgg ggc tac gag aag gag Leu Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys Glu 165 170 175	528
gac atc gcc gag ttc tac aag cgc cag ctg aag ctg acc cag gag tac Asp Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu Tyr 180 185 190	576
acc gac cac tgc gtg aag tgg tac aac gtg ggt cta gac aag ctc cgc Thr Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu Arg 195 200 205	624
ggc agc agc tac gag agc tgg gtg aac ttc aac cgc tac cgc cgc gag Gly Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg Glu 210 215 220	672
atg acc ctg acc gtg ctg gac ctg atc gcc ctg ttc ccc ctg tac gac Met Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr Asp 225 230 235 240	720
gtg cgc ctg tac ccc aag gag gtg aag acc gag ctg acc cgc gac gtg Val Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp Val 245 250 255	768
ctg acc gac ccc atc gtg ggc gtg aac aac ctg cgc ggc tac ggc acc Leu Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly Thr 260 265 270	816
acc ttc agc aac atc gag aac tac atc cgc aag ccc cac ctg ttc gac Thr Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe Asp 275 280 285	864
tac ctg cac cgc atc cag ttc cac acg cgt ttc cag ccc ggc tac tac Tyr Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr Tyr 290 295 300	912
ggc aac gac agc ttc aac tac tgg agc ggc aac tac gtg agc acc cgc Gly Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr Arg 305 310 315 320	960
ccc agc atc ggc agc aac gac atc atc acc agc ccc ttc tac ggc aac Pro Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly Asn 325 330 335	1008
aag agc agc gag ccc gtg cag aac ctt gag ttc aac ggc gag aag gtg	1056

Lys	Ser	Ser	Glu	Pro	Val	Gln	Asn	Leu	Glu	Phe	Asn	Gly	Glu	Lys	Val	
			340					345					350			
tac	cgc	gcc	gtg	gct	aac	acc	aac	ctg	gcc	gtg	tgg	ccc	tct	gca	gtg	1104
Tyr	Arg	Ala	Val	Ala	Asn	Thr	Asn	Leu	Ala	Val	Trp	Pro	Ser	Ala	Val	
		355					360					365				
tac	agc	ggc	gtg	acc	aag	gtg	gag	ttc	agc	cag	tac	aac	gac	cag	acc	1152
Tyr	Ser	Gly	Val	Thr	Lys	Val	Glu	Phe	Ser	Gln	Tyr	Asn	Asp	Gln	Thr	
	370					375					380					
gac	gag	gcc	agc	acc	cag	acc	tac	gac	agc	aag	cgc	aac	gtg	ggc	gcc	1200
Asp	Glu	Ala	Ser	Thr	Gln	Thr	Tyr	Asp	Ser	Lys	Arg	Asn	Val	Gly	Ala	
385					390					395					400	
gtg	agc	tgg	gac	agc	atc	gac	cag	ctg	ccc	ccc	gag	acc	acc	gac	gag	1248
Val	Ser	Trp	Asp	Ser	Ile	Asp	Gln	Leu	Pro	Pro	Glu	Thr	Thr	Asp	Glu	
			405					410						415		
ccc	ctg	gag	aag	ggc	tac	agc	cac	cag	ctg	aac	tac	gtg	atg	tgc	ttc	1296
Pro	Leu	Glu	Lys	Gly	Tyr	Ser	His	Gln	Leu	Asn	Tyr	Val	Met	Cys	Phe	
		420						425				430				
ctg	atg	cag	ggc	agc	cgc	ggc	acc	atc	ccc	gtg	ctg	acc	tgg	acc	cac	1344
Leu	Met	Gln	Gly	Ser	Arg	Gly	Thr	Ile	Pro	Val	Leu	Thr	Trp	Thr	His	
		435					440					445				
aag	agc	gtc	gac	ttc	ttc	aac	atg	atc	gac	agc	aag	aag	atc	acc	cag	1392
Lys	Ser	Val	Asp	Phe	Phe	Asn	Met	Ile	Asp	Ser	Lys	Lys	Ile	Thr	Gln	
	450					455					460					
ctg	ccc	ctg	gtg	aag	gcc	tac	aag	ctc	cag	agc	ggc	gcc	agc	gtg	gtg	1440
Leu	Pro	Leu	Val	Lys	Ala	Tyr	Lys	Leu	Gln	Ser	Gly	Ala	Ser	Val	Val	
465				470				475						480		
gca	ggc	ccc	cgc	ttc	acc	ggc	ggc	gac	atc	atc	cag	tgc	acc	gag	aac	1488
Ala	Gly	Pro	Arg	Phe	Thr	Gly	Gly	Asp	Ile	Ile	Gln	Cys	Thr	Glu	Asn	
			485					490					495			
ggc	agc	gcc	gcc	acc	atc	tac	gtg	acc	ccc	gac	gtg	agc	tac	agc	cag	1536
Gly	Ser	Ala	Ala	Thr	Ile	Tyr	Val	Thr	Pro	Asp	Val	Ser	Tyr	Ser	Gln	
		500					505					510				
aag	tac	cgc	gcc	cgc	atc	cac	tac	gcc	agc	acc	agc	cag	atc	acc	ttc	1584
Lys	Tyr	Arg	Ala	Arg	Ile	His	Tyr	Ala	Ser	Thr	Ser	Gln	Ile	Thr	Phe	
	515						520					525				
acc	ctg	agc	ctg	gac	ggg	gcc	ccc	gct	gca	ccg	ttc	tac	ttc	gac	aag	1632
Thr	Leu	Ser	Leu	Asp	Gly	Ala	Pro	Ala	Ala	Pro	Phe	Tyr	Phe	Asp	Lys	
	530					535					540					
acc	atc	aac	aag	ggc	gac	acc	ctg	acc	tac	aac	agc	ttc	aac	ctg	gcc	1680
Thr	Ile	Asn	Lys	Gly	Asp	Thr	Leu	Thr	Tyr	Asn	Ser	Phe	Asn	Leu	Ala	
545				550						555				560		

agc ttc agc acc cct ttc gag ctg agc ggc aac aac ctc cag atc ggc 1728
 Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu Gln Ile Gly
 565 570 575

gtg acc ggc ctg agc gcc ggc gac aag gtg tac atc gac aag atc gag 1776
 Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp Lys Ile Glu
 580 585 590

ttc atc ccc gtg aac tag 1794
 Phe Ile Pro Val Asn
 595

<210> 13
 <211> 597
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <222> (1609)..(1620)
 <223> Cathepsin G recognition site coding sequence

<400> 13
 Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys
 1 5 10 15

Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val
 20 25 30

Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe
 35 40 45

Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu
 50 55 60

Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn
 65 70 75 80

Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr
 85 90 95

Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Val Ser Ser Arg Asn
 100 105 110

Pro His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser
 115 120 125

His Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu Val
 130 135 140

Leu Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe Leu
 145 150 155 160

Leu Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys Glu
 165 170 175
 Asp Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu Tyr
 180 185 190
 Thr Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu Arg
 195 200 205
 Gly Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg Glu
 210 215 220
 Met Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr Asp
 225 230 235 240
 Val Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp Val
 245 250 255
 Leu Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly Thr
 260 265 270
 Thr Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe Asp
 275 280 285
 Tyr Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr Tyr
 290 295 300
 Gly Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr Arg
 305 310 315 320
 Pro Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly Asn
 325 330 335
 Lys Ser Ser Glu Pro Val Gln Asn Leu Glu Phe Asn Gly Glu Lys Val
 340 345 350
 Tyr Arg Ala Val Ala Asn Thr Asn Leu Ala Val Trp Pro Ser Ala Val
 355 360 365
 Tyr Ser Gly Val Thr Lys Val Glu Phe Ser Gln Tyr Asn Asp Gln Thr
 370 375 380
 Asp Glu Ala Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Val Gly Ala
 385 390 395 400
 Val Ser Trp Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp Glu
 405 410 415
 Pro Leu Glu Lys Gly Tyr Ser His Gln Leu Asn Tyr Val Met Cys Phe
 420 425 430
 Leu Met Gln Gly Ser Arg Gly Thr Ile Pro Val Leu Thr Trp Thr His
 435 440 445

Lys Ser Val Asp Phe Phe Asn Met Ile Asp Ser Lys Lys Ile Thr Gln
 450 455 460
 Leu Pro Leu Val Lys Ala Tyr Lys Leu Gln Ser Gly Ala Ser Val Val
 465 470 475 480
 Ala Gly Pro Arg Phe Thr Gly Gly Asp Ile Ile Gln Cys Thr Glu Asn
 485 490 495
 Gly Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser Gln
 500 505 510
 Lys Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr Phe
 515 520 525
 Thr Leu Ser Leu Asp Gly Ala Pro Ala Ala Pro Phe Tyr Phe Asp Lys
 530 535 540
 Thr Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser Phe Asn Leu Ala
 545 550 555 560
 Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu Gln Ile Gly
 565 570 575
 Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp Lys Ile Glu
 580 585 590
 Phe Ile Pro Val Asn
 595

<210> 14
 <211> 1816
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> CDS
 <222> (1)..(1812)
 <223> Maize optimized modified cry3A058 coding sequence.

<220>
 <221> misc_feature
 <222> (1621)..(1632)
 <223> Cathepsin G recognition site coding sequence

<400> 14
 atg acg gcc gac aac aac acc gag gcc ctg gac agc agc acc acc aag 48
 Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys
 1 5 10 15
 gac gtg atc cag aag ggc atc agc gtg gtg ggc gac ctg ctg ggc gtg 96
 Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val

20	25	30	
gtg ggc ttc ccc ttc ggc ggc gcc ctg gtg agc ttc tac acc aac ttc Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe 35 40 45			144
ctg aac acc atc tgg ccc agc gag gac ccc tgg aag gcc ttc atg gag Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu 50 55 60			192
cag gtg gag gcc ctg atg gac cag aag atc gcc gac tac gcc aag aac Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn 65 70 75 80			240
aag gca ctg gcc gag cta cag ggc ctc cag aac aac gtg gag gac tat Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr 85 90 95			288
gtg agc gcc ctg agc agc tgg cag aag aac ccc gtc tcg agc cgc aac Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Val Ser Ser Arg Asn 100 105 110			336
ccc cac agc cag ggc cgc atc cgc gag ctg ttc agc cag gcc gag agc Pro His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser 115 120 125			384
cac ttc cgc aac agc atg ccc agc ttc gcc atc agc ggc tac gag gtg His Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu Val 130 135 140			432
ctg ttc ctg acc acc tac gcc cag gcc gcc aac acc cac ctg ttc ctg Leu Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe Leu 145 150 155 160			480
ctg aag gac gcc caa atc tac gga gag gag tgg ggc tac gag aag gag Leu Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys Glu 165 170 175			528
gac atc gcc gag ttc tac aag cgc cag ctg aag ctg acc cag gag tac Asp Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu Tyr 180 185 190			576
acc gac cac tgc gtg aag tgg tac aac gtg ggt cta gac aag ctc cgc Thr Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu Arg 195 200 205			624
ggc agc agc tac gag agc tgg gtg aac ttc aac cgc tac cgc cgc gag Gly Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg Glu 210 215 220			672
atg acc ctg acc gtg ctg gac ctg atc gcc ctg ttc ccc ctg tac gac Met Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr Asp 225 230 235 240			720

gtg cgc ctg tac ccc aag gag gtg aag acc gag ctg acc cgc gac gtg Val Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp Val 245 250 255	768
ctg acc gac ccc atc gtg ggc gtg aac aac ctg cgc ggc tac ggc acc Leu Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly Thr 260 265 270	816
acc ttc agc aac atc gag aac tac atc cgc aag ccc cac ctg ttc gac Thr Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe Asp 275 280 285	864
tac ctg cac cgc atc cag ttc cac acg cgt ttc cag ccc ggc tac tac Tyr Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr Tyr 290 295 300	912
ggc aac gac agc ttc aac tac tgg agc ggc aac tac gtg agc acc cgc Gly Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr Arg 305 310 315 320	960
ccc agc atc ggc agc aac gac atc atc acc agc ccc ttc tac ggc aac Pro Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly Asn 325 330 335	1008
aag agc agc gag ccc gtg cag aac ctt gag ttc aac ggc gag aag gtg Lys Ser Ser Glu Pro Val Gln Asn Leu Glu Phe Asn Gly Glu Lys Val 340 345 350	1056
tac cgc gcc gtg gct aac acc aac ctg gcc gtg tgg ccc tct gca gtg Tyr Arg Ala Val Ala Asn Thr Asn Leu Ala Val Trp Pro Ser Ala Val 355 360 365	1104
tac agc ggc gtg acc aag gtg gag ttc agc cag tac aac gac cag acc Tyr Ser Gly Val Thr Lys Val Glu Phe Ser Gln Tyr Asn Asp Gln Thr 370 375 380	1152
gac gag gcc agc acc cag acc tac gac agc aag cgc aac gtg ggc gcc Asp Glu Ala Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Val Gly Ala 385 390 395 400	1200
gtg agc tgg gac agc atc gac cag ctg ccc ccc gag acc acc gac gag Val Ser Trp Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp Glu 405 410 415	1248
ccc ctg gag aag ggc tac agc cac cag ctg aac tac gtg atg tgc ttc Pro Leu Glu Lys Gly Tyr Ser His Gln Leu Asn Tyr Val Met Cys Phe 420 425 430	1296
ctg atg cag ggc agc cgc ggc acc atc ccc gtg ctg acc tgg acc cac Leu Met Gln Gly Ser Arg Gly Thr Ile Pro Val Leu Thr Trp Thr His 435 440 445	1344
aag agc gtc gac ttc ttc aac atg atc gac agc aag aag atc acc cag Lys Ser Val Asp Phe Phe Asn Met Ile Asp Ser Lys Lys Ile Thr Gln	1392

450	455	460	
ctg ccc ctg gtg aag gcc tac aag ctc cag agc ggc gcc agc gtg gtg			1440
Leu Pro Leu Val Lys Ala Tyr Lys Leu Gln Ser Gly Ala Ser Val Val			
465	470	475	480
gca ggc ccc cgc ttc acc ggc ggc gac atc atc cag tgc acc gag aac			1488
Ala Gly Pro Arg Phe Thr Gly Gly Asp Ile Ile Gln Cys Thr Glu Asn			
	485	490	495
ggc agc gcc gcc acc atc tac gtg acc ccc gac gtg agc tac agc cag			1536
Gly Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser Gln			
	500	505	510
aag tac cgc gcc cgc atc cac tac gcc agc acc agc cag atc acc ttc			1584
Lys Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr Phe			
	515	520	525
acc ctg agc ctg gac ggg gcc ccc ttc aac caa tac gct gca ccg ttc			1632
Thr Leu Ser Leu Asp Gly Ala Pro Phe Asn Gln Tyr Ala Ala Pro Phe			
	530	535	540
tac ttc gac aag acc atc aac aag ggc gac acc ctg acc tac aac agc			1680
Tyr Phe Asp Lys Thr Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser			
545	550	555	560
ttc aac ctg gcc agc ttc agc acc cct ttc gag ctg agc ggc aac aac			1728
Phe Asn Leu Ala Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn			
	565	570	575
ctc cag atc ggc gtg acc ggc ctg agc gcc ggc gac aag gtg tac atc			1776
Leu Gln Ile Gly Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile			
	580	585	590
gac aag atc gag ttc atc ccc gtg aac tag atc tga gctc			1816
Asp Lys Ile Glu Phe Ile Pro Val Asn Ile			
	595	600	

<210> 15

<211> 601

<212> PRT

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (1621)..(1632)

<223> Cathepsin G recognition site coding sequence

<400> 15

Met	Thr	Ala	Asp	Asn	Asn	Thr	Glu	Ala	Leu	Asp	Ser	Ser	Thr	Thr	Lys
1				5					10					15	

Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val

20					25					30					
Val	Gly	Phe	Pro	Phe	Gly	Gly	Ala	Leu	Val	Ser	Phe	Tyr	Thr	Asn	Phe
		35					40					45			
Leu	Asn	Thr	Ile	Trp	Pro	Ser	Glu	Asp	Pro	Trp	Lys	Ala	Phe	Met	Glu
	50					55					60				
Gln	Val	Glu	Ala	Leu	Met	Asp	Gln	Lys	Ile	Ala	Asp	Tyr	Ala	Lys	Asn
65					70					75					80
Lys	Ala	Leu	Ala	Glu	Leu	Gln	Gly	Leu	Gln	Asn	Asn	Val	Glu	Asp	Tyr
				85					90					95	
Val	Ser	Ala	Leu	Ser	Ser	Trp	Gln	Lys	Asn	Pro	Val	Ser	Ser	Arg	Asn
			100						105					110	
Pro	His	Ser	Gln	Gly	Arg	Ile	Arg	Glu	Leu	Phe	Ser	Gln	Ala	Glu	Ser
		115					120					125			
His	Phe	Arg	Asn	Ser	Met	Pro	Ser	Phe	Ala	Ile	Ser	Gly	Tyr	Glu	Val
	130					135					140				
Leu	Phe	Leu	Thr	Thr	Tyr	Ala	Gln	Ala	Ala	Asn	Thr	His	Leu	Phe	Leu
145					150					155					160
Leu	Lys	Asp	Ala	Gln	Ile	Tyr	Gly	Glu	Glu	Trp	Gly	Tyr	Glu	Lys	Glu
				165					170					175	
Asp	Ile	Ala	Glu	Phe	Tyr	Lys	Arg	Gln	Leu	Lys	Leu	Thr	Gln	Glu	Tyr
		180						185					190		
Thr	Asp	His	Cys	Val	Lys	Trp	Tyr	Asn	Val	Gly	Leu	Asp	Lys	Leu	Arg
	195						200					205			
Gly	Ser	Ser	Tyr	Glu	Ser	Trp	Val	Asn	Phe	Asn	Arg	Tyr	Arg	Arg	Glu
	210					215					220				
Met	Thr	Leu	Thr	Val	Leu	Asp	Leu	Ile	Ala	Leu	Phe	Pro	Leu	Tyr	Asp
225					230					235					240
Val	Arg	Leu	Tyr	Pro	Lys	Glu	Val	Lys	Thr	Glu	Leu	Thr	Arg	Asp	Val
				245					250					255	
Leu	Thr	Asp	Pro	Ile	Val	Gly	Val	Asn	Asn	Leu	Arg	Gly	Tyr	Gly	Thr
		260						265					270		
Thr	Phe	Ser	Asn	Ile	Glu	Asn	Tyr	Ile	Arg	Lys	Pro	His	Leu	Phe	Asp
		275					280					285			
Tyr	Leu	His	Arg	Ile	Gln	Phe	His	Thr	Arg	Phe	Gln	Pro	Gly	Tyr	Tyr
	290					295					300				
Gly	Asn	Asp	Ser	Phe	Asn	Tyr	Trp	Ser	Gly	Asn	Tyr	Val	Ser	Thr	Arg

305		310		315		320
Pro Ser Ile Gly	Ser Asn Asp Ile Ile	Thr Ser Pro Phe Tyr Gly Asn				
	325	330				335
Lys Ser Ser Glu Pro Val Gln Asn Leu Glu Phe Asn Gly Glu Lys Val						
	340	345				350
Tyr Arg Ala Val Ala Asn Thr Asn Leu Ala Val Trp Pro Ser Ala Val						
	355	360				365
Tyr Ser Gly Val Thr Lys Val Glu Phe Ser Gln Tyr Asn Asp Gln Thr						
	370	375				380
Asp Glu Ala Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Val Gly Ala						
	385	390				395
Val Ser Trp Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp Glu						
	405	410				415
Pro Leu Glu Lys Gly Tyr Ser His Gln Leu Asn Tyr Val Met Cys Phe						
	420	425				430
Leu Met Gln Gly Ser Arg Gly Thr Ile Pro Val Leu Thr Trp Thr His						
	435	440				445
Lys Ser Val Asp Phe Phe Asn Met Ile Asp Ser Lys Lys Ile Thr Gln						
	450	455				460
Leu Pro Leu Val Lys Ala Tyr Lys Leu Gln Ser Gly Ala Ser Val Val						
	465	470				480
Ala Gly Pro Arg Phe Thr Gly Gly Asp Ile Ile Gln Cys Thr Glu Asn						
	485	490				495
Gly Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser Gln						
	500	505				510
Lys Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr Phe						
	515	520				525
Thr Leu Ser Leu Asp Gly Ala Pro Phe Asn Gln Tyr Ala Ala Pro Phe						
	530	535				540
Tyr Phe Asp Lys Thr Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser						
	545	550				555
Phe Asn Leu Ala Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn						
	565	570				575
Leu Gln Ile Gly Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile						
	580	585				590
Asp Lys Ile Glu Phe Ile Pro Val Asn						

595 600

<210> 16
 <211> 1813
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> CDS
 <222> (1)..(1812)
 <223> Maize optimized modified cry3A057 coding sequence.

<220>
 <221> misc_feature
 <222> (322)..(333)
 <223> Cathepsin G recognition site coding sequence

<220>
 <221> misc_feature
 <222> (1618)..(1629)
 <223> Cathepsin G recognition site coding sequence

<400> 16

atg acg gcc gac aac aac acc gag gcc ctg gac agc agc acc acc aag	48
Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys	
1 5 10 15	
gac gtg atc cag aag ggc atc agc gtg gtg ggc gac ctg ctg ggc gtg	96
Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val	
20 25 30	
gtg ggc ttc ccc ttc ggc ggc gcc ctg gtg agc ttc tac acc aac ttc	144
Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe	
35 40 45	
ctg aac acc atc tgg ccc agc gag gac ccc tgg aag gcc ttc atg gag	192
Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu	
50 55 60	
cag gtg gag gcc ctg atg gac cag aag atc gcc gac tac gcc aag aac	240
Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn	
65 70 75 80	
aag gca ctg gcc gag cta cag ggc ctc cag aac aac gtg gag gac tat	288
Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr	
85 90 95	
gtg agc gcc ctg agc agc tgg cag aag aac ccc gct gca ccg ttc ccc	336
Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Ala Ala Pro Phe Pro	
100 105 110	
cac agc cag ggc cgc atc cgc gag ctg ttc agc cag gcc gag agc cac	384
His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser His	
115 120 125	

ttc cgc aac agc atg ccc agc ttc gcc atc agc ggc tac gag gtg ctg	432
Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu Val Leu	
130 135 140	
ttc ctg acc acc tac gcc cag gcc gcc aac acc cac ctg ttc ctg ctg	480
Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe Leu Leu	
145 150 155 160	
aag gac gcc caa atc tac gga gag gag tgg ggc tac gag aag gag gac	528
Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys Glu Asp	
165 170 175	
atc gcc gag ttc tac aag cgc cag ctg aag ctg acc cag gag tac acc	576
Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu Tyr Thr	
180 185 190	
gac cac tgc gtg aag tgg tac aac gtg ggt cta gac aag ctc cgc ggc	624
Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu Arg Gly	
195 200 205	
agc agc tac gag agc tgg gtg aac ttc aac cgc tac cgc cgc gag atg	672
Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg Glu Met	
210 215 220	
acc ctg acc gtg ctg gac ctg atc gcc ctg ttc ccc ctg tac gac gtg	720
Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr Asp Val	
225 230 235 240	
cgc ctg tac ccc aag gag gtg aag acc gag ctg acc cgc gac gtg ctg	768
Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp Val Leu	
245 250 255	
acc gac ccc atc gtg ggc gtg aac aac ctg cgc ggc tac ggc acc acc	816
Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly Thr Thr	
260 265 270	
ttc agc aac atc gag aac tac atc cgc aag ccc cac ctg ttc gac tac	864
Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe Asp Tyr	
275 280 285	
ctg cac cgc atc cag ttc cac acg cgt ttc cag ccc ggc tac tac ggc	912
Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr Tyr Gly	
290 295 300	
aac gac agc ttc aac tac tgg agc ggc aac tac gtg agc acc cgc ccc	960
Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr Arg Pro	
305 310 315 320	
agc atc ggc agc aac gac atc atc acc agc ccc ttc tac ggc aac aag	1008
Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly Asn Lys	
325 330 335	
agc agc gag ccc gtg cag aac ctt gag ttc aac ggc gag aag gtg tac	1056

Ser	Ser	Glu	Pro	Val	Gln	Asn	Leu	Glu	Phe	Asn	Gly	Glu	Lys	Val	Tyr	
			340					345					350			
cgc	gcc	gtg	gct	aac	acc	aac	ctg	gcc	gtg	tgg	ccc	tct	gca	gtg	tac	1104
Arg	Ala	Val	Ala	Asn	Thr	Asn	Leu	Ala	Val	Trp	Pro	Ser	Ala	Val	Tyr	
			355				360					365				
agc	ggc	gtg	acc	aag	gtg	gag	ttc	agc	cag	tac	aac	gac	cag	acc	gac	1152
Ser	Gly	Val	Thr	Lys	Val	Glu	Phe	Ser	Gln	Tyr	Asn	Asp	Gln	Thr	Asp	
			370			375					380					
gag	gcc	agc	acc	cag	acc	tac	gac	agc	aag	cgc	aac	gtg	ggc	gcc	gtg	1200
Glu	Ala	Ser	Thr	Gln	Thr	Tyr	Asp	Ser	Lys	Arg	Asn	Val	Gly	Ala	Val	
					390					395					400	
agc	tgg	gac	agc	atc	gac	cag	ctg	ccc	ccc	gag	acc	acc	gac	gag	ccc	1248
Ser	Trp	Asp	Ser	Ile	Asp	Gln	Leu	Pro	Pro	Glu	Thr	Thr	Asp	Glu	Pro	
				405					410					415		
ctg	gag	aag	ggc	tac	agc	cac	cag	ctg	aac	tac	gtg	atg	tgc	ttc	ctg	1296
Leu	Glu	Lys	Gly	Tyr	Ser	His	Gln	Leu	Asn	Tyr	Val	Met	Cys	Phe	Leu	
			420					425					430			
atg	cag	ggc	agc	cgc	ggc	acc	atc	ccc	gtg	ctg	acc	tgg	acc	cac	aag	1344
Met	Gln	Gly	Ser	Arg	Gly	Thr	Ile	Pro	Val	Leu	Thr	Trp	Thr	His	Lys	
			435				440					445				
agc	gtc	gac	ttc	ttc	aac	atg	atc	gac	agc	aag	aag	atc	acc	cag	ctg	1392
Ser	Val	Asp	Phe	Phe	Asn	Met	Ile	Asp	Ser	Lys	Lys	Ile	Thr	Gln	Leu	
			450			455					460					
ccc	ctg	gtg	aag	gcc	tac	aag	ctc	cag	agc	ggc	gcc	agc	gtg	gtg	gca	1440
Pro	Leu	Val	Lys	Ala	Tyr	Lys	Leu	Gln	Ser	Gly	Ala	Ser	Val	Val	Ala	
					470					475					480	
ggc	ccc	cgc	ttc	acc	ggc	ggc	gac	atc	atc	cag	tgc	acc	gag	aac	ggc	1488
Gly	Pro	Arg	Phe	Thr	Gly	Gly	Asp	Ile	Ile	Gln	Cys	Thr	Glu	Asn	Gly	
				485				490						495		
agc	gcc	gcc	acc	atc	tac	gtg	acc	ccc	gac	gtg	agc	tac	agc	cag	aag	1536
Ser	Ala	Ala	Thr	Ile	Tyr	Val	Thr	Pro	Asp	Val	Ser	Tyr	Ser	Gln	Lys	
			500					505					510			
tac	cgc	gcc	cgc	atc	cac	tac	gcc	agc	acc	agc	cag	atc	acc	ttc	acc	1584
Tyr	Arg	Ala	Arg	Ile	His	Tyr	Ala	Ser	Thr	Ser	Gln	Ile	Thr	Phe	Thr	
			515				520					525				
ctg	agc	ctg	gac	ggg	gcc	ccc	ttc	aac	caa	tac	gct	gca	ccg	ttc	tac	1632
Leu	Ser	Leu	Asp	Gly	Ala	Pro	Phe	Asn	Gln	Tyr	Ala	Ala	Pro	Phe	Tyr	
			530			535					540					
ttc	gac	aag	acc	atc	aac	aag	ggc	gac	acc	ctg	acc	tac	aac	agc	ttc	1680
Phe	Asp	Lys	Thr	Ile	Asn	Lys	Gly	Asp	Thr	Leu	Thr	Tyr	Asn	Ser	Phe	
			545		550					555					560	

aac ctg gcc agc ttc agc acc cct ttc gag ctg agc ggc aac aac ctc 1728
 Asn Leu Ala Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu
 565 570 575

cag atc ggc gtg acc ggc ctg agc gcc ggc gac aag gtg tac atc gac 1776
 Gln Ile Gly Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp
 580 585 590

aag atc gag ttc atc ccc gtg aac tag atc tga gct c 1813
 Lys Ile Glu Phe Ile Pro Val Asn Ile Ala
 595 600

<210> 17
 <211> 600
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <222> (322)..(333)
 <223> Cathepsin G recognition site coding sequence

<220>
 <221> misc_feature
 <222> (1618)..(1629)
 <223> Cathepsin G recognition site coding sequence

<400> 17
 Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys
 1 5 10 15
 Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val
 20 25 30
 Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe
 35 40 45
 Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu
 50 55 60
 Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn
 65 70 75 80
 Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr
 85 90 95
 Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Ala Ala Pro Phe Pro
 100 105 110
 His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser His
 115 120 125

Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu Val Leu
 130 135 140
 Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe Leu Leu
 145 150 155 160
 Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys Glu Asp
 165 170 175
 Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu Tyr Thr
 180 185 190
 Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu Arg Gly
 195 200 205
 Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg Glu Met
 210 215 220
 Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr Asp Val
 225 230 235 240
 Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp Val Leu
 245 250 255
 Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly Thr Thr
 260 265 270
 Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe Asp Tyr
 275 280 285
 Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr Tyr Gly
 290 295 300
 Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr Arg Pro
 305 310 315 320
 Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly Asn Lys
 325 330 335
 Ser Ser Glu Pro Val Gln Asn Leu Glu Phe Asn Gly Glu Lys Val Tyr
 340 345 350
 Arg Ala Val Ala Asn Thr Asn Leu Ala Val Trp Pro Ser Ala Val Tyr
 355 360 365
 Ser Gly Val Thr Lys Val Glu Phe Ser Gln Tyr Asn Asp Gln Thr Asp
 370 375 380
 Glu Ala Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Val Gly Ala Val
 385 390 395 400
 Ser Trp Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp Glu Pro
 405 410 415

Leu Glu Lys Gly Tyr Ser His Gln Leu Asn Tyr Val Met Cys Phe Leu
 420 425 430
 Met Gln Gly Ser Arg Gly Thr Ile Pro Val Leu Thr Trp Thr His Lys
 435 440 445
 Ser Val Asp Phe Phe Asn Met Ile Asp Ser Lys Lys Ile Thr Gln Leu
 450 455 460
 Pro Leu Val Lys Ala Tyr Lys Leu Gln Ser Gly Ala Ser Val Val Ala
 465 470 475 480
 Gly Pro Arg Phe Thr Gly Gly Asp Ile Ile Gln Cys Thr Glu Asn Gly
 485 490 495
 Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser Gln Lys
 500 505 510
 Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr Phe Thr
 515 520 525
 Leu Ser Leu Asp Gly Ala Pro Phe Asn Gln Tyr Ala Ala Pro Phe Tyr
 530 535 540
 Phe Asp Lys Thr Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser Phe
 545 550 555 560
 Asn Leu Ala Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu
 565 570 575
 Gln Ile Gly Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp
 580 585 590
 Lys Ile Glu Phe Ile Pro Val Asn
 595 600

<210> 18

<211> 1819

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(1818)

<223> Maize optimized modified cry3A056 coding sequence.

<220>

<221> misc_feature

<222> (322)..(333)

<223> Cathepsin G recognition site coding sequence.

<220>

<221> misc_feature

<222> (1624)..(1635)

<223> Cathepsin G recognition site coding sequence.

<400> 18

atg acg gcc gac aac aac acc gag gcc ctg gac agc agc acc acc aag	48
Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys	
1 5 10 15	
gac gtg atc cag aag ggc atc agc gtg gtg ggc gac ctg ctg ggc gtg	96
Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val	
20 25 30	
gtg ggc ttc ccc ttc ggc ggc gcc ctg gtg agc ttc tac acc aac ttc	144
Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe	
35 40 45	
ctg aac acc atc tgg ccc agc gag gac ccc tgg aag gcc ttc atg gag	192
Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu	
50 55 60	
cag gtg gag gcc ctg atg gac cag aag atc gcc gac tac gcc aag aac	240
Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn	
65 70 75 80	
aag gca ctg gcc gag cta cag ggc ctc cag aac aac gtg gag gac tat	288
Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr	
85 90 95	
gtg agc gcc ctg agc agc tgg cag aag aac ccc gct gca ccg ttc cgc	336
Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Ala Ala Pro Phe Arg	
100 105 110	
aac ccc cac agc cag ggc cgc atc cgc gag ctg ttc agc cag gcc gag	384
Asn Pro His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu	
115 120 125	
agc cac ttc cgc aac agc atg ccc agc ttc gcc atc agc ggc tac gag	432
Ser His Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu	
130 135 140	
gtg ctg ttc ctg acc acc tac gcc cag gcc gcc aac acc cac ctg ttc	480
Val Leu Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe	
145 150 155 160	
ctg ctg aag gac gcc caa atc tac gga gag gag tgg ggc tac gag aag	528
Leu Leu Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys	
165 170 175	
gag gac atc gcc gag ttc tac aag cgc cag ctg aag ctg acc cag gag	576
Glu Asp Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu	
180 185 190	
tac acc gac cac tgc gtg aag tgg tac aac gtg ggt cta gac aag ctc	624
Tyr Thr Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu	

195	200	205	
cgc ggc agc agc tac gag agc tgg gtg aac ttc aac cgc tac cgc cgc Arg Gly Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg 210 215 220			672
gag atg acc ctg acc gtg ctg gac ctg atc gcc ctg ttc ccc ctg tac Glu Met Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr 225 230 235 240			720
gac gtg cgc ctg tac ccc aag gag gtg aag acc gag ctg acc cgc gac Asp Val Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp 245 250 255			768
gtg ctg acc gac ccc atc gtg ggc gtg aac aac ctg cgc ggc tac ggc Val Leu Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly 260 265 270			816
acc acc ttc agc aac atc gag aac tac atc cgc aag ccc cac ctg ttc Thr Thr Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe 275 280 285			864
gac tac ctg cac cgc atc cag ttc cac acg cgt ttc cag ccc ggc tac Asp Tyr Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr 290 295 300			912
tac ggc aac gac agc ttc aac tac tgg agc ggc aac tac gtg agc acc Tyr Gly Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr 305 310 315 320			960
cgc ccc agc atc ggc agc aac gac atc atc acc agc ccc ttc tac ggc Arg Pro Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly 325 330 335			1008
aac aag agc agc gag ccc gtg cag aac ctt gag ttc aac ggc gag aag Asn Lys Ser Ser Glu Pro Val Gln Asn Leu Glu Phe Asn Gly Glu Lys 340 345 350			1056
gtg tac cgc gcc gtg gct aac acc aac ctg gcc gtg tgg ccc tct gca Val Tyr Arg Ala Val Ala Asn Thr Asn Leu Ala Val Trp Pro Ser Ala 355 360 365			1104
gtg tac agc ggc gtg acc aag gtg gag ttc agc cag tac aac gac cag Val Tyr Ser Gly Val Thr Lys Val Glu Phe Ser Gln Tyr Asn Asp Gln 370 375 380			1152
acc gac gag gcc agc acc cag acc tac gac agc aag cgc aac gtg ggc Thr Asp Glu Ala Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Val Gly 385 390 395 400			1200
gcc gtg agc tgg gac agc atc gac cag ctg ccc ccc gag acc acc gac Ala Val Ser Trp Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp 405 410 415			1248

gag ccc ctg gag aag ggc tac agc cac cag ctg aac tac gtg atg tgc	1296
Glu Pro Leu Glu Lys Gly Tyr Ser His Gln Leu Asn Tyr Val Met Cys	
420 425 430	
ttc ctg atg cag ggc agc cgc ggc acc atc ccc gtg ctg acc tgg acc	1344
Phe Leu Met Gln Gly Ser Arg Gly Thr Ile Pro Val Leu Thr Trp Thr	
435 440 445	
cac aag agc gtc gac ttc ttc aac atg atc gac agc aag aag atc acc	1392
His Lys Ser Val Asp Phe Phe Asn Met Ile Asp Ser Lys Lys Ile Thr	
450 455 460	
cag ctg ccc ctg gtg aag gcc tac aag ctc cag agc ggc gcc agc gtg	1440
Gln Leu Pro Leu Val Lys Ala Tyr Lys Leu Gln Ser Gly Ala Ser Val	
465 470 475 480	
gtg gca ggc ccc cgc ttc acc ggc ggc gac atc atc cag tgc acc gag	1488
Val Ala Gly Pro Arg Phe Thr Gly Gly Asp Ile Ile Gln Cys Thr Glu	
485 490 495	
aac ggc agc gcc gcc acc atc tac gtg acc ccc gac gtg agc tac agc	1536
Asn Gly Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser	
500 505 510	
cag aag tac cgc gcc cgc atc cac tac gcc agc acc agc cag atc acc	1584
Gln Lys Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr	
515 520 525	
ttc acc ctg agc ctg gac ggg gcc ccc ttc aac caa tac gct gca ccg	1632
Phe Thr Leu Ser Leu Asp Gly Ala Pro Phe Asn Gln Tyr Ala Ala Pro	
530 535 540	
ttc tac ttc gac aag acc atc aac aag ggc gac acc ctg acc tac aac	1680
Phe Tyr Phe Asp Lys Thr Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn	
545 550 555 560	
agc ttc aac ctg gcc agc ttc agc acc cct ttc gag ctg agc ggc aac	1728
Ser Phe Asn Leu Ala Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn	
565 570 575	
aac ctc cag atc ggc gtg acc ggc ctg agc gcc ggc gac aag gtg tac	1776
Asn Leu Gln Ile Gly Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr	
580 585 590	
atc gac aag atc gag ttc atc ccc gtg aac tag atc tga gct c	1819
Ile Asp Lys Ile Glu Phe Ile Pro Val Asn Ile Ala	
595 600	

<210> 19

<211> 602

<212> PRT

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (322)..(333)

<223> Cathepsin G recognition site coding sequence.

<220>

<221> misc_feature

<222> (1624)..(1635)

<223> Cathepsin G recognition site coding sequence.

<400> 19

Met	Thr	Ala	Asp	Asn	Asn	Thr	Glu	Ala	Leu	Asp	Ser	Ser	Thr	Thr	Lys
1				5					10					15	

Asp	Val	Ile	Gln	Lys	Gly	Ile	Ser	Val	Val	Gly	Asp	Leu	Leu	Gly	Val
			20				25						30		

Val	Gly	Phe	Pro	Phe	Gly	Gly	Ala	Leu	Val	Ser	Phe	Tyr	Thr	Asn	Phe
		35					40					45			

Leu	Asn	Thr	Ile	Trp	Pro	Ser	Glu	Asp	Pro	Trp	Lys	Ala	Phe	Met	Glu
	50					55					60				

Gln	Val	Glu	Ala	Leu	Met	Asp	Gln	Lys	Ile	Ala	Asp	Tyr	Ala	Lys	Asn
65					70					75					80

Lys	Ala	Leu	Ala	Glu	Leu	Gln	Gly	Leu	Gln	Asn	Asn	Val	Glu	Asp	Tyr
			85					90						95	

Val	Ser	Ala	Leu	Ser	Ser	Trp	Gln	Lys	Asn	Pro	Ala	Ala	Pro	Phe	Arg
			100					105					110		

Asn	Pro	His	Ser	Gln	Gly	Arg	Ile	Arg	Glu	Leu	Phe	Ser	Gln	Ala	Glu
		115					120					125			

Ser	His	Phe	Arg	Asn	Ser	Met	Pro	Ser	Phe	Ala	Ile	Ser	Gly	Tyr	Glu
	130					135					140				

Val	Leu	Phe	Leu	Thr	Thr	Tyr	Ala	Gln	Ala	Ala	Asn	Thr	His	Leu	Phe
145					150					155					160

Leu	Leu	Lys	Asp	Ala	Gln	Ile	Tyr	Gly	Glu	Glu	Trp	Gly	Tyr	Glu	Lys
			165						170					175	

Glu	Asp	Ile	Ala	Glu	Phe	Tyr	Lys	Arg	Gln	Leu	Lys	Leu	Thr	Gln	Glu
			180					185					190		

Tyr	Thr	Asp	His	Cys	Val	Lys	Trp	Tyr	Asn	Val	Gly	Leu	Asp	Lys	Leu
		195					200					205			

Arg	Gly	Ser	Ser	Tyr	Glu	Ser	Trp	Val	Asn	Phe	Asn	Arg	Tyr	Arg	Arg
	210					215					220				

Glu	Met	Thr	Leu	Thr	Val	Leu	Asp	Leu	Ile	Ala	Leu	Phe	Pro	Leu	Tyr
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

225		230		235		240
Asp Val Arg Leu Tyr	Pro Lys Glu Val	Lys Thr Glu Leu Thr	Arg Asp			
	245	250	255			
Val Leu Thr Asp	Pro Ile Val Gly	Val Asn Asn Leu Arg	Gly Tyr Gly			
	260	265	270			
Thr Thr Phe Ser	Asn Ile Glu Asn	Tyr Ile Arg Lys	Pro His Leu Phe			
	275	280	285			
Asp Tyr Leu His Arg	Ile Gln Phe His	Thr Arg Phe Gln	Pro Gly Tyr			
	290	295	300			
Tyr Gly Asn Asp Ser	Phe Asn Tyr Trp	Ser Gly Asn Tyr	Val Ser Thr			
	305	310	315			320
Arg Pro Ser Ile Gly	Ser Asn Asp Ile	Ile Thr Ser Pro	Phe Tyr Gly			
	325	330	335			
Asn Lys Ser Ser Glu	Pro Val Gln Asn	Leu Glu Phe Asn	Gly Glu Lys			
	340	345	350			
Val Tyr Arg Ala Val	Ala Asn Thr Asn	Leu Ala Val Trp	Pro Ser Ala			
	355	360	365			
Val Tyr Ser Gly Val	Thr Lys Val Glu	Phe Ser Gln Tyr	Asn Asp Gln			
	370	375	380			
Thr Asp Glu Ala Ser	Thr Gln Thr Tyr	Asp Ser Lys Arg	Asn Val Gly			
	385	390	395			400
Ala Val Ser Trp Asp	Ser Ile Asp Gln	Leu Pro Pro Glu	Thr Thr Asp			
	405	410	415			
Glu Pro Leu Glu Lys	Gly Tyr Ser His	Gln Leu Asn Tyr	Val Met Cys			
	420	425	430			
Phe Leu Met Gln Gly	Ser Arg Gly Thr	Ile Pro Val Leu	Thr Trp Thr			
	435	440	445			
His Lys Ser Val Asp	Phe Phe Asn Met	Ile Asp Ser Lys	Lys Ile Thr			
	450	455	460			
Gln Leu Pro Leu Val	Lys Ala Tyr Lys	Leu Gln Ser Gly	Ala Ser Val			
	465	470	475			480
Val Ala Gly Pro Arg	Phe Thr Gly Gly	Asp Ile Ile Gln	Cys Thr Glu			
	485	490	495			
Asn Gly Ser Ala Ala	Thr Ile Tyr Val	Thr Pro Asp Val	Ser Tyr Ser			
	500	505	510			
Gln Lys Tyr Arg Ala	Arg Ile His Tyr	Ala Ser Thr Ser	Gln Ile Thr			

515	520	525
Phe Thr Leu Ser Leu Asp Gly Ala Pro Phe Asn Gln Tyr Ala Ala Pro		
530	535	540
Phe Tyr Phe Asp Lys Thr Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn		
545	550	555
Ser Phe Asn Leu Ala Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn		
565	570	575
Asn Leu Gln Ile Gly Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr		
580	585	590
Ile Asp Lys Ile Glu Phe Ile Pro Val Asn		
595	600	

<210> 20
 <211> 1797
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> CDS
 <222> (1)..(1791)
 <223> Maize optimized modified cry3A083 coding sequence.

<220>
 <221> misc_feature
 <222> (322)..(333)
 <223> Cathepsin G recognition site coding sequence.

<220>
 <221> misc_feature
 <222> (1612)..(1623)
 <223> cathepsin G recognition site coding sequence

<400> 20		
atg acg gcc gac aac aac acc gag gcc ctg gac agc agc acc acc aag		48
Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys		
1	5	10
20	25	30
gac gtg atc cag aag ggc atc agc gtg gtg ggc gac ctg ctg ggc gtg		96
Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val		
20	25	30
gtg ggc ttc ccc ttc ggc ggc gcc ctg gtg agc ttc tac acc aac ttc		144
Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe		
35	40	45
ctg aac acc atc tgg ccc agc gag gac ccc tgg aag gcc ttc atg gag		192
Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu		
50	55	60

cag gtg gag gcc ctg atg gac cag aag atc gcc gac tac gcc aag aac Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn 65 70 75 80	240
aag gca ctg gcc gag cta cag ggc ctc cag aac aac gtg gag gac tat Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr 85 90 95	288
gtg agc gcc ctg agc agc tgg cag aag aac ccc gct gca ccg ttc cgc Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Ala Ala Pro Phe Arg 100 105 110	336
aac ccc cac agc cag ggc cgc atc cgc gag ctg ttc agc cag gcc gag Asn Pro His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu 115 120 125	384
agc cac ttc cgc aac agc atg ccc agc ttc gcc atc agc ggc tac gag Ser His Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu 130 135 140	432
gtg ctg ttc ctg acc acc tac gcc cag gcc gcc aac acc cac ctg ttc Val Leu Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe 145 150 155 160	480
ctg ctg aag gac gcc caa atc tac gga gag gag tgg ggc tac gag aag Leu Leu Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys 165 170 175	528
gag gac atc gcc gag ttc tac aag cgc cag ctg aag ctg acc cag gag Glu Asp Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu 180 185 190	576
tac acc gac cac tgc gtg aag tgg tac aac gtg ggt cta gac aag ctc Tyr Thr Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu 195 200 205	624
cgc ggc agc agc tac gag agc tgg gtg aac ttc aac cgc tac cgc cgc Arg Gly Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg 210 215 220	672
gag atg acc ctg acc gtg ctg gac ctg atc gcc ctg ttc ccc ctg tac Glu Met Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr 225 230 235 240	720
gac gtg cgc ctg tac ccc aag gag gtg aag acc gag ctg acc cgc gac Asp Val Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp 245 250 255	768
gtg ctg acc gac ccc atc gtg ggc gtg aac aac ctg cgc ggc tac ggc Val Leu Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly 260 265 270	816
acc acc ttc agc aac atc gag aac tac atc cgc aag ccc cac ctg ttc	864

Thr	Thr	Phe	Ser	Asn	Ile	Glu	Asn	Tyr	Ile	Arg	Lys	Pro	His	Leu	Phe	
		275					280					285				
gac	tac	ctg	cac	cgc	atc	cag	ttc	cac	acg	cgt	ttc	cag	ccc	ggc	tac	912
Asp	Tyr	Leu	His	Arg	Ile	Gln	Phe	His	Thr	Arg	Phe	Gln	Pro	Gly	Tyr	
		290				295					300					
tac	ggc	aac	gac	agc	ttc	aac	tac	tgg	agc	ggc	aac	tac	gtg	agc	acc	960
Tyr	Gly	Asn	Asp	Ser	Phe	Asn	Tyr	Trp	Ser	Gly	Asn	Tyr	Val	Ser	Thr	
305					310					315					320	
cgc	ccc	agc	atc	ggc	agc	aac	gac	atc	atc	acc	agc	ccc	ttc	tac	ggc	1008
Arg	Pro	Ser	Ile	Gly	Ser	Asn	Asp	Ile	Ile	Thr	Ser	Pro	Phe	Tyr	Gly	
				325					330					335		
aac	aag	agc	agc	gag	ccc	gtg	cag	aac	ctt	gag	ttc	aac	ggc	gag	aag	1056
Asn	Lys	Ser	Ser	Glu	Pro	Val	Gln	Asn	Leu	Glu	Phe	Asn	Gly	Glu	Lys	
			340					345					350			
gtg	tac	cgc	gcc	gtg	gct	aac	acc	aac	ctg	gcc	gtg	tgg	ccc	tct	gca	1104
Val	Tyr	Arg	Ala	Val	Ala	Asn	Thr	Asn	Leu	Ala	Val	Trp	Pro	Ser	Ala	
		355					360					365				
gtg	tac	agc	ggc	gtg	acc	aag	gtg	gag	ttc	agc	cag	tac	aac	gac	cag	1152
Val	Tyr	Ser	Gly	Val	Thr	Lys	Val	Glu	Phe	Ser	Gln	Tyr	Asn	Asp	Gln	
		370				375					380					
acc	gac	gag	gcc	agc	acc	cag	acc	tac	gac	agc	aag	cgc	aac	gtg	ggc	1200
Thr	Asp	Glu	Ala	Ser	Thr	Gln	Thr	Tyr	Asp	Ser	Lys	Arg	Asn	Val	Gly	
385					390					395				400		
gcc	gtg	agc	tgg	gac	agc	atc	gac	cag	ctg	ccc	ccc	gag	acc	acc	gac	1248
Ala	Val	Ser	Trp	Asp	Ser	Ile	Asp	Gln	Leu	Pro	Pro	Glu	Thr	Thr	Asp	
				405					410					415		
gag	ccc	ctg	gag	aag	ggc	tac	agc	cac	cag	ctg	aac	tac	gtg	atg	tgc	1296
Glu	Pro	Leu	Glu	Lys	Gly	Tyr	Ser	His	Gln	Leu	Asn	Tyr	Val	Met	Cys	
			420					425				430				
ttc	ctg	atg	cag	ggc	agc	cgc	ggc	acc	atc	ccc	gtg	ctg	acc	tgg	acc	1344
Phe	Leu	Met	Gln	Gly	Ser	Arg	Gly	Thr	Ile	Pro	Val	Leu	Thr	Trp	Thr	
		435					440					445				
cac	aag	agc	gtc	gac	ttc	ttc	aac	atg	atc	gac	agc	aag	aag	atc	acc	1392
His	Lys	Ser	Val	Asp	Phe	Phe	Asn	Met	Ile	Asp	Ser	Lys	Lys	Ile	Thr	
		450				455					460					
cag	ctg	ccc	ctg	gtg	aag	gcc	tac	aag	ctc	cag	agc	ggc	gcc	agc	gtg	1440
Gln	Leu	Pro	Leu	Val	Lys	Ala	Tyr	Lys	Leu	Gln	Ser	Gly	Ala	Ser	Val	
465					470					475					480	
gtg	gca	ggc	ccc	cgc	ttc	acc	ggc	ggc	gac	atc	atc	cag	tgc	acc	gag	1488
Val	Ala	Gly	Pro	Arg	Phe	Thr	Gly	Gly	Asp	Ile	Ile	Gln	Cys	Thr	Glu	
				485					490					495		

aac ggc agc gcc gcc acc atc tac gtg acc ccc gac gtg agc tac agc 1536
 Asn Gly Ser Ala Ala Thr Ile Tyr Val Thr Pro Asp Val Ser Tyr Ser
 500 505 510

cag aag tac cgc gcc cgc atc cac tac gcc agc acc agc cag atc acc 1584
 Gln Lys Tyr Arg Ala Arg Ile His Tyr Ala Ser Thr Ser Gln Ile Thr
 515 520 525

ttc acc ctg agc ctg gac ggg gcc ccc gct gca ccg ttc tac ttc gac 1632
 Phe Thr Leu Ser Leu Asp Gly Ala Pro Ala Ala Pro Phe Tyr Phe Asp
 530 535 540

aag acc atc aac aag ggc gac acc ctg acc tac aac agc ttc aac ctg 1680
 Lys Thr Ile Asn Lys Gly Asp Thr Leu Thr Tyr Asn Ser Phe Asn Leu
 545 550 555 560

gcc agc ttc agc acc cct ttc gag ctg agc ggc aac aac ctc cag atc 1728
 Ala Ser Phe Ser Thr Pro Phe Glu Leu Ser Gly Asn Asn Leu Gln Ile
 565 570 575

ggc gtg acc ggc ctg agc gcc ggc gac aag gtg tac atc gac aag atc 1776
 Gly Val Thr Gly Leu Ser Ala Gly Asp Lys Val Tyr Ile Asp Lys Ile
 580 585 590

gag ttc atc ccc gtg aactag 1797
 Glu Phe Ile Pro Val
 595

<210> 21
 <211> 597
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <222> (322)..(333)
 <223> Cathepsin G recognition site coding sequence.

<220>
 <221> misc_feature
 <222> (1612)..(1623)
 <223> cathepsin G recognition site coding sequence

<400> 21
 Met Thr Ala Asp Asn Asn Thr Glu Ala Leu Asp Ser Ser Thr Thr Lys
 1 5 10 15

Asp Val Ile Gln Lys Gly Ile Ser Val Val Gly Asp Leu Leu Gly Val
 20 25 30

Val Gly Phe Pro Phe Gly Gly Ala Leu Val Ser Phe Tyr Thr Asn Phe
 35 40 45

Leu Asn Thr Ile Trp Pro Ser Glu Asp Pro Trp Lys Ala Phe Met Glu
 50 55 60
 Gln Val Glu Ala Leu Met Asp Gln Lys Ile Ala Asp Tyr Ala Lys Asn
 65 70 75 80
 Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Val Glu Asp Tyr
 85 90 95
 Val Ser Ala Leu Ser Ser Trp Gln Lys Asn Pro Ala Ala Pro Phe Arg
 100 105 110
 Asn Pro His Ser Gln Gly Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu
 115 120 125
 Ser His Phe Arg Asn Ser Met Pro Ser Phe Ala Ile Ser Gly Tyr Glu
 130 135 140
 Val Leu Phe Leu Thr Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Phe
 145 150 155 160
 Leu Leu Lys Asp Ala Gln Ile Tyr Gly Glu Glu Trp Gly Tyr Glu Lys
 165 170 175
 Glu Asp Ile Ala Glu Phe Tyr Lys Arg Gln Leu Lys Leu Thr Gln Glu
 180 185 190
 Tyr Thr Asp His Cys Val Lys Trp Tyr Asn Val Gly Leu Asp Lys Leu
 195 200 205
 Arg Gly Ser Ser Tyr Glu Ser Trp Val Asn Phe Asn Arg Tyr Arg Arg
 210 215 220
 Glu Met Thr Leu Thr Val Leu Asp Leu Ile Ala Leu Phe Pro Leu Tyr
 225 230 235 240
 Asp Val Arg Leu Tyr Pro Lys Glu Val Lys Thr Glu Leu Thr Arg Asp
 245 250 255
 Val Leu Thr Asp Pro Ile Val Gly Val Asn Asn Leu Arg Gly Tyr Gly
 260 265 270
 Thr Thr Phe Ser Asn Ile Glu Asn Tyr Ile Arg Lys Pro His Leu Phe
 275 280 285
 Asp Tyr Leu His Arg Ile Gln Phe His Thr Arg Phe Gln Pro Gly Tyr
 290 295 300
 Tyr Gly Asn Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Ser Thr
 305 310 315 320
 Arg Pro Ser Ile Gly Ser Asn Asp Ile Ile Thr Ser Pro Phe Tyr Gly
 325 330 335

- 58 -

<210> 22
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> misc_feature
 <222> (1)..(21)
 <223> BamExt1 Primer

 <400> 22
 ggatccacca tgacggccga c 21

 <210> 23
 <211> 29
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> misc_feature
 <222> (1)..(29)
 <223> AAPFtail3 Primer

 <400> 23
 gaacggtgca gcgggggttct tctgccagc 29

 <210> 24
 <211> 29
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> misc_feature
 <222> (1)..(29)
 <223> AAPFtail4 Primer

 <400> 24
 gctgcaccgt tccccacag ccagggccg 29

 <210> 25
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> misc_feature
 <222> (1)..(21)
 <223> XbaIExt2 Primer

 <400> 25
 tctagacca cgttgtagca c 21

<210> 26
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(29)
<223> Tail5mod Primer

<400> 26
gctgcaccgt tccgcaaccc ccacagcca 29

<210> 27
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(19)
<223> SalExt Primer

<400> 27
gagcgtcgac ttcttcaac 19

<210> 28
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(30)
<223> AAPF-Y2 Primer

<400> 28
gaacggtgca gcgtattggt tgaagggggc 30

<210> 29
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(30)
<223> AAPF-Y1 Primer

<400> 29
gctgcaccgt tctacttcga caagaccatc 30

<210> 30
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(21)
<223> SacExt Primer

<400> 30
gagctcagat ctagttcacg g 21

<210> 31
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(32)
<223> BBmod1 Primer

<400> 31
cgggggcccc gctgcaccgt tctacttcga ca 32

<210> 32
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(32)
<223> BBmod2 Primer

<400> 32
tgtcgaagta gaacggtgca gcggggggccc cg 32

<210> 33
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature

<222> (1)..(48)
<223> mo3Aext Primer

<400> 33
ggatccacca tgaactacaa ggagttcctc cgcattgaccg ccgacaac 48

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(20)
<223> CMS16 Primer

<400> 34
cctccacctg ctccatgaag 20